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3. Abstract 
 
Single shot spinal anaesthesia for caesarean section is currently accepted as 
the favoured method in the absence of contraindications, for reasons of safety 
and comfort.  Firstly, there is an increased risk of failed intubation associated 
with general anaesthesia.  Secondly, spinal anaesthesia, if practiced correctly, 
allows for a superior experience of the delivery and improved bonding with the 
infant.  Maternal haemodynamic stability is desirable both for maternal and 
neonatal safety, and to diminish maternal side-effects such as nausea and 
vomiting.  Therefore, after an extensive literature review, clinically relevant 
aspects of spinal anaesthesia were studied, with a view to contributing to 
knowledge which could improve safety and outcome.   
 
The central themes explored in this thesis were fluid management during 
spinal anaesthesia for caesarean section in healthy parturients, the 
haemodynamic effects of the vasoactive agents ephedrine, phenylephrine and 
oxytocin during spinal anaesthesia for caesarean section in healthy patients 
and in patients with preeclampsia, and short term neonatal outcome after 
spinal anaesthesia in patients with severe preeclampsia.  Research 
methodology included non-invasive measures as well as the use of a pulse 
wave form analysis monitor to measure maternal cardiac output.  A validation 
study was performed comparing this method with thermodilution in patients 
with postpartum complications of preeclampsia. 
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The results of these studies showed that: 
 The pulse wave form monitor employed showed acceptable limits of 
agreement with the thermodilution method.   
 Crystalloid coload was associated with lower vasopressor requirements 
than conventional preload.   
 Spinal anaesthesia was associated with afterload reduction, which was 
more pronounced in healthy patients than in preeclamptics.   
 Ephedrine maintained or increased, and phenylephrine reduced maternal 
cardiac output in healthy patients.   
 Oxytocin was associated with transient haemodynamic instability in 
healthy and preeclamptic patients, which was obtunded by phenylephrine 
in the healthy population.   
 Spinal anaesthesia for caesarean section was associated with a greater 
umbilical arterial base deficit than general anaesthesia in patients with 
preeclampsia.   
 
Overall, these studies should contribute to improved knowledge of 
haemodynamic responses during spinal anaesthesia for caesarean section, 
and ultimately to improved maternal morbidity and mortality. 
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8. Foreword 
 
My role since 1999 as lead clinician in Obstetric Anaesthesia in the 
Department of Anaesthesia at the University of Cape Town, has involved 
anaesthesia and analgesia for healthy parturients, as well as a large 
proportion of high risk mothers with a number of life-threatening comorbidities, 
of which the most frequent is preeclampsia.  Currently our Department 
provides anaesthesia support for approximately 18,000 obstetric admissions 
per annum.  Single shot spinal anaesthesia is the technique of choice for 
caesarean section in our institution in the absence of contraindications, due to 
the fact that this technique allows for rapid onset and very reliable surgical 
anaesthesia, while permitting maternal enjoyment of the delivery and 
immediate bonding with the infant.  
 
I became increasingly interested in the haemodynamic consequences of this 
technique, both from the maternal and neonatal point of view, because 
haemodynamic stability impacts upon maternal safety and comfort and on 
neonatal outcome.  This interest was further stimulated by my involvement as 
an assessor for the South African Confidential Enquiry into Maternal Deaths, 
as I realised that although the paradigm shift from general to spinal 
anaesthesia in obstetrics was beneficial, spinal anaesthesia is associated with 
a significant morbidity and mortality.  My research is strongly aligned with 
Millennium goal 5: “Improve maternal health”.   
 
The initial research preceded the intention to write a dissertation.  Some of the 
studies presented in the thesis have already been published in international 
peer reviewed journals, but the data have been re-worked and expanded to 
form a single coherent text.  The central research question that was followed 
was, “What are the haemodynamic consequences of spinal anaesthesia for 
non-emergency caesarean section, and what are the most appropriate 
interventions for improvement of maternal stability and fetal outcome?”  
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The intention was thus to make a contribution to the improvement of local and 
international obstetric anaesthesia practice by throwing light on the 
mechanisms of the maternal response to spinal anaesthesia.  In this regard, 
the work includes basic research involving mothers with a normal 
cardiovascular system, as well as patients with preeclampsia.  In the latter 
patients, my research has contributed to establishing the safety of the practice 
of spinal anaesthesia for caesarean section in this high risk group, as well as 
to knowledge regarding neonatal outcome.  Very rapid changes in maternal 
haemodynamics may occur during spinal anaesthesia for caesarean section.  
New research tools, such as pulse wave form-derived minimally invasive 
methods for cardiac output measurement, have facilitated this work, since 
beat by beat responses can be measured, giving a unique perspective into 
the mechanism of the changes.  In turn, some of my studies have contributed 
to the scientific validation of these monitors. 
 
In addition, the studies contributing to this thesis have also stimulated the 
interest of my junior colleagues in research, and have been hypothesis-
generating, in that several further studies are envisaged in this field, to be 
commenced in the near future. 
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9. Aim and outline of the dissertation 
 
In our unit, and in most units worldwide, standard single shot spinal 
anaesthesia for caesarean section is contraindicated in patients with severely 
impaired cardiac function, and in patients with significant valvular heart 
disease, particularly in the presence of stenotic lesions.  In these patients, 
epidural, sequential combined spinal-epidural, or general anaesthesia is 
preferred.  This thesis thus examines the haemodynamic consequences of 
single shot spinal anaesthesia for caesarean section in patients with clinically 
good ventricular function, namely healthy and pre-eclamptic patients.  
Interventions to reduce haemodynamic instability due mainly to spinal 
anaesthesia but also to the administration of oxytocin, are also studied.  
 
Chapter 1 is a review of the literature pertinent to this field of study. 
 
Chapter 2 outlines the setting in which the studies were conducted, and 
presents some relevant considerations concerning research methodology. 
 
Chapter 3 presents the results of a comparison between thermodilution and 
pulse wave form analysis in the measurement of maternal cardiac output in 
patients with postpartum complications of severe preeclampsia.  These data 
contribute to the validation of the non-invasive cardiac output monitor. 
 
Chapter 4 describes a randomised trial which examines the influence of the 
timing of intravenous crystalloid administration on vasopressor requirements 
during elective caesarean section. 
 
In Chapter 5, the effects of spinal anaesthesia on the haemodynamics of 
healthy subjects, is described.  The results are presented of a randomised 
study comparing the effects of the two most commonly used vasopressors on 
maternal haemodynamics, using pulse wave form analysis and transthoracic 
bioimpedance measurements.  
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Again, using the former technique, the haemodynamic changes associated 
with spinal anaesthesia and vasopressor management in patients with severe 
preeclampsia are described in an observational study in Chapter 6.   
 
The administration of oxytocin at delivery during caesarean section is 
associated with haemodynamic instability.  Non-contemporaneous 
observational data of haemodynamic changes in response to oxytocin in 
healthy and pre-eclamptic women are presented in Chapter 7.  Also shown, 
are the results of a pilot study comparing the effects of oxytocin with those of 
a mixture of oxytocin and an α-agonist, on maternal haemodynamics. 
 
Neonatal outcome has been extensively studied in healthy parturients (see 
Literature review, above).  Chapter 8 presents the only randomised trial in 
patients with severe preeclampsia comparing the effects of spinal versus 
general anaesthesia on neonatal acid base balance. 
 
In the final chapter (Chapter 9) the conclusions derived from the research are 
presented and recommendations made for the practice of spinal anaesthesia 
for caesarean section.  Overall, these studies contribute to improved 
knowledge of haemodynamic responses during spinal anaesthesia for 
caesarean section, and improved management strategies.  Ultimately, the aim 
is to reduce maternal morbidity and mortality. 
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10. Abbreviations 
 
The following abbreviations are used in the text throughout the thesis: 
 
CO  = cardiac output 
CS  = caesarean section 
HR  = heart rate 
IV  = intravenous 
MAP  = mean arterial pressure 
SA  = spinal anaesthesia 
SV  = stroke volume 
SVR  = systemic vascular resistance 
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1. Chapter 1  
1. Literature review 
1.1. Background 
 
The benefits of regional anaesthesia in obstetrics were first recognised in July 
1900, when the obstetrician Oscar Kreis administered spinal cocaine to 6 
parturients in labour.  Cleland’s classic experiments on anaesthetised dogs 
provided the anatomical basis for regional anaesthesia in obstetrics in 1933 
(Cleland, 1933).  However these pain relief methods in obstetrics were initially 
to fall into disrepute, since inadequate training and monitoring led to a high 
morbidity and mortality; a recent editorial points out that the mortality after 
spinal anaesthesia (SA) was 1 in 1000 surgical patients prior to 1944, and as 
high as 1 in 139 in obstetrics (Gogarten and Van Aken, 2000). 
 
As understanding of maternal and fetal physiology developed, outcomes 
improved.  Of particular importance was the early work on aortocaval 
compression in the third trimester (Marx, 1992).  Initially, caudal and epidural 
anaesthesia were more popular than SA in labour, due to the fear of post 
dural puncture headache associated with SA. A major advance in SA in 
obstetrics was the introduction of atraumatic pencil point needles by Whitacre 
in 1951 (Hart and Whitacre, 1951). 
 
Since the first Confidential Enquiry into Maternal Deaths was performed (1952 
– 1954), the decreasing mortality associated with obstetric anaesthesia in the 
UK has been due both to the adoption of SA for caesarean section (CS) as 
the preferred method, and to safer general anaesthesia.  The incidence of 
failed tracheal intubation in obstetrics is approximately 1/250 (Hawthorne et al, 
1996), and this complication continues to contribute significantly to maternal 
deaths (Cooper and McClure, 2005; Cooper and McClure, 2008).  The 
development of obstetric anaesthesia as a subspeciality, and the introduction 
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of strict supervision of junior anaesthetists have also influenced obstetric 
anaesthesia safety. 
 
In the USA, general anaesthesia for CS was shown to be associated with a 
16.7 times higher case fatality rate than general anaesthesia for the period 
1985-1990 (Hawkins et al, 1997).  More recently the case fatality rate for 
general anaesthesia has decreased, and the fatality rate for regional 
anaesthesia has increased from 1.9 (1985 – 1990) to 3.8 (1997 – 2002) per 
million anaesthetics, so that the risk ratio for general versus regional 
anaesthesia has decreased to 1.7.  Thus SA does have an associated 
morbidity and mortality, although mortality is rare (Hawkins, 2009). 
 
In South Africa, the first report of the National Committee for the Confidential 
Enquiries into Maternal Deaths (1999 – 2001) showed that although more 
deaths were associated with general anaesthesia, there was a significant 
mortality associated with SA for CS.  During this period 25 patients died under 
SA, with little or no co-morbidity in most cases (Kruger, 2003).  During the 
latest triennium (2005 – 2007), there were 74 direct anaesthesia deaths, of 
which 53 were associated with spinal and 18 with general anaesthesia.  
Although denominator data are not known, the use of spinal anaesthesia has 
increased significantly since the previous triennium, and 93% of deaths due to 
spinal anaesthesia were deemed avoidable.  Contributing factors included 
inappropriate case selection for spinal anaesthesia, and inadequate 
management of severe hypotension or high motor block, including failed 
intubation in one case (Lamacraft G, Rout CC, personal communication).  
Most problems are avoidable or amenable to treatment by attention to details 
of safe practice, hence the importance of the provision of detailed 
recommendations for the management of haemodynamic instability during SA 
for CS (Dyer et al, 2004).  Such recommendations, as well as ongoing 
research into this important subject, should contribute to improved maternal 
and neonatal safety and greater maternal comfort during and after the 
procedure. 
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1.2. Haemodynamic consequences of spinal anaesthesia for non-
emergency caesarean section 
 
SA for CS is associated with hypotension, due to a combination of increased 
venous capacitance and a decreased systemic vascular resistance (SVR).  
Since uterine blood flow is pressure dependent, hypotension results in a 
decrease in uterine blood flow and potential compromise to fetal oxygenation.  
Maternal cardiovascular collapse may rarely occur.  Unpleasant symptoms 
such as nausea and vomiting are common. 
 
Haemodynamic stability during single shot SA for non-emergency CS (defined 
as cases in which there is no immediate threat to the life of the woman or 
fetus [Levy, 2006]) depends, first and foremost, upon the effects of SA in a 
pregnant patient predisposed to aortocaval compression. 
 
These effects may be modified by: 
 The baricity and dose of local anaesthetic and opioid employed 
 The rational use of fluids 
 The goal-directed use of vasopressors 
 Careful administration of oxytocin 
 
All of these aspects impact on maternal and neonatal safety and comfort.  
Special considerations apply in the management of SA for patients with 
severe preeclampsia. 
 
Intraoperative assessment tools have included maternal symptoms, non-
invasive measures such as heart rate (HR) and manual or oscillometric blood 
pressure readings, as well as central venous pressure and cardiac output 
(CO) measurements, including non-invasive, minimally invasive and invasive 
methods (Dyer and James, 2008).  In addition, recent studies have suggested 
that haemodynamic instability may be predictable preoperatively in some 
patients, either by virtue of an assessment of preoperative sympathovagal 
balance (Hanss et al, 2006), or employing a preoperative supine stress test 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1 
4 
 
(Dahlgren et al, 2007).  Short term neonatal outcome has most commonly 
been assessed by umbilical arterial and venous blood gas values and Apgar 
scores (Reynolds and Seed, 2005). 
 
1.2.1. Effects of spinal anaesthesia and aortocaval compression 
 
The association between arterial hypotension and the supine position in late 
pregnancy was first recognised by the Swedish obstetrician Ahltorp in 1931, 
as described in a recent review (Kinsella, 1994).  The correct aetiology was 
described in 1951, and classic case reports alerted anaesthesiologists to the 
importance of avoiding this complication (Holmes, 1960).  Early studies 
demonstrated both vena caval and aortic compression in late pregnancy.  The 
methodology included the measurement of right heart filling and inferior vena 
caval pressures, CO, differences in brachial arterial and femoral arterial 
pressures in the supine and the lateral or lateral tilt position, and abdominal 
angiography (Marx, 1992).  Aortic compression, shown by a decrease in 
femoral artery pressure, occurs earlier in pregnancy than inferior vena caval 
compression, as indicated by a decreased femoral artery pressure in the 
supine position (Marx et al, 1980).  Compensatory increases in SVR and HR 
in the supine position, result in the phenomenon that less than 20% of women 
experience arterial hypotension and the “supine hypotensive syndrome”; 
however the fetus may be subjected to diminished intervillous blood flow 
because of a rise in uterine vascular resistance secondary to aortic 
compression.  Fetal bradycardia has been shown to occur during supine 
recumbency of the mother associated with hypotension (Reed et al, 1970), 
and HR decelerations can be reversed by turning the mother into the lateral 
position.  
 
During SA, sympathetic blockade diminishes the compensatory mechanisms 
and results in a higher incidence of clinically significant hypotension.  An early 
study of intermittent CO measurement during SA for CS, using indicator 
dilution, showed that SA was associated with a significant depression of CO in 
10/12 patients (Ueland et al, 1968).  A more recent study employing 
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intermittent suprasternal Doppler flow measurements, showed that SA 
employing a median dose of 11mg bupivacaine was associated with a 
decrease in CO of >1L/min in 9/16 patients (the comparison in this study with 
a group of patients receiving epidural anaesthesia was made difficult to 
interpret in view of co-administration of adrenaline with the epidural local 
anaesthetic) (Robson et al, 1992).  By contrast, a further investigation 
employing lower doses of local anaesthetic (7mg and 10mg bupivacaine) in 
conjunction with subarachnoid sufentanil, demonstrated an increase in CO 
following SA, using pulse wave form analysis (Langesaeter et al, 2008).  
These different findings may relate to the limitation of aortocaval compression  
by effective lateral tilting of the parturient in more recent studies, after the 
demonstration of the importance of adequate venous return by earlier 
researchers.  Improved stability may also relate to the recent use of smaller 
doses of spinal local anaesthetic.  Pulse wave form analysis may also allow 
for more accurate beat by beat analysis of CO changes immediately after 
induction of SA. 
 
CO has been shown to be greatly improved by a change from the supine to 
the left lateral position, during SA for CS (Ueland et al, 1968).  Umbilical 
venous and arterial saturation was demonstrated to improve during SA in 
patients receiving lateral tilt (Ansari et al, 1970).  However, as much as 34 
degrees of lateral tilt may be necessary to completely eliminate the effects of 
aortocaval compression (Kinsella et al, 1992), and some investigators have 
recommended the performance of SA for CS in the lateral or modified lateral 
position (Stoneham et al, 1999).  The effects of maternal position on the 
human fetal circulation have been studied using umbilical artery scanning with 
real-time Doppler signals during epidural anaesthesia.  The results showed a 
higher umbilical artery vascular resistance in the supine position (Marx et al, 
1986). 
 
Overall, maternal and fetal morbidity have been greatly reduced by the 
recognition of the effects and the avoidance of aortocaval compression during 
SA for CS.  A recent editorial discusses the relative contribution of the venous 
and arterial circulation to spinal hypotension during CS (Sharwood-Smith and 
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Drummond, 2009).  The point is made that despite careful attention to fluid 
management and positioning in order to minimise aortocaval compression, 
significant hypotension still occurs in a large percentage of patients, due to the 
effects of SA on the arterial circulation.  This thought-provoking publication 
suggests that there is a “lesson” to be learned “from preeclampsia”, in that 
one would expect greater haemodynamic instability in these patients if 
intravascular depletion and decreased venous were the predominant 
contributor to spinal hypotension.  Chapters 5 and 6 of this thesis address in 
detail the important issue of the effects of SA and vasopressors on the arterial 
circulation in healthy and preeclamptic patients. 
 
1.2.2. Baricity, dose and volume of spinal local anaesthetic, and combination 
with opiate 
Currently, most anaesthetists employ hyperbaric bupivacaine for SA for CS.  
In support of this practice, a recent randomised trial suggested that isobaric 
and hypobaric solutions were associated with more motor block, as well as 
more hypotension and a higher number of cervical blocks than hyperbaric 
bupivacaine, if SA was performed in the sitting position (Hallworth et al, 2005). 
 
Since the early adoption of 0.5% bupivacaine for SA for CS, interest has 
focussed on the optimal local anaesthetic/opioid combination and dose to 
achieve the goals of effective surgical anaesthesia and postoperative 
analgesia, with minimal maternal and neonatal side effects.  This is 
particularly important in view of the fact that maternal pain is the commonest 
reason for failure of technique, particularly if the uterus is exteriorised.  Pain is 
also the most commonly cited anaesthetic cause of litigation in obstetric 
practice (Bogod, 2000).  Despite several recent studies on dose response and 
efficacy, currently there seems no advantage of either levobupivacaine or 
ropivacaine over bupivacaine (Dyer and Joubert, 2004). 
 
Most anaesthetists employ hyperbaric 0.5% bupivacaine in a dose of 7.5mg – 
15.0mg (1.5mL - 3.0mL).  The use of less than 10mg alone or 8mg in 
combination with an opioid is considered “low dose”.  Some investigators have 
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examined the lower dose range, with a view to reducing side-effects such as 
hypotension, nausea and vomiting, and prolonged motor blockade.  The 
incidence of visceral pain has been shown to be related to the dose of spinal 
bupivacaine.  In a comparative study of three different doses of hyperbaric 
bupivacaine, the use of 7.5mg of bupivacaine was advocated in the interests 
of haemodynamic stability; however many patients rated analgesia as poor 
(Kiran and Singal, 2002).  Furthermore, a recent study, employing a 
suprasternal Doppler flow technique, was unable to demonstrate improved 
haemodynamic stability when comparing the initiation of SA for CS with a 
standard local anaesthetic dose versus a smaller dose as part of a combined 
spinal-epidural technique (Bray et al, 2006).  The addition of various doses of 
different intrathecal opiates may allow the reduction of the local anaesthetic 
dose, with an equivalent success rate and less severe side effects.  Adequate 
surgical anaesthesia has been reported in parturients receiving only 5mg 
hyperbaric bupivacaine, to which 25µg fentanyl was added, with less 
hypotension, and less nausea and vomiting than the group receiving 10mg of 
bupivacaine only (Ben David et al, 2000).  Other investigators reported that 
8mg of bupivacaine was sufficient if 10µg fentanyl was added (Choi et al, 
2000).  All studies suggest that a combination of local anaesthetic and opiate 
allows for a reduction in local anaesthetic dose.  Most studies investigating 
low local anaesthetic doses have employed hyperbaric bupivacaine, which 
allows the use of positioning to manipulate dermatomal spread.  In this regard, 
low dose (6.6mg) hyperbaric bupivacaine has been shown to produce more 
reliable cephalad spread of anaesthesia, with less hypotension and nausea, 
than the isobaric solution (Vercauteren et al, 1998). 
 
When the effects of low dose SA are studied, a combined spinal-epidural 
(CSE) technique is often employed, since this allows for epidural 
supplementation should analgesia be inadequate.  It should be noted that the 
interpretation of the results of these studies may however be influenced by the 
fact that single shot SA may result in less sensorimotor anaesthesia than an 
identical dose administered as part of a CSE technique for elective CS (Ithnin 
et al, 2006).  A recent study, in which cerebrospinal fluid pressure was 
measured, has been unable to reproduce these findings (Horstman et al, 
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2009).  One recent investigation into the dose-response relationship for 
intrathecal hyperbaric bupivacaine coadministered with intrathecal fentanyl 
and morphine, demonstrated an ED50 of 7.6mg and an ED95 of 11.2mg for 
bupivacaine (Ginosar et al, 2004). 
 
The analgesic benefits of the addition of intrathecal opiates to the local 
anaesthetic are to be balanced against side effects, namely nausea and 
vomiting, sedation, pruritis, urinary retention and hypotension, which are dose 
related.  Respiratory depression, early and delayed, does occur, but is seldom 
life-threatening in obstetric patients (Carvalho, 2008).  In a systematic review 
of randomised controlled trials investigating intra- and postoperative analgesic 
efficacy of intrathecal opiates, intrathecal morphine consistently reduced 
postoperative pain and analgesic consumption (median time to first analgesic 
27 hours).  However there was no clear dose response effect using 0.05mg, 
0.1mg and 0.2mg, and in view of the dose dependent increase in risk of 
pruritis, nausea and vomiting and possibly respiratory depression, the authors 
recommended a maximum dose of 0.1mg (Dahl et al, 1999). 
 
Using various effective doses of fentanyl, the median time to first analgesic 
request was 4 hours.  There was evidence of a dose response relationship in 
a study where 20µg, 40µg or 60µg was administered (analgesia prolonged 
from 3[control] to 13 hours); the higher doses were associated with increased 
pruritis.  Overall, only 24% of patients in the control groups receiving no 
intrathecal opioids, required intraoperative analgesia supplementation, hence 
many patients were exposed to unnecessary side effects (Dahl et al, 1999). 
 
The addition of intrathecal sufentanil (2.5µg - 5µg) to hyperbaric bupivacaine 
has been shown to provide effective postoperative analgesia for 
approximately 4 - 5 hours (Dahlgren et al, 1997). 
 
Meperidine (pethidine) is a unique opioid, which has local anaesthetic 
properties independent of its µ-agonist activity.  It has a molecular weight and 
pKa similar to the commonly used amide local anaesthetics, and a lipid 
solubility intermediate between that of fentanyl and morphine.   
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Two studies employing intrathecal pethidine as the sole agent for CS, showed 
that while the drug gave effective surgical anaesthesia, the duration was short 
(60 and 78 minutes) (Talafre et al, 1987; Kafle, 1993), and the incidence of 
hypotension was high (32 and 50%) when an intrathecal dose of 1 mg/kg was 
used.  
 
Recent studies have investigated the intraoperative efficacy of diamorphine, 
which has kinetics resulting in an onset time is similar to that of fentanyl (6 – 9 
minutes), and considerably shorter than that of morphine (30 – 60 minutes).  
The lowest dose of intrathecal diamorphine required to reduce intraoperative 
supplementation, has been determined (Saravanan et al, 2003).  The study 
showed that an ED95 of 0.4mg for intrathecal diamorphine was required to 
reduce the requirement for intraoperative analgesic supplementation to < 5% 
of patients.  Other agents have been investigated for intrathecal 
administration.  Although neostigmine has recently been shown to produce 
modest postoperative analgesia, shivering and sedation were increased (Kaya 
et al, 2004).  A high incidence of nausea and vomiting were associated with its 
intrathecal use (Krukowski et al, 1997).  Intrathecal midazolam has a 
significant antinociceptive effect (Sen et al, 2001), and may reduce 
postoperative nausea and vomiting (Prakash et al, 2006).  There is currently 
insufficient evidence to recommend either of these drugs for clinical 
intrathecal use.  
 
In summary, surgical anaesthesia during single shot SA should not be 
compromised due to unrealistic concerns about the management of 
cardiovascular instability.  A dose of no less than 8mg hyperbaric bupivacaine 
combined with an opioid, or 10mg of hyperbaric bupivacaine alone, would 
seem appropriate.  If doses lower than these are envisaged, SA should only 
be performed as part of a CSE technique.  The use of a long-acting opioid as 
part of a single shot SA technique depends upon facilities available for 
postoperative monitoring.  Having selected the optimal combination of local 
anaesthetic and opiate for SA in this manner, with a view to attaining ideal 
surgical anaesthesia and a minimal requirement for intraoperative 
supplementation of analgesia, haemodynamic instability will occur in a 
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significant percentage of patients.  This requires careful attention to fluid and 
vasopressor therapy. 
 
1.2.3. Fluid management during spinal anaesthesia for caesarean section 
Considerable controversy exists as to the most appropriate IV fluid regimen 
for SA for elective CS.  Widespread use of crystalloid preload was initiated by 
the demonstration of improvements in uterine blood flow in pregnant ewes in 
response to rapid fluid administration after SA-induced hypotension (Greiss 
and Crandell, 1965).  The rationale for “preload” was that SA-induced 
venodilatation results in a decrease in stroke volume (SV) which more than 
offsets the increase due to afterload reduction, and thus CO may decrease 
precipitously.  Early promising results (Wollman and Marx, 1968; Marx et al, 
1969) may have been due to the inclusion of patients in labour, an inadequate 
understanding of the importance of prevention of aortocaval compression, and 
other aspects of study design such as blinding, randomisation and local 
anaesthetic dose.  
 
A qualitative systematic review evaluated the efficacy of increasing blood 
volume in reducing the incidence of hypotension during elective SA for CS 
(Morgan et al, 2001).  Secondary outcomes were maternal nausea, 
vasopressor use, and umbilical cord pH and Apgar scores.  The studies fell 
into 4 categories: large versus small volumes of crystalloid, colloid versus 
crystalloid, different colloid regimes, and mechanical methods for increasing 
blood volume (total n = 1504).  Crystalloid solutions were ineffective as a 
preload.  Of the 9 studies examining crystalloids, only three showed a 
significant reduction in the incidence of hypotension in the group receiving a 
higher volume of preload (Marx et al, 1969; Clark et al, 1976; Rout et al, 
1993b).  There were considerable differences in the study protocols, which 
probably accounts for the heterogeneity of the results (Morgan et al, 2001).  
Colloids were effective in reducing, but not eliminating, hypotension in all but 
one of a total of 23 randomised controlled trials.  Of the 7 studies comparing 
crystalloid and colloid (albumin, hetastarch, gelatin, pentastarch or dextran), 5 
showed a decreased incidence of hypotension in the colloid relative to the 
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crystalloid group (Mathru et al, 1980; Riley et al, 1995; French et al, 1999; Lin 
et al, 1999; Ueyama et al, 1999).  Only one study showed a better neonatal 
outcome in the colloid group (Mathru et al, 1980).  A limitation of the results 
was the variability in the volumes of colloids chosen in the studies, as well as 
differing definitions of hypotension and ephedrine protocols.  Due to variation 
in study design, it was also not possible to determine whether prophylactic 
fluid administration affected vasopressor requirements.  Wrapping the legs 
consistently reduced the incidence of hypotension compared with leg 
elevation or controls (Rout et al, 1993a).  However, this is not regarded as a 
readily practicable intervention. 
 
The latest update of the Cochrane Data Base in this field is in general 
agreement with findings from the above systematic review, reporting that 
“Crystalloids were more effective than no fluids (relative risk 0.78, 95% 
confidence interval 0.60 to 1.00; one trial, 140 women, sequential analysis) 
and colloids were more effective than crystalloids (relative risk 0.68, 95% 
confidence interval 0.52 to 0.89; 11 trials, 698 women) in preventing 
hypotension following SA at CS.  No differences were detected for different 
doses, rates or methods of administering colloids or crystalloids” (Cyna et al, 
2006). 
 
Despite the proven advantages of colloids in terms of reducing hypotension, 
colloids have not been uniformLy adopted for fluid management for elective 
CS.  This is partly because of their expense, as well as the risk of 
anaphylactic reactions, albeit very low in the case of the hydroxyethyl 
starches.  Recent studies have therefore investigated the timing of 
administration of crystalloid.  The relevance of the duration and timing of 
infusion of a crystalloid preload prior to SA for CS, has been evaluated (Rout 
et al, 1992a).  This study demonstrated that there was no difference in the 
incidence of hypotension whether 20 mL/kg of crystalloid was given over 10 or 
20 minutes prior to induction of SA.  Central venous pressure increases were 
greater, but increases in HR were less, and HR returned to baseline in a 
shorter period in the 10 minute group than in the 20 minute group, suggesting 
a benefit in administering the fluid closer to the time of induction of SA.   
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In a more recent investigation the authors hypothesised that in order for a fluid 
bolus to effectively reduce post-spinal hypotension, the administration of the 
fluid should produce a sustained increase in CO.  Patients were preloaded 
with 1.5L Ringer’s lactate, 0.5L or 1.0L hydroxyethyl starch.  CO and blood 
volume were assessed before and 30 minutes after fluid loading, using a non-
invasive pulse spectrophotometric technique for detecting indocyanine green.  
All groups had an increase in blood volume after fluid loading, but only 28% of 
the Ringer’s lactate solution remained in the intravascular space after 30 
minutes, compared with 100% of the hydroxyethyl starch solution.  CO was 
only increased in the hydroxyethyl starch groups, and only in the 1.0L 
hydroxyethyl starch group was spinal hypotension statistically and clinically 
significantly reduced, with an incidence of 17%, versus 75% in the Ringer’s 
and 58% in the 0.5L hydroxyethyl starch group (Ueyama et al, 1999). 
 
In the non-obstetric population, a sustained rise in CO has been has been 
demonstrated in a group of patients given lactated Ringer's solution after the 
initiation of SA (Kamenik and Paver-Erzen, 2001).  A kinetic analysis of an IV 
infusion of Ringer’s solution as preload, suggested that a rapid fluid load given 
over 2 minutes after induction of both spinal and general anaesthesia for non-
obstetric surgery, might prevent hypotension caused by central hypovolaemia 
(Ewaldsson and Hahn, 2005). 
 
These findings prompted a study of crystalloid administration after initiation of 
SA for CS (coload), to overcome the problem of rapid re-distribution of 
crystalloid fluid (see Chapter 4, below).  Subsequent to this study, crystalloid 
coloading has been employed in combination with phenylephrine infusion, in 
an attempt to obtain optimal haemodynamic stability during SA for CS (Ngan 
Kee et al, 2005).  Patients receiving rapid coloading in combination with 
phenylephrine had significantly less hypotension than those who received only 
a phenylephrine infusion.  
 
Recent studies have also examined the optimal volume and timing of colloid 
administration.  In this regard, a pentastarch preload of 10 mL/kg has been 
found to be more effective than 5 mL/kg at preventing hypotension following 
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SA (Davies and French, 2006).  As might be expected, colloid coloading with 
6% hydroxyethyl starch was found to be similarly effective in reducing 
hypotension compared with preloading (Nishikawa et al, 2007).  Similar 
results were shown using hetastarch (Carvalho et al, 2009).  There are no 
studies comparing crystalloid coload with colloid preload. 
 
In summary, colloids are more effective than crystalloids in preventing 
hypotension during SA for elective CS, particularly in women who have a 
positive preoperative supine stress test (Dahlgren et al, 2007).  Routine use of 
colloids is probably not justified in view of the expense, the potential for 
anaphylactic reactions, and the efficacy of crystalloid co-loading in 
combination with judicious use of vasopressors. 
 
1.2.4. Vasopressor use 
Fluids alone are inadequate to treat spinal hypotension in 40 – 60% of cases 
(Macarthur and Riley, 2007).  Worldwide, the most commonly used 
vasopressors are ephedrine and phenylephrine; this discussion will thus be 
mostly limited to the intravenous administration of these agents, since 
prophylactic intramuscular administration may cause hypertension (Rout et al, 
1992b) or inadequate reduction of hypotensive episodes (Ayorinde et al, 
2001), depending on the exact timing.  The choice of vasopressor should be 
based upon a knowledge of the maternal haemodynamic effects of the agent, 
efficacy (preferably rapid onset and short duration), maternal and fetal side-
effects. 
 
Ephedrine is a slow onset and relatively long-acting, non-catecholamine, 
direct-acting -receptor agonist, with indirect -effects via noradenaline 
release.  However the exact mechanism of action remains controversial; one 
study in a rat model suggested mainly indirect effects via noradrenaline 
release (Kobayashi et al, 2003), and another supported direct  effects (Liles 
et al, 2006).  In either case, the fact that the uteroplacental circulation is 
relatively devoid of sympathetic innervation, suggests a resistance to uterine 
arterial vasoconstrictive effects of this agent (Kobayashi et al, 2003).  In 
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support of this finding, ephedrine has been found to cause relatively more 
femoral than uterine artery vasoconstriction in pregnant ewes (Tong and 
Eisenach, 1992).  The vasodilatory effects of increased nitric oxide synthase 
activity in the uterine artery endothelium of pregnant ewes (Li et al, 1996) 
suggests that ephedrine might preferentially shunt blood to the uterus in 
pregnancy (Macarthur and Riley, 2007).  A dose response meta-analysis of 
prophylactic IV ephedrine for the prevention of spinal hypotension, suggested 
a dose of 12mg as a balance between benefit as a vasopressor and risk of 
causing hypertension.  Clinical disadvantages in terms of haemodynamic 
effects include a low efficacy for vasopressor effect (Ngan Kee et al, 2000), 
the development of tachyphylaxis to the pressor effects (Persky et al, 2004), 
and tachycardia and arrhythmias (Ngan Kee and Khaw, 2006).  Probably due 
to the low efficacy, and possibly due to an inherent emetic effect of ephedrine, 
phenylephrine may be preferable for the reduction of nausea and vomiting 
(Cooper et al, 2002). 
 
One of the further chief objections to ephedrine is the fetal acidosis associated 
with its use.  The decreased umbilical arterial pH and increased base deficit 
have been attributed to an ephedrine-generated increase in fetal metabolic 
rate, evidenced by an increase in an umbilical arteriovenous PCO2 difference 
in patients receiving ephedrine when compared with phenylephrine (Cooper, 
et al, 2002).  Ephedrine also increases fetal catecholamine concentrations 
(LaPorta et al, 1995).  No study of the use of ephedrine has demonstrated 
acid base derangements as severe as those which are associated with an 
increased risk of cerebral palsy in the infant (pH < 7.00, base deficit > 16 
mmol/L [MacLennan, 1999]).  This suggests that its use is safe in healthy, low 
risk deliveries, but in compromised infants already at risk of acidosis and 
intrapartum hypoxia, ephedrine may have a clinically deleterious effect, 
particularly by virtue of increased oxygen consumption.  Minor increases in 
fetal metabolic rate may be beneficial to the normal fetus; one investigation 
showed that neonatal respiratory rates were higher in patients randomised to 
placebo than the -agonist terbutaline prior to elective CS.  Neonates in the 
Un
iv
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 1 
15 
 
treated group also had lower airways resistance and higher pulmonary 
compliance (Eisler et al, 1999). 
 
The basis for the long-established use of ephedrine as a first-line drug for the 
management of spinal hypotension in obstetrics, was a paper showing 
reductions of uterine blood flow in pregnant ewes following administration of 
-agonists (Ralston et al, 1974).  Extrapolation from sheep to humans may be 
invalid, since the epitheliochorial placenta of the sheep differs vastly from the 
human haemochorial system.  In the latter case, flow is very dependent upon 
pressure in the uterine arteries. 
 
Phenylephrine is a potent direct-acting -1 agonist which has a rapid onset 
and is shorter acting by virtue of metabolism by monoamine oxidase.  A study 
comparing infusions of phenylephrine and ephedrine suggested a potency 
ratio of 81.2 (95% confidence intervals 73.0 – 89.7) (Saravanan et al, 2006).  
The time to peak pressor effect has been studied employing beat by beat 
finger arterial pressure.  Phenylephrine has a significantly shorter time to peak 
effect than ephedrine (median 27 seconds vs. 78 seconds, P-value = 0.006) 
(Thomas and Gardner, 2004). 
 
Several studies have searched for the ideal method of administration of 
phenylephrine (Ngan Kee et al, 2004a; Ngan Kee et al, 2004b; Ngan Kee et 
al, 2005).  A comparison of a prophylactic infusion of 100 µg/min 
phenylephrine with the administration of 100µg boluses in response to a 
decrease in blood pressure to < 80% of baseline, showed a greater number of 
hypotensive episodes in the treatment group, with no benefit in terms of cord 
blood gases.  The prophylaxis group received approximately 3 times the dose 
of phenylephrine (Ngan Kee et al, 2004b).  A subsequent investigation, using 
phenylephrine infusions to control blood pressure at 80, 90 or 100% of 
baseline values, suggested that tight control of blood pressure was associated 
with a lower incidence of nausea and vomiting, and a statistically, but not 
clinically significantly higher umbilical arterial pH (Ngan Kee et al, 2004a).  
Recently, a closed -loop feedback computer controlled infusion has been used 
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to maintain baseline blood pressure, using an on-off algorithm for a 
phenylephrine infusion at 100 µg/min (Ngan Kee et al, 2007).  No patients 
were symptomatic, and umbilical arterial pH was above 7.2 in all 53 cases.  
Hypertension occurred in 38% of patients.  A study of pregnant ewes has 
shown that the uterine artery in pregnancy is less responsive to -agonist 
effects than in the non-pregnant state (Magness and Rosenfeld, 1986).  This 
finding, together with the well preserved cord gas values after high dose 
phenylephrine (Ngan Kee et al, 2004a), suggests that phenylephrine is 
effective in sustaining uterine blood flow during SA by its effects on uterine 
artery perfusion pressure. 
 
Combinations of ephedrine and phenylephrine have been studied.  
Phenylephrine added to an infusion of ephedrine halved the incidence of 
hypotension and increased umbilical cord pH (Mercier et al, 2001), but there is 
no apparent benefit over phenylephrine alone.  In a study employing varying 
proportions of the two vasopressors by infusion, increasing proportions of 
ephedrine resulted in less favourable haemodynamic control as assessed by 
HR and blood pressure, and decreasing umbilical arterial pH and base excess 
(Ngan Kee et al, 2008). 
 
There are few available data on maternal CO responses to ephedrine and 
phenylephrine during SA for elective CS.  Three published investigations have 
employed intermittent suprasternal doppler flow measurements.  In the first 
study, comparing bolus doses of the vasopressors, overall CO changes were 
not different between groups; however, bradycardia in the phenylephrine 
group was treated with atropine, which make the results difficult to interpret 
(Thomas et al, 1996).  The primary outcome variable in this study was 
umbilical artery pH, and not maternal haemodynamic changes.  A second 
study, employing infusions of vasopressors, suggested that phenylephrine 
may depress maternal CO (Ashpole et al, 2005).  Recently a reduction in HR 
and CO has been shown in parturients receiving phenylephrine at 100 µg/min 
(Stewart et al, 2008).  Pulse wave form analysis has been employed to 
compare the effects of two different intrathecal doses of bupivacaine, with or 
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without intravenous phenylephrine infusion, on CO and systolic blood 
pressure.  It was concluded that low dose bupivacaine plus sufentanil, in 
combination with fluid coload and an infusion of phenylephrine (0.25 
µg/kg/min) gave “the best haemodynamic stability”, although no conclusions 
can be drawn about any treatment regimes other than those employed in the 
study (Langesaeter et al, 2008).  A detailed consideration of CO responses to 
SA and to the two vasopressors is the subject of Chapter 5 of this thesis. 
 
1.2.5. Administration of oxytocin  
The nonapeptide oxytocin is an essential drug for the prevention of 
postpartum haemorrhage, and is the first line drug for this purpose.  Oxytocin 
has complex cardiovascular effects, including peripheral vasodilatation and 
hypotension, probably via calcium dependent stimulation of the nitric oxide 
pathway, as well as release of atrial and brain natriuretic peptide (Carvalho et 
al, 2004).  Oxytocin and/or the preservative chlorbutanol also has a negative 
inotropic effect on atrial myocytes (Rosaeg et al, 1998).  It causes selective 
vasoconstriction of coronary, renal, splanchnic and skeletal muscle arteries, 
as well as of the umbilical vessels (Evron et al, 1986).  A recent study 
employing vectorcardiography showed signs of myocardial ischaemia after 
10IU oxytocin given IV after delivery at CS, and to non-pregnant controls 
(Svanstrom et al, 2008).  By contrast, a further investigation using Holter 
monitoring during CS, found that ST segment changes were infrequent, and 
there was no evidence of myocardial injury (Dogan et al, 2008).  Due to a 
structural similarity with vasopressin, oxytocin in large doses may cause water 
retention and hyponatraemia in large doses. 
 
Common maternal side effects are nausea, vomiting, headache and 
arrhythmias.  Less common, but potentially serious, are chest pain, pulmonary 
oedema (Chilvers et al, 2003), anaphylaxis, and amniotic fluid embolism, 
presumably associated with tetanic uterine contractions (James et al, 2004). 
 
During SA for CS, the haemodynamic effects of oxytocin have been studied 
by measuring transthoracic bioimpedance changes (Pinder et al, 2002), and 
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by pulse wave form analysis (Langesaeter et al, 2006).  Both investigations 
showed statistically and clinically significant increases in HR and CO following 
oxytocin boluses of 5 – 10IU.  The second study, employing an intra-arterial 
catheter for blood pressure measurement, showed a 67% decrease in systolic 
blood pressure, a 39% decrease in SVR, and a 61% increase in cardiac 
index.  These effects occurred 45 seconds after administration of oxytocin.  
The effects of oxytocin during SA in normal and in preeclamptic patients, as 
well as a study examining the efficacy of the co-administration of 
phenylephrine with oxytocin in obtunding the unwanted cardiovascular effects, 
are the subject of Chapter 7 of this thesis.  HR and blood pressure changes 
can be restricted to within 10% of baseline in elective healthy parturients, if 
5IU oxytocin is given as a slow infusion rather than as a rapid bolus, although 
the efficacy of this method in terms of prevention of blood loss remains to be 
established (Thomas et al, 2007).  In addition, less changes in heart rate and 
blood pressure are have been demonstrated after a bolus of 2 than 5IU 
(Sartain et al, 2008). 
 
There are little published data on a dose-response curve for oxytocin during 
SA for CS, both in terms of efficacy as an oxytocic, and with respect to 
cardiovascular effects.  Using an up-down sequential allocation technique, the 
ED90 was found to be only 0.35IU in 40 patients not at high risk of uterine 
atony (Carvalho et al, 2004).  The authors concluded that no more than 1IU 
oxytocin is required in cases at low risk for postpartum haemorrhage.  Using 
similar methodology, the dose required at CS for labour arrest, was 3IU, 
suggesting the possibility of receptor desensitisation in this situation (Balki et 
al, 2006).  Further work is required on oxytocin dose-response curves and on 
the issue of receptor desensitisation with multiple doses (Magalhaes et al, 
2009). 
 
1.2.6. Special considerations in preeclampsia 
When one considers the cardiovascular pathophysiology of severe 
preeclampsia, including decreased intravascular volume and markedly raised 
SVR (Young and Johanson, 2001), there has been an understandable caution 
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as regards regional anaesthesia in these patients, due to the theoretical 
possibility of precipitous hypotension, decreased CO and associated placental 
hypoperfusion.  Epidural anaesthesia for labour has been found to be 
associated with remarkable haemodynamic stability, as demonstrated by the 
use of pulmonary artery catheterization, in patients with severe preeclampsia 
who were receiving magnesium therapy (Newsome et al, 1986). 
 
SA has only recently been recognized to have a place in operative 
management in preeclampsia.  In 1995, 3 groups of patients with severe 
preeclampsia were randomised to receive epidural, combined spinal-epidural 
or general anaesthesia for CS, with similar haemodynamic stability (as 
assessed by HR and blood pressure) and fetal outcome in each group.  
Patients with non-reassuring fetal heart traces were excluded from this study 
(Wallace et al, 1995). 
 
Thereafter an editorial highlighted a study demonstrating, albeit 
retrospectively, that haemodynamic stability was equivalent in patients 
receiving spinal or epidural anaesthesia for non-emergency CS (Hood and 
Curry, 1999; Santos, 1999).  Fluid requirements were however higher in the 
spinal group.  Despite the gradually emerging evidence that SA was safe in 
preeclampsia, at least one editorial called for caution, and stressed the value 
of epidural anaesthesia (Howell, 2001). 
 
In a recent randomised multicentre study, SA was associated with a higher 
incidence of hypotension and a higher ephedrine requirement than epidural 
anaesthesia for CS for preeclampsia, but these differences were not of clinical 
significance (Visalyaputra et al, 2005). 
 
Several authors have shown that SA for CS in severe preeclampsia is 
associated with less hypotension and/or vasopressor requirements than in 
healthy parturients (Sharwood-Smith et al, 1999; Aya et al, 2003; Aya et al, 
2005; Clark et al, 2005).  One such study used a control group consisting of 
healthy patients having a preterm caesarean delivery, in whom the neonatal 
weights were similar to those in the preeclampsia group.  This ensured that 
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observed differences in blood pressure were not due to varying degrees of 
aortocaval compression in the two groups, as might have been the case in a 
previous study by the same authors (Aya et al, 2005).  Although the findings 
are valid, some methodological aspects in this study should be noted, 
including differing blood pressure criteria for interventions with vasopressors 
in each study group.  Also, their recommended administration of large 
volumes (1500 - 2000 mL) of crystalloid fluid in the preeclamptic group would 
be considered by many to be inadvisable, since the risk of pulmonary oedema 
is very real in these patients, and may be associated with life-threatening 
hypoxia.  There are however no definitive data on fluid management during 
SA for CS in patients with severe preeclampsia.  Mean central venous 
pressure has been shown to increase significantly after a preload of one litre 
of crystalloid, but returned to normal shortly after induction of anaesthesia 
(Karinen et al, 1996).  Atrial natriuretic peptide release after a crystalloid 
preload is exaggerated in patients with preeclampsia relative to healthy 
parturients, and this may aid in the adaptation of maternal circulation to a 
volume load at elective caesarean delivery (Pouta et al, 1996a). 
 
There are limited CO data in the setting of SA for CS in severe preeclampsia.  
Due to a significant incidence of complications using the pulmonary artery 
catheter (Young and Johanson, 2001), the research focus has moved to non-
invasive technologies.  Employing whole body impedance changes in the first 
study of maternal CO changes associated with SA for CS in preeclampsia, the 
authors reported on 10 preeclamptics, of whom 6 had severe disease 
(Tihtonen et al, 2006).  After recovery from SA, stroke index and cardiac index 
in the preeclamptic group were significantly lower than pre-surgery levels.  A 
further study employing pulse wave form analysis during SA for CS in patients 
with severe preeclampsia, forms the basis of Chapter 6 of this thesis.  Such 
studies could provide useful information on best practices for fluid 
management and administration of vasopressors and oxytocic drugs.  
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1.2.7. Neonatal outcome 
The direct effect of drugs on the neonate is insignificant when SA is 
administered.  However indirect effects secondary to maternal physiological or 
biochemical changes are considerable.  A multivariate analysis of factors 
associated with umbilical arterial pH and base deficit after CS under SA, 
factors predicting umbilical arterial pH included use of ephedrine, uterine 
incision-to-delivery time, and maximum decrease in systolic arterial pressure.  
Factors predicting umbilical artery base deficit were ephedrine use and the 
interaction between its use and the duration of hypotension (Ngan Kee and 
Lee, 2003). 
 
A realistic cut-off point for defining pathological fetal acidaemia that correlates 
with an increasing risk of neurological deficit has been found to be a pH of 
less than 7.00 and a base deficit of more than 16 meq/L (MacLennan, 1999).  
Decreased umbilical arterial pH and increased base deficit are currently the 
most widely accepted markers of poor short-term neonatal outcome, although 
some degree of fetal catecholamine stimulation before delivery may be 
beneficial (Eisler et al, 1999; Cooper et al, 2002). 
 
The effects of the generic methods of anaesthesia, spinal epidural and 
general, on neonatal acid-base balance, the most widely accepted marker of 
short term neonatal outcome, have recently been the subject of a meta-
analysis (Reynolds and Seed, 2005).  In view of the fact that there was little 
precise information on vasopressors, and that no studies stated whether 
vasopressor was given before delivery, a “surrogate ephedrine score” was 
created, based on the total dose used and on the difference in dose between 
groups.  This was an attempt to establish the effect of ephedrine on umbilical 
arterial pH and base deficit, and is a limitation of the analysis. 
 
In 27 of 33 studies identified it was possible to extract the minimum data 
required.  In 6 out of 12 randomised studies included in the analysis, general 
anaesthesia was associated with lower Apgar scores at one minute, but not at 
5 minutes, than regional anaesthesia.  When only randomised studies were 
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included in the analysis, pH was significantly lower with spinal than general 
anaesthesia (P-value = 0.034), but there was no difference between the spinal 
and epidural groups (P-value = 0.074).  Too few of the randomised trials 
reported base deficit to allow useful analysis.  When all 16 studies including 
the base deficit were analysed, this parameter was significantly greater for 
spinal than for general (difference 1.109; 95% confidence interval 0.434 - 
1.784 meq/L; seven studies, n = 695) and epidural anaesthesia (difference 
0.910; 95% confidence interval 0.222 - 1.598 meq/L; seven studies, n = 497).  
Random effects maximum likelihood regression suggested that larger doses 
of ephedrine contributed to the differences between pH values in the epidural 
and spinal groups, as well as in the spinal and general anaesthesia groups.  
These between-group differences could be reduced with the resurgence of the 
use of phenylephrine since this meta-analysis was performed (Ngan Kee et al, 
2004a).  The authors of the meta-analysis point out, however, that the mean 
values for base deficit, indicating metabolic acidosis, were higher in every 
study for spinal than epidural or general anaesthesia, independent of 
ephedrine use. 
 
In the context of preeclampsia, Chapter 8 of this thesis addresses the issue of 
neonatal acid base balance in a randomised comparison of general versus SA 
for CS. 
 
1.3. Summary and Research Questions 
In summary, the above literature review emphasises that there are many 
influences on maternal haemodynamic stability during CS.  When aortocaval 
compression has been minimised, effective fluid management can further 
improve stability, but by no means eliminate hypotension.  
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A formula fundamental to safe practice in anaesthesiology, is: 
 
CO = MAP / SVR = SV HR 
 
CO is thus only proportional to mean arterial pressure (MAP) if SVR is 
constant, which is seldom the case during SA for CS.  This makes the 
interpretation of blood pressure problematic.  An understanding of the detailed 
haemodynamic effects of SA would thus be advantageous, as would a 
detailed knowledge of the effects of the commonly used vasopressors, and 
vasoactive substances such as oxytocin.  Thus this review posed certain as 
yet unanswered research questions in the management of patients 
undergoing SA for non-emergency CS, which were addressed in Chapters 3 – 
8 of the thesis: 
 
 Is pulse wave form analysis a useful research tool, and can this minimally 
invasive technique be usefully applied in the management of critically ill 
obstetric patients? 
 What is the most effective method of administration of crystalloid? 
 What are the haemodynamic effects of phenylephrine and ephedrine? 
 What are haemodynamic effects of SA in healthy and preeclamptic 
patients? 
 What are the haemodynamic effects of oxytocin? 
 How does SA affect neonatal outcome in patients with severe 
preeclampsia? 
 
The answers to these questions would constitute an advance in the safe 
anaesthesia management of healthy and critically ill mothers and their infants. 
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2. Chapter 2 
3. Research setting and methods 
 
2.1. Introduction 
The details of research methodology in each study in this thesis are outlined 
in the relevant chapters.  This chapter outlines the research setting, the basis 
for the methodology employed, and the ethical issues involved. 
 
2.2. Research setting 
All the research upon which this dissertation is based, was conducted in one 
of two settings.  In South Africa, the public health system is structured into 
primary, secondary and tertiary health care.  The first location for the research 
was the Mowbray Maternity Hospital, situated 3km away from Groote Schuur 
Hospital in Cape Town.  This is a secondary level hospital, where 
approximately 7000 deliveries are performed per annum, many in patients 
with no co-morbidity, but also in patients with uncomplicated preeclampsia or 
fetal indications requiring referral from the primary health care level.  This site 
was appropriate for the study of the influence of SA, fluids, vasopressors and 
oxytocin on maternal haemodynamics.  The second site for the research was 
the Maternity Centre of the New Groote Schuur Hospital, Cape Town, which is 
a tertiary referral centre for high risk obstetrics (approximately 6000 deliveries 
per annum).  A high proportion of deliveries involve patients with severe 
preeclampsia.  This provided the opportunity for the study of clinically relevant 
aspects of SA in these patients.  Close cooperation with the Department of 
Obstetrics and Gynaecology of the University of Cape Town was required at 
all times for the success of the work.  In two of the studies, a senior 
obstetrician was a co-author and provided valuable assistance with the 
recruitment process.  The research was conducted under the auspices of the 
University of Cape Town and the Provincial Government of the Western Cape. 
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2.3. Research methodology 
For some of the studies undertaken, it was appropriate and clinically relevant 
to measure simple markers of maternal and fetal wellbeing such as HR, non-
invasive blood pressure, vasopressor requirement, Apgar scores and 
umbilical cord acid base balance.  In the studies analysing the detailed 
haemodynamic effects of SA, vasopressors and oxytocin on the maternal 
circulation, more advanced technology was necessary.  Minimally invasive 
measurement of maternal CO was performed, using beat by beat pulse wave 
form analysis in two clinical and one validation study (LiDCOplusTM, LiDCO, 
Cambridge, UK).  In one of these studies, this was combined with the non-
invasive measurement of CO, using transthoracic bioimpedance 
measurements (BioZ, Cardio Dynamics International, San Diego, CA, USA).  
 
 
2.2.1.  Pulse wave form analysis 
 
As early as 1904, Erlanger and Hooker stated that “Upon the amount of blood 
that is thrown out by the heart during systole then, does the magnitude of the 
pulse-pressure in the aorta depend” (Erlanger J, 1904).  Estimation of the SV 
from the aortic/arterial pulse pressure is complicated by a number of factors.  
Firstly, calibration is required.  Secondly, early studies showed that aortic 
compliance is lower at higher blood pressures, so that pulse pressure must be 
corrected for the non-linearity of the compliance of the arterial wall 
(Remington and Noback, 1948).  SV can thus not simply be estimated from 
the pulse pressure.  Early “pulse contour” methods were based upon the 
integration of the area of the systolic part of the corrected linear 
pressure/volume waveform (Kouchoukos et al, 1970; Jansen et al, 1990).  
Wave reflection and damping are further limitations on the accuracy of pulse 
contour methods.  Theoretically, the pulse power algorithm employed in the 
LiDCOplus monitor has certain advantages over traditional Fourier analysis-
based pulse contour algorithms.  These include the ability to derive CO 
accurately independent of the artery from which the measurement is made, 
the ability to correct for the non-linearity of aortic compliance, as well as being 
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minimally affected by changes in systemic vascular resistance, and a lack of 
dependence upon identifying details of wave morphology (Rhodes and 
Sunderland, 2005).  In addition, its performance is less affected by damping of 
the arterial trace (Pittman et al, 2005).    
 
The LiDCOplus device uses Lithium indicator dilution to calibrate an arterial 
waveform analysis algorithm.  Lithium dilution for CO determination was first 
described in 1993 (Linton et al, 1993), and has been well validated (Kurita et 
al, 1997; Linton et al, 1997).  Lithium 0.3mmol is injected via a central or 
peripheral venous line (Mason et al, 2002), (a single lithium chloride 
determination at 0.3mmol is the equivalent to a steady state plasma lithium 
concentration of 1/240th of the therapeutic level).  A concentration-time curve 
is then generated by an ion-selective electrode.  The sampling is from an 
arterial catheter at 4 mL/minute, using a peristaltic pump.  CO is calculated 
from the lithium dose and the area under the concentration-time curve, 
according to the equation: 
 
CO = Lithium dose (mmol) x 60 / Area x (1- PCV) (mmol/second), where the 
area is the integral of the primary curve, and PCV is packed cell volume 
 
At the levels used, lithium is pharmacologically inert (Jonas et al, 2001), and a 
high signal to noise ratio is generated since lithium does not normally occur in 
the plasma. 
 
The LiDCOplus machine calculates SV on a beat by beat basis, using a 3 step 
transformation of the arterial blood pressure trace (Jonas et al, 2002; Rhodes 
and Sunderland, 2005).  The first step transforms the arterial pressure trace 
into a volume-time waveform, using the following equation:  
 
V/ bp = calibration x 250 x e–k.bp,  
where V = volume, bp = blood pressure, and k is the curve coefficient 
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The number 250 is the maximal additional volume in mL above the starting 
volume, to which the aorta and arterial tree can fill. 
 
Using a look-up table, the pressure waveform can thus be used as the basis 
for generating a trace, which describes the general form of the arterial volume 
changes with every cardiac cycle.  The second step involves the derivation of 
a nominal SV (a value proportional to the actual SV) and the heart beat 
duration.  This is done by applying the mathematical technique of 
autocorrelation to the standardised volume waveform obtained in step one.  
Finally, the nominal SV is scaled to actual SV by a lithium dilution 
measurement.  The calibration factor changes the value of the maximum 
volume of the arterial tree which is used in the compliance correcting equation 
described above.  
 
When comparing two methods for CO determination employing bias and 
precision statistics, a meta-analysis suggests that acceptance of a new 
technique should rely on limits of agreement of up to 30% (Critchley and 
Critchley, 1999).  However, a knowledge of the precision of the reference 
technique is important if the conclusions relating to the new technique are to 
be accepted as valid (Cecconi et al, 2009b).  Two recent studies have 
confirmed good agreement between beat by beat CO measurement using this 
monitor calibrated with lithium dilution, and thermodilution or lithium dilution 
(Hamilton et al, 2002; Pittman et al, 2005; Kim et al, 2006;).  In 2 of these 
studies, measurements remained reliable without re-calibration for at least 8 
hours, but a recent investigation in critically ill patients suggests a limit of 4 
hours (Cecconi et al, 2008).  A validation study in patients with preeclampsia 
complicated by pulmonary oedema, which compared thermodilution CO 
measurements with the LiDCOplus system calibrated with lithium dilution, is 
the subject of Chapter 3 of this thesis. 
 
Three studies have demonstrated acceptable agreement between the 
LiDCOplus-derived CO and Lithium dilution (Hallowell and Corley, 2005; 
Pittman et al, 2005), or thermodilution (Yamashita et al, 2007) in the setting of 
SVR changes of up to 200%.  This system was regarded as the best device 
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for the demonstration of rapid haemodynamic changes which occur during SA 
for CS, and following the administration of vasopressors and oxytocin during 
this procedure.  The limitations of other available devices for CO 
determination in the setting of obstetric anaesthesia are the subject of a 
recent editorial (Dyer and James, 2008). 
2.3.2. Transthoracic electrical bioimpedance (TEB) techniques 
 
In studies examining short term haemodynamic changes in response to SA, 
vasopressors and oxytocin, described in Chapters 5 and 7 in this thesis, 
transthoracic bioimpedance changes were measured simultaneously with 
pulse wave form analysis using the LiDCOplus monitor.  This was done in 
order to corroborate the findings recorded by LiDCOplus in the setting of 
rapidly changing SVR. 
 
TEB CO measurements are non-invasive and provide continuous real-time 
data.  In 1966, a method of CO measurement was developed based on 
measuring impedance changes in the thorax during left ventricular ejection 
(Kubicek et al, 1966).  Clinically, an alternating current of constant magnitude, 
low amplitude (1 – 4 mA), and high frequency (50 – 100 kHz) is “injected” 
through the thoracic volume, and any changes in voltage measured by the 
sensing electrodes, are a result of changes in thoracic impedance during the 
cardiac cycle (Critchley, 1998).  The current is introduced by electrodes 
placed on either side of the neck, and via another pair on both sides of the 
lower thorax.  The potential difference is sensed by two further pairs of 
electrodes in the neck and thorax.  The impedance changes during the 
cardiac cycle are small, resulting in a low signal to noise ratio.  The algorithms 
developed depend upon three variables to calculate SV.  The first is the 
baseline impedance of the thorax (Z0).  The second factor is the maximum 
upslope of the impedance waveform at the beginning of systole (dZ/dt (max)), 
which is proportional to peak blood flow in the thorax, and the third is the 
ventricular ejection time (Critchley, 1998). 
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The basic principle is embodied in the formula: 
 
V/V = Z/Z0, 
 
Where V is the SV, V is the aortic volume immediately before the onset of 
systole; Z is the impedance variation during systole, and Z0 baseline 
impedance (Moshkovitz et al, 2004). 
 
A calibration factor is employed, which represents the volume of conducting 
thoracic tissue, and which depends upon thoracic shape and the resistance of 
the blood.  In the generation of devices developed by Bernstein and Sramek 
in the 1980’s, the BoMed NCCOM3 series, the thorax is treated as a truncated 
cone.  The BioZ device, employed in the studies described in Chapters 5 and 
7, is a stand-alone version of the BoMed NCCOM3, with an analogue visual 
display and digital signal processing.  The mathematical basis of the algorithm 
employed depends upon a modification of the original formula employed by 
Kubicek (Bernstein, 1986). 
 
Many validation studies have been performed comparing TEB with invasive 
CO determination.  Most deal with accuracy and repeatability, and few 
examine the ability to produce trend data, which was the goal in the studies 
described in Chapters 5 and 7.  Several reports using the BioZ device have 
shown good correlation with the thermodilution and Fick methods, but results 
are not consistent, with correlation coefficients varying from 0.71 - 0.82 
(Raaijmakers et al, 1999).  Disadvantages of TEB devices include movement 
artefact, and inaccuracies in the setting of thoracic fluid overload, making the 
use of TEB devices unreliable in critically ill patients.  Further inaccuracy 
arises in patients with valvular heart disease, intra-and extracardiac shunts 
and tachyarrhythmias (Moshkovitz et al, 2004). 
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Several studies have examined the validity of TEB techniques in the pregnant 
patient.  Using the BoMed NCCOM3 device in a study of 9 patients requiring 
pulmonary artery catheterisation for peripartum management, good 
agreement was reported in 8 cases (+/- 20%) (Masaki et al, 1989).  Fair 
agreement was found in a study of 15 patients with preeclampsia, comparing 
the BioZ device with echocardiographic M-mode estimates of CO (Scardo et 
al, 2000).  In a comparison of the BoMed NCCOM3 device with oxygen 
extraction estimates of CO, good agreement was demonstrated.  However 
bioimpedance estimates were only reliable in the lateral recumbent positions 
(Clark et al, 1994).  In the field of obstetric anaesthesia, two studies have 
used whole body impedance cardiography during SA for CS (Tihtonen et al, 
2005; Tihtonen, 2006).  A further investigation employed a TEB device to 
demonstrate the haemodynamic effects of oxytocin during this procedure 
(Pinder et al, 2002).  In healthy parturients for elective CS, the BioZ 
instrument was considered an appropriate device for comparison of short term 
trends in CO, in order to corroborate the results obtained from the LiDCOplus 
device in the setting of rapid changes in SVR (Chapters 5 and 7). 
 
2.4. Research Ethics 
All studies contributing to this thesis were conducted in keeping with ethical 
guidelines for research in obstetric anaesthesia (Yentis, 2001).  Informed 
consent was obtained from all study participants.  All studies were approved 
by the Ethics Committee of the University of Cape Town, Faculty of Health 
Sciences.  In each case, the purpose of the study was explained to the patient 
in a sensitive manner, and relevant written information was supplied in 
English, Afrikaans or Xhosa.  In the case of Xhosa speaking patients, trained 
translators fluent in Xhosa were present at the recruitment interviews, in order 
to ensure a full understanding of the study.   
 
In one of the studies, there were time constraints on the recruitment, in that 
CS was urgent, but not an emergency.  These patients were recruited 
immediately after the decision to proceed to operative delivery, in order to 
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allow the maximum time for an adequate explanation to the patient.  In the 
case of recruitment of a patient in labour, consent was witnessed by a 
practitioner independent of the research.  All patients recruited were assured 
that their participation was voluntary, and that declining to participate would in 
no way affect the quality of their management.  Patients were also informed 
that all data would be handled anonymously and confidentially. 
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3. Chapter 3 
A comparison between pulse wave form analysis 
and thermodilution cardiac output determination 
in patients with severe preeclampsia 
 
3.1. Introduction 
Validation of the LiDCOplus system is discussed in Chapter 2.  There are no 
validation studies in the peripartum period.  Indications for invasive monitoring 
in severe preeclampsia include pulmonary oedema, persistent oliguria, and 
hypovolaemic shock (American College of Obstetricians and Gynecologists, 
1993; Martin and Foley, 2006).  The pulmonary artery catheter (PAC) provides 
valuable haemodynamic data in this setting, in particular pulmonary capillary 
wedge pressure, CO, SVR and mixed venous oxygen saturation.  A 
knowledge of these variables guides management decisions on fluid, diuretic 
and vasodilator therapy, which affect morbidity and mortality.  The insertion of 
the PAC is however an invasive procedure, with well described complications, 
particularly in patients with thrombocytopaenia (Young and Johanson, 2001).  
It would thus be desirable to use a minimally invasive monitor of CO in this 
setting. 
 
A prospective validation study was thus undertaken in patients who had had a 
PAC placed for the management of complications of severe preeclampsia in 
the immediate postpartum period.  In view of the fact that only approximately 
0.5% of patients with severe preeclampsia who are admitted to the Groote 
Schuur Hospital Maternity Unit require a PAC, the study period was 3 years, 
during which time 18 patients were recruited. 
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3.2. Patients and methods 
After approval from the University of Cape Town Ethics Committee, informed 
written consent was obtained for the use of the LiDCOplus monitor in 18 
patients in whom a PAC (Edwards Life Sciences, Irvine, CA, USA) had been 
introduced via the right internal jugular vein, to assist in the medical 
management of complicated severe preeclampsia.  Arterial cannulation had 
been performed in all cases to assist blood pressure control and for arterial 
blood gas determinations, before recruitment into the study.  The aim of the 
study was to establish the bias and limits of agreement between CO 
measurements using the two monitors, after central and peripheral venous 
calibration with lithium chloride.  In addition, the comparison was continued in 
8 patients for up to 4 hours after peripheral calibration, in order to establish 
whether there was a time-based effect necessitating re-calibration. 
 
The protocol for the comparison between the CO measurements was as 
follows:  During stable haemodynamic conditions (< 15% change in heart rate 
and MAP for 3 minutes), two calibrations, 5 minutes apart, were performed 
with 0.3 mmol lithium chloride administered via the central venous pressure 
port of the PAC.  If the calibration factors differed by more than 15%, a third 
determination was performed, and the average calibration factor of the two 
closest readings used for subsequent beat by beat estimation of the CO from 
the LiDCOplus monitor.  Four consecutive thermodilution (TD) determinations, 
one minute apart, were then performed via the central venous port of the 
PAC, using cold saline.  The three closest values were averaged and 
recorded.  This step was repeated twice at 15 minute intervals.  At each 
epoch, the CO obtained from the TD measurements was compared with the 
mean of the LiDCOplus values averaged during the 30 seconds subsequent 
to the injection of the cold saline for the TD measurements.  The LiDCOplus 
monitor was then re-calibrated by an identical method using lithium chloride 
injection via a forearm vein, and the comparison with the TD method repeated 
as described above.  In addition, further comparisons were performed in 8 
patients at 120 and 240 minutes after peripheral venous calibration.  
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Statistical Analysis: 
A linear mixed effects regression model was used to examine the CO method 
(LiDCOplus and TD), calibration method (central and peripheral venous) and 
measurement time epochs, and the possible interactions of these factors.  
This model takes into account the repeated measurements done in each 
patient.  The patient was specified as the random effect.  The difference 
between methods at each time point or for pooled data was estimated by least 
square means based on the model specified.  Since there was an interaction 
between CO method and calibration method, separate analyses were done for 
each route of calibration.  The comparison between CO methods at 120 and 
240 minutes after peripheral calibration also employed a linear mixed effects 
regression model and this analysis included all the measurement time epochs 
in all patients to improve precision and power. 
 
The mean values for LiDCOplus and TD were compared during each 
measurement time epoch (0, 15 and 30 minutes).  Using the method 
described by Bland and Altman for assessing agreement between 
measurement techniques (Bland and Altman, 1986), differences between 
LiDCOplus and TD CO determinations were plotted against the mean values 
for these pairs at each measuring point.  The bias (mean difference) and limits 
of agreement (bias ± 2 SD of the difference) were determined and used to 
summarise the level of agreement between the methods. 
 
3.3. Results 
Eighteen patients were recruited during the period April 2006 – March 2009.  
These patients were admitted to the Special Care Unit at the Maternity Centre 
at Groote Schuur hospital, Cape Town with complications of severe 
preeclampsia.  The indication for pulmonary artery catheterisation was a 
clinical diagnosis of pulmonary oedema in 13 cases.  Two of these patients 
had abruptio placentae.  The remaining 5 patients had oliguric renal failure.  
One of these was associated with severe Haemolysis, Elevated Liver 
Enzymes and Low Platelets (HELLP) syndrome, 3 with abruptio placentae 
and 1 with a ruptured uterus.   
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No patients were mechanically ventilated during the study.  The median 
(range) time post-delivery at recruitment was 48 (24-96) hours. 
 
Five patients required 3 central venous calibrations, and 6 required 3 
peripheral venous calibrations.  For central and peripheral lithium calibration, 
the data from 17 of 18, and 16 of 18 recruited subjects respectively, were 
analysed.  In one exclusion, peripheral oedema precluded adequate flow for a 
peripheral calibration curve, and in the other, the arterial cannula was 
dislodged by a restless patient. 
 
A description of mean values for the two CO methods at the specified 
measurement time epochs, appears in Table 3.1. 
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Table 3.1. Mean cardiac output values for each cardiac output method 
and calibration method at the specified measurement time epoch 
CO 
Method 
Calibration 
method 
Time 
(min) 
N Mean CO 
(L/min) 
SD Minimum Maximum 
LiDCO Peripheral 0 16 7.27 1.63 3.9 10.4 
  15 16 7.36 1.65 4.0 10.5 
  30 16 7.41 1.72 4.1 10.4 
  120 7 7.38 1.74 5.2 9.7 
  240 7 7.66 1.65 4.9 9.4 
 Central 0 17 7.16 1.48 3.6 9.4 
  15 16 6.87 1.38 3.6 8.9 
  30 17 7.00 1.49 3.7 9.1 
TD Peripheral 0 16 7.49 1.43 4.3 9.6 
  15 16 7.44 1.44 4.3 10.1 
  30 16 7.57 1.58 4.4 11.0 
  120 7 7.57 1.52 5.4 9.2 
  240 7 8.14 1.93 5.2 11.1 
 Central 0 17 7.75 1.52 4.2 9.2 
  15 16 7.55 1.58 4.1 10.8 
  30 17 7.47 1.44 4.3 9.8 
 
 
There was no time based effect associated with the comparison between 
LiDCOplus and TD for the time epochs 0, 15 and 30 minutes after calibration.  
There was a significant difference between the comparisons between 
monitors, related to whether calibration was central or peripheral.  For the 
comparison between TD and LiDCOplus employing central venous calibration, 
TD exhibited a significant positive bias.  After peripheral venous calibration, 
there was no significant bias between the methods. 
 
Since the bias or lack thereof was consistent with time, data were pooled for 
the epochs 0, 15 and 30 minutes.  Scatter plots of individual CO 
measurements by LiDCOplus versus TD are shown in Figures 3.1. and 3.2., 
and Bland – Altman plots are depicted in Figures 3.3. and 3.4.  The estimated 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 3 
37 
 
limits of agreement for central venous and peripheral venous calibration were 
-2.12 to 0.96 and -1.50 to 1.20 L/min respectively. 
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Figure 3.1. Scatter plot of individual cardiac output measurements at 0, 
15 and 30 minutes post central venous calibration 
 
 
Figure 3.2. Scatter plot of individual cardiac output measurements at 0, 
15 and 30 minutes post peripheral venous calibration 
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Figure 3.3. Bland and Altman comparison between thermodilution and 
LiDCOplus after central venous calibration  
Bias -0.58 L/min, 95% confidence interval: -2.12 to 0.96 L/min 
 
 
 
Figure 3.4. Bland and Altman comparison between thermodilution and 
LiDCOplus peripheral venous calibration 
Bias – 0.16 L/min, 95% confidence interval: - 1.5 to 1.2 L/min 
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Of the 8 patients in whom the measurements were continued to 120 and 240 
minutes after peripheral calibration, the data from 7 were analysed.  (In one 
patient peripheral calibration was performed before central venous calibration, 
in error).  Employing a linear mixed effects regression model, differences in 
mean CO at the specified measurement times, were derived (Table 3.2.).  
When comparing LiDCOplus and TD, there was no time based effect at 120 or 
240 minutes post calibration. There was a significant time effect overall with 
the 0,15, and 30 minutes mean values being significantly lower than the CO 
mean at 240 minutes. 
 
Table 3.2. Differences in cardiac output at the specified measurement 
time epochs (least squares means) 
Time Difference in CO 
(LiDCOTD) 
P-value 95% CI lower 95% CI upper 
0 0.23 0.30 0.65 0.20 
15 0.08 0.71 0.51 0.35 
30 0.16 0.45 0.59 0.27 
120 0.19 0.57 0.84 0.46 
240 0.49 0.14 1.14 0.16 
 0.23* 0.06 0.46 0.01 
 
*Mean value over 5 measurement times 
CI = confidence intervals 
 
3.4. Discussion 
This study is the first in the peripartum period to compare CO measurements 
obtained from TD, with central and peripheral lithium chloride calibration of the 
LiDCOplus device.  In addition, the effect of time on the agreement between 
TD and LiDCOplus measurements after peripheral calibration, was examined. 
 
Three studies in the non-obstetric population have examined the validity of the 
peripheral versus central venous route for calibration (Jonas et al, 1999; 
Garcia-Rodriguez et al, 2002; Mason et al, 2002).  All showed good 
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correlation between CO measurements obtained after central and peripheral 
venous calibration.  One investigation showed that there was better 
agreement between CO readings if the peripheral injection was made 
proximal to the wrist (Garcia-Rodriguez et al, 2002).  In the present study, the 
first in the peripartum period, the peripheral calibration injection was done via 
a forearm vein.  In only one patient was flow inadequate for calibration, due to 
severe peripheral oedema.  At least two calibrations were performed via each 
route.  This has recently been shown to improve the coefficient of variation to 
6% and allows for the detection of a change of 17% between 2 measurements 
(Cecconi et al, 2009a). 
 
The present investigation suggests that in the immediate postpartum period in 
preeclamptic patients, peripheral venous calibration is associated with an 
insignificant bias when compared with TD, and that bias is less than when 
calibration is via the central route.  Results from a previous study differed in 
that CO measurements after both central and peripheral lithium calibration 
were lower than simultaneously obtained TD measurements, by 0.53 and 0.54 
L/min respectively (Garcia-Rodriguez et al, 2002). 
 
The absence of a time based effect when comparing the monitors for the first 
4 hours after calibration, is in agreement with 2 publications from the non-
obstetric literature (Hamilton et al, 2002; Pittman et al, 2005).  A recent 
investigation in a small number of critically ill patients suggested that re-
calibration is required after 4 hours (Cecconi et al, 2008).  In all the studies 
presented in this thesis, the CO monitoring period was less than 4 hours after 
calibration. 
 
Current opinion is that a new CO technique should be accepted if the limits of 
agreement are up to 30% when compared with current reference methods 
(Critchley and Critchley, 1999).  This study showed confidence intervals of 
1.5 – 1.2 L/min, which are very similar to those quoted in a recent study on 
post cardiac surgical patients, comparing LiDCOplus to continuous cardiac 
index monitoring via a pulmonary artery catheter (± 1.3 L/min) (McCoy et al, 
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2009).  For the average cardiac output in the region of 7 L/min in the present 
study population group, this is well within the 30% range.  Although the 
confidence intervals are relatively wide, the very low bias when compared with 
the pulmonary artery catheter suggests that this form of pulse wave form 
analysis could be used in place of the more invasive monitor in the 
perioperative management of complicated severe preeclampsia.  This is 
particularly relevant in view of recent literature suggesting that the 
measurement of central venous and/or pulmonary capillary wedge pressure is 
a poor guide to fluid volume responsiveness in critical care (Kumar et al, 
2004). 
 
The comparison between bioimpedance measurements and LiDCOplus in the 
setting of short term significant changes in vascular tone (Chapters 5 and 7), 
together with the data presented in this chapter, suggest that this form of 
pulse wave form analysis may be of great value both in obstetric anaesthesia 
research, and the management of critically ill obstetric patients.  In situations 
when vascular tone is rapidly changing, trend measurements are of greater 
value than absolute values.  During stable monitoring conditions, the results 
presented in this Chapter suggest adequate accuracy for the measurement of 
absolute values. 
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4. Chapter 4 
4. Fluid management during spinal anaesthesia 
for caesarean section 
4.1. Introduction 
Although colloid is superior to crystalloid in the prevention of hypotension 
during SA for CS, its use has not been routinely adopted during CS, as 
discussed in Chapter 1.  As described in the literature review, recent literature 
has questioned the value of traditional preloading techniques prior to the 
administration of SA for CS, and has suggested that such preloading is 
relatively ineffective in the prevention of hypotension or maintenance of 
cardiac output (Ueyama et al, 1999).  Preload is rapidly redistributed and will 
have a relatively brief effect on CO, and a more rational approach might be to 
apply fluid loading at the time that the local anaesthetic block is starting to 
take effect.  This might maximise the expansion of intravascular volume 
during vasodilatation from the local anaesthesia-induced sympathetic 
blockade and limit fluid redistribution and excretion.  Therefore a study was 
designed to investigate the hypothesis that rapid administration of crystalloid 
at the time of induction of SA (coload) is associated with less hypotension 
than the administration of an equivalent volume of preload over 20 minutes.  
Of particular importance was the analysis of ephedrine requirements pre-
delivery, the time period during which the risk of maternal hypotension and 
consequent fetal acidosis is greatest. 
 
4.2. Patients and methods 
The study was approved by the University of Cape Town Ethics Committee, 
and all patients gave written informed consent.  Patients considered eligible 
for the study were those weighing less than 90kg without significant 
intercurrent disease (ASA 1 and 2 status), with a singleton pregnancy and 
presenting for elective CS under SA.  Preeclamptic patients were excluded. 
Patients were kept nil by mouth from 22h00, and received cimetidine 400mg 
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orally on the night before surgery, and again 2 hours prior to surgery.  On 
arrival in the operating theatre, 30mL of 0.3M sodium citrate was given.  A 16 
gauge intravenous line was placed, and modified ringers lactate solution 
warmed to a temperature of 38ºC was used. 
 
Patients were randomly allocated to receive either preload (Group P) or 
coload (Group C), according to an allocation card contained within a sealed 
envelope.  After urinary catheterisation, patients were placed in the left lateral 
position, and initial non-invasive MAP (DinamapTM, Critikon) and HR 
measurements performed (Table 4.1.).  The patient then received either a 
preload of 20 mL/kg of modified Ringer’s lactate (Group P) over a period of 20 
minutes, or no fluid (Group C).  One complete litre bag was infused; the exact 
fluid volume from the second bag was determined by prior removal of excess 
fluid into a measuring cylinder. 
 
Immediately before starting SA, three MAP readings were taken in the left 
lateral position, with the cuff positioned at the level of the heart, at intervals of 
one minute.  The average of the MAP (Table 4.1.) formed the baseline for 
later interventions.  SA was induced in both groups using 0.5% hyperbaric 
bupivacaine 9mg and fentanyl 10µg (total volume 2.0mL) injected slowly over 
20 seconds at the L3/4 level with a 25G Sprotte pencil-point needle (B Braun).   
At the time of identification of cerebrospinal fluid, Group C patients received 
an identical fluid load to that given to Group P of 20 mL/kg.  A pressurised 
giving set was opened to the patient, to administer the fluid at the maximal 
possible rate.  Patients in both groups were then positioned supine, with 15 
degrees of left lateral tilt and no additional fluid was given other than a very 
slow infusion to ensure continued patency of the IV line. 
 
Non-invasive blood pressure measurements were recorded in both groups at 
one minute intervals from the start of the regional block for the first 20 
minutes, and then at 3 minute intervals until the completion of surgery.  At 
least two further readings were taken 3 minutes apart after completion of 
surgery, and if ephedrine was still required, readings were continued until at 
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least ten minutes had passed without vasopressor.  If surgery was concluded 
in less than 30 minutes, readings were continued each 3 minutes until at least 
30 minutes or until no further vasopressor was required.  Pulse oximetry and 
electrocardiograph monitors were also used. 
 
The height of the sensory block was assessed using cold sensitivity to ethyl 
chloride spray.  Surgery was allowed to proceed after a block to T6 had been 
established, and the block level at the end of surgery was also documented 
(Table 4.2.). 
 
Interventions were as follows:  If the mean arterial blood pressure decreased 
to less than 80% of the calculated baseline value, 5mg ephedrine doses were 
administered every minute until MAP recovered to within 80% of the starting 
value.  If the blood pressure decreased to less than 70% of the calculated 
baseline value, 10mg boluses of ephedrine were administered until a return to 
within 80% of the baseline pressure occurred.  Since there was a clearly pre-
defined target MAP for vasopressor administration for each individual, the 
study was not blinded.  In the event of excessive blood loss (>800 mL as 
assessed by suction bottle and weighing of swabs), the patient was to be 
removed from the trial and treated appropriately. 
 
Time periods recorded were: 
 Time from completion of baseline arterial pressure determination to 
induction of anaesthesia (CSF time) 
 Induction to skin incision 
 Induction to uterine incision time 
 Uterine incision to delivery 
 Duration of administration of calculated coload volume 
 
At delivery all patients received 5IU of oxytocin IV, after which no ephedrine 
was administered within 3 minutes and no further oxytocin was given intra-
operatively.  Maternal urine output was noted, Apgar scores were recorded at 
1 and 5 minutes, and umbilical arterial pH and base deficit were measured 
using an automated blood gas analyser. 
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Statistical Analysis: 
Estimation of sample size was based on a pilot study in which fluid volume 
was used to assess the efficacy of the strategies in reducing the number 
ephedrine doses administered.  Power analysis, based on a 25% reduction in 
ephedrine requirement as a clinically valid endpoint, indicated that 20 patients 
per group were likely to be sufficient, so we included 25 subjects per group.  
The Null hypothesis was that there was no difference in ephedrine 
requirement.  The primary outcome variable was the ephedrine dose 
requirement in the pre-delivery period. 
 
A comparison of the number of patients in each group who did not require 
vasopressor employed the Fisher’s Exact Test.  A between-group comparison 
of median ephedrine dose and median number of doses administered before 
and after delivery in each group used Kruskal-Wallis non-parametric ANOVA.  
For the purposes of this evaluation, each 5mg increment of ephedrine was 
regarded as a unit dose.  The ephedrine dose administered at each time 
period, in each group, was analysed using ANOVA for repeated measures.  
Maternal haemodynamic recordings at the various time-points were compared 
using repeated measures ANOVA.  Once significant differences between 
groups had been defined, individually significant data points were identified 
using Fisher's LSD test.  Maternal age, height and weight were compared 
using a t-test, the level of block using a Mann Whitney U Test and neonatal 
acid-base data using unpaired Student’s t-tests. 
 
Statistical significance was assumed at a P-value of <0.05. 
 
4.3. Results 
Demographic data and baseline blood pressures are presented in Table 4.1.  
No patients were withdrawn, leaving 25 patients in each group.  There were 
no significant differences between groups with respect to demographic 
variables.  Fluid loading resulted in no significant change in MAP in group P 
(1.6 (6.2) mmHg), and during the equivalent rest period in Group C there a 
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non-significant decrease (2.9 (5.2) mmHg).  The target arterial pressures 
(baseline) to guide ephedrine administration were not significantly different. 
 
Table 4.1. Demographic data, initial and baseline arterial pressures 
 
Preload  
(n = 25) 
Coload  
(n = 25) P-value 
Age (years) 26.8 (4.9) 27.4 (6.0) 0.32 
Weight (kg) 73.3 (10.2) 66.8 (13.7) 0.89 
Height (cm) 156.6 (6.6) 158.4 (6.8) 0.16 
Gravidity (median, range) 2(1-3) 2(1-5) 0.49 
Parity (median, range) 1(0-3) 1(0-4) 0.60 
Initial MAP (mmHg) 81.8 (7.6) 80.4 (9.4) 0.65 
Baseline MAP (mmHg) 83.5 (8.9) 77.5 (9.4) 0.07 
 
Values are mean (SD), unless stated 
 
Data pertaining to fluid and anaesthesia management appear in Table 4.2.  
There were no between-group differences in crystalloid volume infused, in 
keeping with the study design.  The coload was administered over a 
significantly shorter period of time, according to protocol (20 vs. 9.8 minutes, 
P-value = 0.01).  There were no between-group differences in any of the other 
clinically relevant time intervals recorded.  Two patients in each group 
experienced nausea.  Neonatal data were similar (Table 4.3.). Un
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Table 4.2. Fluid and anaesthesia data 
 Preload Coload P-value 
Volume infused (mL) 1474(206) 1386(177) 0.13 
Duration of infusion (min) 20(0) 9.8(4) 0.01 
CSF Time (min) 4.8(2.0) 5.2(3.5) 0.58 
Induction to skin incision (min) 7.0(1.9) 7.6(2.3) 0.39 
Induction to uterine incision (min) 11.6(3.8) 13.1(3.8) 0.16 
Uterine incision to delivery (min) 1.3(0.8) 1.4(0.6) 0.76 
Duration of anaesthesia (min) 31(11) 34(7) 0.23 
Duration of surgery (min) 24(10) 27(7) 0.34 
Block height (median (range)) T3(T1-T6) T4(T2-T5) 0.09 
Blood loss (mL) 351(87) 382(101) 0.25 
Urine output (mL) 223(100) 173(89) 0,07 
 
Values are mean (SD), unless stated 
 
Table 4.3. Neonatal data 
 Preload Coload P-value 
Neonatal weight           
(g)(mean (SD)) 
2969 
(426) 
3140 
(534) 0.28 
Apgar score 1 minute 
(median(range)) 
9 
(5-9) 
9 
(6-9) 0.96 
Apgar score 5 minutes 
(median(range)) 
10 
(9-10) 
10 
(9-10) 0.82 
Umbilical arterial pH       
(range) 
7.34 
(7.21-7.4) 
7.35 
(7.28-7.42) 0.76 
Umbilical arterial base deficit 
(mmol/L)(median (range)) 
0.32 
(-4.9-4.5) 
1.11 
(-6-1.9) 0.99 
 
There were significant differences between groups in MAP at 7, 8 and 9 
minutes after the induction of SA (Figure 4.1.).  Results for vasopressor 
management appear in Table 4.4.  The median cumulative dose of ephedrine 
required by Group C was significantly lower in the pre-delivery period (0 [0-10] 
vs. 10 [0-20] mg, P-value = 0.03).  There were no significant differences 
between groups post-delivery or for total dose.   
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There was no significant difference between groups in the median number of 
unit doses of ephedrine required (P-value = 0.054), but Group C required a 
significantly lower number of unit doses pre-delivery (0 vs. 2, P-value = 0.04) 
(Figure 4.2).  There were significant between group differences in the dose 
used at 2, 3, 4 and 6 minutes post induction of anaesthesia (Figure 4.3).  
Significantly more patients in Group C did not require ephedrine in the pre-
delivery period (P-value = 0.047).  There was a trend to more patients in 
Group C not requiring vasopressor during the entire procedure (P-value = 
0.057) (Table 4.4.).  
 
Both groups showed an increase in HR with fluid loading.  In Group P, the 
mean maximum increase in HR (22.3 +/-19.8 beats per minute) occurred 4 
minutes after the end of fluid administration.  In Group C, the mean maximum 
increase (16.2 +/- 16.1 beats per minute) occurred at 7 minutes after 
commencement of the fluid load.  From 8 minutes after induction of 
anaesthesia, the increase in HR did not differ from baseline value in either 
group. 
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Figure 4.1. Mean (SD) arterial pressure during study period 
Pre = Mean arterial pressures prior to fluid loading 
Post = Mean arterial pressures prior to the performance of SA 
*P-value < 0.05 
 
 
Table 4.4. Vasopressor management 
 Preload Coload P-value 
Ephedrine cumulative dose (mg) 20(10-30) 5(0-20) 0.052 
Pre-delivery (mg) 10(0-20) 0(0-10) 0.03 
Post-delivery (mg) 5(5-15) 0(0-15) 0.49 
Ephedrine total number of unit doses 4(0-15) 1(0-12) 0.054 
Ephedrine unit doses pre-delivery 2(0-13) 0(0-5) 0.04 
Number of patients not requiring 
ephedrine pre-delivery 9/25 16/25 0.047 
Number of patients not requiring 
ephedrine for entire procedure 4/25 10/25 0.057 
 
Values are median (interquartile range) 
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Figure 4.2. Ephedrine doses pre-delivery 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Ephedrine dose (mg) at each time point  
*P-value < 0.05 (adjusted for multiple comparisons) 
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4.4. Discussion 
This study found that, in the pre-delivery period when the parturient is most at 
risk for hypotension after SA, patients receiving a rapid crystalloid infusion 
immediately after the induction of anaesthesia (coload), required significantly 
less ephedrine than those receiving a conventional preload.  This was 
represented by a reduction in both the cumulative mean and number of unit 
doses of ephedrine administered.  In addition, more of these patients required 
no ephedrine pre-delivery.  
 
The physiological objective during SA for CS is the maintenance of CO, and 
more specifically uteroplacental blood flow, although blood pressure is usually 
used as a surrogate index of CO. A judicious combination of fluid loading and 
vasopressor therapy appears the most logical method of obtaining this 
objective.   
 
Current methods of crystalloid loading have in general been ineffective in the 
prevention of hypotension, and the concept of preloading has been called into 
question (Pouta et al, 1996b; Rout et al, 1999; Morgan et al, 2001).  One 
study concluded that preloading only reduced the incidence of hypotension 
from 71% to 55% when compared with patients receiving no preload (Rout et 
al, 1993b).  The authors recommended delay for the purpose of administration 
of a preload is not justified before elective CS. 
 
As discussed in Chapter 1, colloid solutions are more effective in the 
prevention of hypotension.  This is due to the fact that colloid solutions are not 
as rapidly redistributed to the extracellular compartment, thus better 
maintaining intravascular volume and hence CO. Significant increases in 
central venous pressure have been noted after both crystalloid and colloid 
preloading (Karinen et al, 1995), but there have been no reports of pulmonary 
oedema in any study (Morgan et al, 2001). 
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In an evaluation of the duration of infusion of a crystalloid preload prior to SA 
for CS, increases in HR were less, and HR returned to baseline in a shorter 
period in patients receiving their preload over 10 minutes than over 20 
minutes (Rout, 1992a).  This suggested a benefit in administering the fluid 
closer to the time of induction of SA.  In the current study, HR changes were 
similar to those described above, in that there was a rapid onset of a lesser 
increase in HR with a shorter duration in patients who received their fluid load 
over a shorter time period, after induction of anaesthesia (Group C). 
 
In the non-obstetric population, a sustained rise in CO was demonstrated in a 
group of patients given lactated ringer's solution after the initiation of SA 
(Kamenik and Paver-Erven, 2001).  A kinetic analysis of an IV infusion of 
Ringer’s lactate solution as preload, suggested that a rapid fluid administration 
over 2 minutes after induction of both spinal and general anaesthesia for non-
obstetric surgery, might prevent hypotension caused by central hypovolaemia 
(Ewaldsson and Hahn, 2005).  A study of the timing of fluid loading in general 
and specialty surgery patients, excluding pregnant women, reported no 
difference in the incidence of hypotension between groups given no fluid, a 
fluid preload over 20 minutes, or an identical fluid load at the time of spinal 
blockade.  However, there was a reduction in the incidence of side effects 
attributable to cardiovascular instability following fluid loading coincident with 
induction of SA, while administration of crystalloid prior to the performance of 
the block failed to prevent these side effects (Mojica et al, 2002). 
 
In keeping with clinical practice and the aforementioned study (Mojica et al, 
2002), baseline blood pressure in the current study was measured 
immediately before the initiation of SA.  Immediately following preload, there 
was a small increase in MAP in Group P, while Group C showed a slight 
decline in pressure during the rest period.  However, the target blood 
pressures were not significantly different.  There were no significant 
differences between groups in MAP for the first 6 minutes after induction of 
SA (during which period significantly more ephedrine was administered to the 
preload group [Figure 4.4.]).  The arterial pressure was statistically 
significantly, lower in the coload group over a three-minute period from 7 to 9 
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minutes, but this was not clinically relevant.  This confirms that less ephedrine 
was required pre-delivery in the coload group in order to maintain similar 
blood pressure to the preload group. 
 
This study suggests that, in comparison with the prior administration of an 
identical fluid load, there is a maternal advantage in administering crystalloid 
rapidly at the time of induction of SA.  In the absence of a control group 
receiving no intravenous fluid loading, it is possible that the results may be no 
better than if no preload were given.  The rapid redistribution of a crystalloid 
preload implies that the most logical time to give such fluid is at the time of 
maximal risk of hypotension, which is immediately after the performance of 
the spinal anaesthetic.  The diminution of benefit after delivery in the coload 
group may reflect this redistribution of crystalloid during this period.  The 
delayed increased requirement for ephedrine in the coload group is not of 
clinical concern, since it occurs after delivery.  
 
Neonatal umbilical arterial pH values were similar and base deficit values 
within normal limits in both groups.  The good pH status of the neonates at 
delivery (pH values higher than in a recent meta-analysis of neonatal blood 
gas values [Lee et al, 2002]), may reflect the fact that only healthy parturients 
with no co-morbidity were studied, and that the induction to delivery and 
uterine incision to delivery times were short.  It is noteworthy that there were 
no between-group differences in this study, despite a higher ephedrine 
requirement in the coload group. 
 
In conclusion, an equivalent volume of crystalloid administered rapidly, 
immediately after the performance of SA for elective CS, is associated with a 
lower pre-delivery requirement for the vasopressor ephedrine than 
conventional preload.  The technique of coloading did not appear to 
disadvantage the neonate.  In view of the fact that colloid has not been 
universally adopted for the reasons discussed, crystalloid coloading appears 
the best option for fluid administration during elective CS. 
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5. Chapter 5 
5. Haemodynamic effects of spinal anaesthesia 
and vasopressors during elective caesarean 
section   
 
5.1. Introduction 
 
Anaesthesiologists conventionally use HR and noninvasive blood pressure 
recordings, as well as patient symptoms, to assess patient wellbeing during 
SA for elective CS.  Vasopressors are used to restore blood pressure to 
baseline values.  However, both from the maternal and fetal point of view, the 
preservation of CO may be as important.  A complete understanding of the 
haemodynamic responses to SA and to the administration of vasopressors 
would thus be of importance in the appropriate choice of vasopressor and 
dose in this clinical situation. 
 
The greater degree of neonatal acidosis and higher incidence of maternal 
side-effects, particularly nausea and vomiting, associated with the use of 
ephedrine, has led to a change in practice and a resurgence of the use of 
phenylephrine for spinal hypotension (Macarthur and Riley, 2007).  There 
have been very few investigations comparing the effects of the two 
vasopressors on maternal cardiovascular indices other than HR and blood 
pressure, during SA for CS.  Only three previously published studies, 
employing intermittent suprasternal Doppler flow measurements, have 
compared CO changes using the two vasopressors.  In the first, which 
compared bolus doses of the vasopressors, bradycardia in the phenylephrine 
group was treated with atropine, which makes the results difficult to interpret 
(Thomas et al, 1996).  The primary outcome variable in this study was 
umbilical artery pH, and not maternal haemodynamic changes.  The second 
study, employing infusions of vasopressors, suggested that phenylephrine 
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may depress maternal CO (Ashpole et al 2005).  Most recently, phenylephrine 
infusions at 100 g/minute were shown to reduce maternal CO by 20% 
(Stewart et al, 2008).  There have been no investigations employing beat by 
beat CO measurements.  Such measurements would give an exact 
description of the temporal framework of haemodynamic changes following 
the administration of the two vasopressors.  There is currently a situation of 
equipoise with regards to the use of the two vasopressors, as far as the 
restoration of maternal blood pressure is concerned.  The hypothesis was that 
phenylephrine, but not ephedrine, decreases CO when administered in 
response to hypotension during SA for CS.  Phenylephrine might be the better 
agent to restore SVR to normal where hypotension is associated with 
vasodilatation and a partial compensatory increase in CO in response to SA 
(Langesaeter et al, 2008).  Ephedrine may be preferable when marked 
hypotension and bradycardia occur, indicating  a decrease in CO.  The goal of 
management should be to maintain baseline maternal cardiac output and thus 
maintain blood pressure. 
 
The primary outcome of this prospective randomised, double blind study was 
thus a comparison of the time based effects on maternal CO of bolus 
administration of the vasopressors phenylephrine and ephedrine during SA for 
CS.  The LiDCOplus monitor was employed for the study.  In addition, a 
monitor of transthoracic bioimpedance changes was also used in each 
patient, in order to corroborate the results (see Chapter 2). 
 
Secondary outcomes were the effects of SA on maternal haemodynamics, a 
comparison of the effects of oxytocin on maternal CO as measured by the two 
monitors, and the effects of the co-administration of phenylephrine with 
oxytocin, in obtunding the unwanted haemodynamic effects of oxytocin.  The 
oxytocin effects are described in Chapter 7.  Also recorded were neonatal 
Apgar scores, umbilical arterial and venous pH, and base deficit. 
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5.2. Patients and Methods 
 
The study was prospective, randomised and double blind.  Forty three healthy 
patients scheduled for elective CS under SA were randomised to receive 
either phenylephrine (Group P) or ephedrine (Group E) as the initial 
vasopressor for the management of hypotension during SA.  Randomisation 
was performed at the time at which a vasopressor was first required.  Blocked 
randomisation was used (randomized block sizes of 4, 6 or 8, using nQuery 
Advisor Version 6, Statistical Solutions, Cork, Ireland), and sealed envelopes 
were prepared by the statistician.  The trigger for vasopressor administration 
was defined as a 20% decrease from baseline MAP, at any time during the 45 
minutes post induction of SA other than during the delivery and for the 3 
minutes thereafter.  In addition, a subgroup of 20 consecutive patients who 
had not received prior ephedrine were randomised to receive either oxytocin 
alone or oxytocin mixed with phenylephrine IV, after delivery.  The flow 
diagram of the protocol is shown in Figure 5.1. 
 
Exclusions were anaemia (Hb < 9g%), expected blood loss more than 700mL, 
body mass index greater than 35 kg/m2, multiple gestation, preeclampsia, 
cardiac, respiratory or renal disease, known allergy to any protocol 
medication, or age below 18 years or above 40 years.  Written informed 
consent was obtained after approval from the University of Cape Town Ethics 
Committee (Cape Town, Western Cape, South Africa).  Technical failure or 
inadequate anaesthesia requiring conversion to general anaesthesia would 
result in inclusion in the analysis of only the data collected before the time of 
the decision to proceed with general anaesthesia. 
 
A detailed consent form was supplied to the patient the day before CS, and 
the procedure was explained to the patient either by the recruiting 
investigator, or by a skilled translator.  Consent was signed a minimum of 12 
hours after the information sheet had been discussed with the patient.  Height 
(cm) and weight (kg) were measured and body mass index calculated. 
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Sodium citrate 30mL was given orally immediately preoperatively.  Prior to 
SA, intravenous access was established employing a 16G cannula, under 
local anaesthesia, and cefazolin 1g was slowly administered IV.  Standard 
non-invasive monitoring consisted of electrocardiography and pulse oximetry.  
CO measurements were derived from two independent monitors in each 
patient.  Transthoracic bioimpedance changes were monitored using the BioZ 
instrument (Cardio Dynamics International, San Diego, CA, USA).  For this 
purpose, 4 pairs of bioimpedance electrodes were placed, 2 pairs opposite 
each other in the lower anterior cervical region, and 2 pairs in the 8th to 11th 
thoracic interspace in the midaxillary line.  A 20 G radial arterial catheter was 
then placed under local anaesthesia.  The LiDCOplus monitor was then 
calibrated using lithium dilution, employing at least 2 but not more than 3 
separate determinations, 5 minutes apart.  The average calibration factor was 
calculated and entered.  Data from each consecutive pulse wave form were 
recorded on an Excel chart, from 5 minutes before SA until the end of surgery, 
or until 45 minutes after induction of anaesthesia, if the duration of surgery 
was less than 45 minutes.  Recorded data consisted of HR, systolic, diastolic 
and MAP, and CO.  Central venous pressure was given an arbitrary value of 
5mm Hg, for the purposes of calculation of SVR.  CO measurements derived 
from bioimpedance changes during left ventricular ejection, were averaged 
every 10 beats and recorded every 5 seconds on an Excel chart.  Beat by 
beat SV estimates and CO were derived from the LiDCOplus monitor using 
the proprietary algorithm.  The time-base for the two monitors was 
synchronized. 
 
Baseline pulse wave form- and bioimpedance-derived data were recorded and 
averaged during a continuous 2 minute period prior to sitting up for SA, with 
the patient in the left lateral position.  During this period, baseline MAP was 
also recorded.  Baseline MAP was taken as the mean of three consecutive 
readings at least 45 seconds apart, not differing from one another by more 
than 10 percent.  The target MAP (80% of baseline) for vasopressor 
administration was calculated from this baseline value. 
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The management of SA was as follows.  Modified Ringer’s lactate solution 20 
mL/kg was administered as a rapid crystalloid coload, initiated after 
cerebrospinal fluid appeared in the hub of the spinal needle.  Less than 
100mL of crystalloid solution was administered thereafter unless blood loss, 
estimated from suction bottle measurement and inspection of swabs, was 
excessive, in which case the patient would be excluded from treatment via the 
trial protocol, and would be treated as per the usual protocol for blood loss.  
All patients received 2.0mL of hyperbaric 0.5% bupivacaine (10mg), plus 10µg 
of fentanyl, administered over 20 seconds at the L3/4 interspace.  After 20 
seconds in the sitting position, patients were positioned supine, with at least 
15 degrees of left lateral tilt, to minimize aortocaval compression.  Block 
height was assessed using cold sensitivity to ethyl chloride spray.  No 
supplemental oxygen was administered unless oxygen saturation decreased 
to less than 92%.   
 
The anaesthesiologist, blinded to the LiDCOplus and BioZ measurements, 
responded to HR and MAP changes as is normal clinical practice during SA 
for CS.  One 5mL syringe containing the randomly assigned vasopressor, and 
another containing the alternative vasopressor (i.e. either phenylephrine 80 
µg/mL, or ephedrine 10 mg/mL in water) were prepared by an 
anaesthesiologist not involved with the intraoperative management.  If MAP 
decreased by 20% from the baseline value, 1mL of the randomLy assigned 
vasopressor was administered every 60 seconds until MAP recovered to 
within 20% of baseline.  Randomisation would thus only be done at the point 
when a vasopressor intervention was indicated.   
 
Should MAP continue to decrease to 40% below baseline after 45 seconds, a 
rescue dose of the same vasopressor would be given.  Should MAP not be 
restored to within 20% of baseline after 2 successive doses of vasopressor 
within 2 minutes, the alternative vasopressor would be used, according to the 
same protocol.  The anaesthesiologist performing SA was blinded to the 
vasopressor used.  Should HR decrease to less than 55 beats per minute in 
association with severe hypotension (30% below baseline), atropine 0.5mg 
and ephedrine 10mg would be administered.  In the event of severe 
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hypotension unresponsive to atropine and ephedrine, adrenaline would be 
administered in titrated boluses.  After a total of 5 doses of the same 
vasopressor, if MAP again decreased by more than 20% of baseline, the 
alternative vasopressor was used.  No patient was to be given more than 5 
doses of ephedrine (50mg), since this would be interpreted as tachyphylaxis. 
 
Thirty seconds after delivery, 2.5IU of oxytocin in 10mL water, was 
administered IV over a period of 30 seconds, to all patients receiving 
ephedrine prior to delivery, and to all other patients except for a subgroup of 
20 consecutive patients not having received ephedrine prior to delivery.  
These 20 patients were randomised to receive IV either 2.5IU of oxytocin, or 
2.5IU of oxytocin mixed with 80µg phenylephrine in 10mL water.  All data 
pertaining to oxytocin administration are presented in Chapter 7.  
  
Intraoperative blood loss was estimated from suction bottle measurements 
and inspection of swabs.  Neonatal Apgar scores, umbilical arterial and 
venous pH and base deficit, and neonatal weight were recorded. 
 
Statistical Analysis  
The primary outcome variable was the change in CO in response to the initial 
dose of vasopressor.  A pilot study in our institution employing the LiDCOplus 
monitor, involving the use of ephedrine and phenylephrine during SA for CS in 
patients with severe preeclampsia, suggested that a between-group difference 
in mean CO change would approximate 0.4 L/minute.  A sample size of 17 in 
each group would have 80% power to detect a difference in means of 0.4 
L/minute, assuming that the common standard deviation was 0.4L using a two 
group t-test with a 0.05 two-sided significance level. Since it was expected 
that only 70% of the women undergoing elective CS would require a 
vasopressor, the study would aim to recruit a minimum of 50 women. 
 
Pre-vasopressor values were taken as the mean value for the period 30 
seconds before vasopressor administration.  Peak effect was taken as the 
mean value for the 5 seconds before and after the time of maximum change in 
CO value recorded in the 150 seconds after vasopressor administration.  The 
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mean absolute CO was calculated as the average CO over 150 seconds 
following vasopressor administration.  The peak and mean percentage 
change from pre-vasopressor values for each vasopressor were calculated.  
CO changes were related to both the pre-vasopressor value and the baseline 
value.  The area under the curve for this period was also calculated and 
compared between vasopressors.  The correlation between percentage 
change in peak CO and HR was compared using a linear regression model.  
The slopes of the group - specific regression lines of CO on HR were 
compared.  
 
A secondary outcome was the response to SA.  The haemodynamic response 
to SA was estimated comparing the haemodynamic measurements at 
baseline with those at the pre-vasopressor time interval in patients receiving 
vasopressor pre-delivery, or with average values for the 30 second period 
immediately prior to uterine incision, if no pre-delivery vasopressor was 
required. 
 
The 2-sample t-test was used for comparison of all the haemodynamic 
parameters.  The estimated mean difference and the 95% confidence 
intervals were reported.  To account for the multiple testing performed, the 
false discovery rate was controlled by applying the method of Benjamini and 
Hochberg (Benjamini and Hochberg, 1995).  The required P-value limit was 
calculated for the main and the sub-study and these bounds are indicated in 
the legends of the tables reporting the inference results. 
 
To depict the summary profile of the response to vasopressor or oxytocin 
administration in the two groups a median smooth was used.  This approach 
gave an estimate that was robust to extreme values and sensitive to acute 
changes in haemodynamic variables.  These were presented as graphic 
ensembles.   
 
The influence of the administration of vasopressor before or after delivery was 
formally evaluated by a regression analysis which included the vasopressor, 
timing and interaction effects for the mean and percentage peak values of the 
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haemodynamic parameters CO and HR during the 150 seconds after 
vasopressor administration. 
 
Using the method described by Bland and Altman (Bland and Altman, 1986) 
for assessing agreement between measurement techniques, the bias (mean 
difference) and limits of agreement (bias +/- 2 SD) between CO measured by 
LiDCOplus and transthoracic bioimpedance technology were determined and 
used to summarize the level of agreement between the methods.  CO was 
compared under baseline conditions, immediately prior to uterine incision and 
after delivery.  The first time interval was taken as averaged CO data for the 
two minute period during baseline measurements, until 30 seconds before the 
patient sat up for SA.  The second period was taken as averaged data for the 
30 seconds prior to uterine incision, and the third employed averaged data for 
one minute, starting at 40 minutes after performance of SA.  The analysis was 
based on all the women recruited into the study.  All statistical analysis was 
performed using SAS Version 12 (SA Institute Inc., Cary, NC). 
 
5.3. Results 
Forty three patients were recruited to this prospective randomized study, 
between 20th November 2007 and 11th March 2008.  The initial power 
analysis assumed that 70% of patients would require a vasopressor.  Thus 50 
patients would have been required in order to randomize 34 patients to 
vasopressor treatment.  In fact only 3 patients of the first 43 did not require 
vasopressor, so that the study could be concluded at this point, with 20 
patients in each treatment group at this time.  The primary outcome data of 
two patients in Group E could not be used.  One computer file was corrupted, 
and in the other, persistent vomiting prior to vasopressor administration 
necessitated the omission of the data.  Thus the final analysis of the primary 
outcome data compared 20 patients in Group P with 18 patients in Group E.  
No patients received both vasopressors pre-delivery.  In Group E, 9/18 and in 
Group P, 12/20 patients in the final analysis received the first dose of 
vasopressor pre-delivery (Figure 5.1.). 
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Figure 5.1. Flow diagram of the trial protocol 
MAP = mean arterial pressure 
In Group P, 13 patients required ephedrine post-delivery, and in Group E, 6 
patients required phenylephrine post-delivery as per protocol. Vasopressor 
use is summarized in Table 5.1. 
 
Patients recruited (N=43) 
Patients randomised (N=40) 
Group E (Ephedrine) 
 N=20 
 pre delivery n=9 
 post delivery n=11 
 
[0: Oxy+P] 
Group P (Phenylephrine)  
N=20 
 pre delivery n=12 
 post delivery n=8 
 
 
 
Final analysis 
N=18 (2 exclusions) 
Final analysis 
N=20 
3 patients required no 
vasopressor 
20% decrease in MAP 
Exclusion: patients receiving E 
prior to delivery 
20 consecutive patients 
randomised to Oxytocin ± P 
Oxytocin 2.5IU 
N=10 
 randomised to P prior to  delivery n=4 
 
Oxytocin 2.5IU + P 80μg 
N=10 
 randomised to P prior to delivery n=3 
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Table 5.1. Details of vasopressor use 
 
Group E (N = 20) Group P (N = 20) 
n 
Dose 
(mg) Range n 
Dose 
(µg) Range 
Ephedrine Pre (mg) 9 22.2 10-40 0 0 - 
Ephedrine Post (mg) 18 21.7 10-50 13 24.6 10-50 
Phenylephrine Pre (µg) 0 0 - 12 166.7 80-240 
Phenylephrine Post (µg) 6 293.3 80-640 20 266 80-800 
 
Demographic and relevant data pertaining to anaesthesia, surgery and 
neonatal outcome appear in Table 5.2.  Considering patients receiving 
vasopressor pre-delivery, there were significant between-group differences in 
standard bicarbonate, umbilical arterial base excess and umbilical arterial 
PO2.  There were no other between-group differences and no patients 
required analgesic supplementation.  The occurrence of nausea and vomiting 
was recorded after the first vasopressor administered.  This occurred in 4 
patients who received ephedrine as the initial vasopressor and 2 patients who 
receive phenylephrine (ns). 
 
The primary outcome of this study was a comparison of the change in CO 
following the first administration of ephedrine or phenylephrine in response to 
hypotension.  Tables 5.3. and 5.4. show haemodynamic data at baseline, at 
the time of randomisation to the vasopressor (i.e. at target mean arterial blood 
pressure, or 80% of baseline), and following vasopressor administration.  
There were no significant between group differences in any measure either at 
baseline or prior to vasopressor administration except for a small baseline 
difference in the CO as measured by the BioZ system. 
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Table 5.2. Demographic and relevant data pertaining to anaesthesia, 
surgery and neonatal outcome 
 
Group E Group P  
Mean/ 
Median 
SD/ 
Range 
Mean/ 
Median 
SD/ 
Range 
P-
value 
Height (cm) 158.4 6.5 156.6 5.7 ns 
Weight (kg) 76.9 11.8 73.7 11.8 ns 
Age (yrs) 26.4 4.1 27.1 3.7 ns 
Gravidity (n) 2 1-4 2 1-4 ns 
Parity (n) 1 0-2 1 0-2 ns 
Uterine incision (sec) 917 185 940 226 ns 
Delivery (sec) 73 28 86 33 ns 
Coload Volume (mL) 1537 234 1480 264 ns 
Coload Time (sec) 1274 435 1259 416 ns 
Block Height T3 T2-T5 T3 T2-T5 ns 
Blood loss (mL) 398 44 378 30 ns 
Apgar 1 min 9 7-10 9 9 ns 
Apgar 5 min 9 9-10 9.5 10 ns 
UA pH * 7.28 0.06 7.31 0.04 ns 
UA PCO2  * (kPa) 6.5 1.8 7.0 1.1 ns 
UA PO2  * (kPa) 2.0 0.5 1.6 0.4 0.049 
UA SBC  * (mmol/L) 18.8 2.2 21.3 2.4 0.036 
UA Base excess  * 
(mmol/L) -4.7 3.0 -1.3 3.1 0.025 
 
Delivery = Time from uterine incision to delivery 
PCO2 = partial pressure of carbon dioxide 
PO2 = partial pressure of oxygen 
SBC = Standard bicarbonate 
UA = umbilical arterial 
Uterine incision = time from induction of spinal anaesthesia to uterine incision 
* Data pertain to patients who received vasopressor pre-delivery 
(n = 9 in Group E, n = 12 in Group P) 
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Table 5.3. Baseline and pre-vasopressor haemodynamics 
 
 Group E (n = 18) Group P (n = 20)  95% CI  
Baseline Mean SD Mean SD Difference Lower Limit Upper Limit P-value 
HR Beats/min 83.6 9.8 80.4 10.7 3.2 -3.5 9.9 0.3 
MAP mmHg 90.5 10.3 91.5 10.9 -1.0 -7.9 5.9 0.8 
SV mL/beat 73.7 15.2 73.5 18.2 0.2 -10.7 11.1 1.0 
SVR Dyne.sec.cm-5 1177.5 315.6 1241.2 266.9 -63.7 -253.0 125.6 0.5 
CO(LiDCO) L/min 6.2 1.6 5.8 1.2 0.4 -0.6 1.3 0.4 
CO(BioZ) L/min 5.3 0.8 4.6 0.9 0.7 0.1 1.2 0.02 
Pre-vasopressor  
HR Beats/min 91.7 12.7 91.5 17.6 0.1 -10.1 10.3 1.0 
MAP mmHg 71.8 7.1 72.8 7.1 -1.0 -5.7 3.7 0.7 
SV mL/beat 85.7 21.0 80.2 16.1 5.5 -6.8 17.7 0.4 
SVR Dyne.sec.cm-5 746.1 272.4 782.6 169.3 -36.5 -184.1 111.1 0.6 
CO(LiDCO) L/min 7.9 2.4 7.2 1.4 0.7 -0.6 2.0 0.3 
CO(BioZ) L/min 6.1 1.1 5.7 1.6 0.5 -0.4 1.4 0.3 Un
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CI = confidence interval 
CO (LiDCO) and CO (BioZ) = cardiac output derived using the LiDCOplus and BioZ monitors respectively 
HR = heart rate 
MAP = mean arterial pressure 
Pre-vasopressor = haemodynamic values prior to the first administration of either vasopressor (at time of randomisation) 
SV = stroke volume, derived from the LiDCOplus monitor 
SVR = systemic vascular resistance 
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Table 5.4. Haemodynamic response to vasopressor administration 
 
Group E (n =18) Group P (n =20)  95% CI  
Mean SD Mean SD Difference Lower Limit Upper Limit P-value* 
Post-vasopressor  
HR          
absolute Beats/min 92.4 12.4 76.9 12.7 15.5 7.2 23.8 0.0005 
auc  59.9 812.7 -2325.0 1638.0 2384.8 1518.6 3250.9 <.0001 
peak Beats/min 97.2 13.3 67.4 11.7 29.8 21.6 38.0 <.0001 
percent-peak  % 7.0 14.8 -25.5 9.8 32.5 24.3 40.7 <.0001 
time to peak Sec 66.3 37.2 62.6 35.3 3.7 37.2 35.3 0.8 
MAP   
absolute mmHg 78.2 8.6 86.3 9.1 -8.1 -13.9 -2.3 0.008 
auc  1020.3 853.6 2104.2 1071.6 -1084.0 -1726.0 -441.7 0.002 
peak mmHg 83.3 11.6 98.5 9.6 -15.2 -22.2 -8.2 <.0001 
percent-peak  % 16.5 14.8 35.7 11.2 -19.2 -27.8 -19.2 <.0001 
time to peak Sec 89.8 38.5 61.8 35.2 28.0 3.8 52.3 0.02 
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SV  
absolute mL/beat 87.9 20.0 81.4 17.2 6.5 -5.7 18.7 0.3 
peak mL/beat 89.4 20.0 80.2 20.8 9.2 -4.3 22.7 0.4 
percent-peak  % 5.7 12.6 0.1 17.7 5.6 -4.6 15.9 0.3 
time to peak Sec 83.2 40.2 76.4 48.7 6.8 -22.8 36.4 0.6 
SVR  
absolute Dyne.sec.cm-5 782.8 265.4 1123.7 259.7 -340.9 -513.8 -168.0 0.0003 
peak Dyne.sec.cm-5 822.6 315.7 1450.5 370.0 -627.9 -855.5 -400.3 <.0001 
percent-peak  % 14.7 37.1 86.0 30.7 -71.3 -93.7 -49.0 <.0001 
time to peak Sec 83.6 46.5 35.4 17.2 48.3 25.7 70.9 0.0004 
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Group E (n =18) Group P (n =20)  95% CI  
Mean SD Mean SD Difference Lower Limit Upper Limit P-value* 
CO(LiDCO)          
absolute L/min 8.1 2.0 6.2 1.3 1.9 0.8 3.1 0.0011 
auc  26.9 150.4 -160.6 122.7 187.4 97.5 277.4 0.0002 
peak L/min 9.0 2.7 5.2 1.4 3.8 2.1 4.0 <.0001 
percent-peak  % 16.0 19.5 -27.8 10.7 43.8 33.6 54.0 <.0001 
time to peak Sec 58.8 36.2 32.2 11.1 26.6 9.4 43.9 0.0072 
CO(BioZ)  
absolute L/min 6.3 1.1 5.2 1.5 1.1 0.3 2.0 0.0111 
auc  15.9 51.1 -77.1 57.5 93.0 57.1 129.0 <.0001 
peak L/min 6.7 1.6 4.5 1.5 2.2 1.2 3.2 0.0001 
Percent-peak  % 8.5 19.3 -21.8 7.3 30.2 20.3 40.1 <.0001 
time to peak Sec 92.7 42.2 68.7 28.8 24.0 0.5 47.6 0.0459 
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Absolute = refers to the averaged change in the absolute value from pre-vasopressor value over 150 sec following vasopressor administration 
AUC = area under curve for change in variable from pre-vasopressor value for 150 sec following vasopressor administration 
CO (LiDCO) and CO (BioZ) = cardiac output derived using the LiDCO and BioZ monitors respectively 
HR = heart rate 
MAP = mean arterial pressure 
CI = confidence interval 
Peak = maximum absolute response of each variable to vasopressor 
Percent-peak = percentage change in variable from pre-vasopressor value at peak value 
Post-vasopressor = haemodynamic values after the first administration of either vasopressor 
SV = stroke volume, derived from the LiDCOplus monitor 
SVR = systemic vascular resistance 
* = false discovery rate bound is 0.0247 
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Detailed data shown pertaining to the response to vasopressor administration 
are the mean absolute values, as well as peak, and percentage change in HR, 
SV, CO, MAP and SVR, the times after vasopressor administration to the 
peak values, and the area under the curve for MAP and CO changes, during 
the 150 seconds following the first administration of vasopressor in the two 
groups.  The CO changes are shown as measured by both the LiDCOplus 
and BioZ monitors.  Following vasopressor administration, between-group 
differences in HR were significant both in absolute terms and in the 
percentage change at peak effect.  Phenylephrine was associated with a 
reduction in HR.  MAP increased in both groups with a greater increase in 
absolute and peak pressure as well as in the sustained response as 
measured by the area under the curve, in Group P.  The time to peak MAP 
was significantly shorter with phenylephrine than with ephedrine.  In both 
groups, the objective was achieved of restoring mean arterial pressures to 
within 20% of baseline.  The mean peak post-vasopressor MAP was 8% 
below the baseline value in Group E, and 8% above baseline in Group P.  SV 
was not significantly different between the two groups.  Mean CO and 
maximum absolute response in CO were significantly lower in the 150 
seconds following phenylephrine administration than after ephedrine: 6.2 vs. 
8.1 L/min, P-value = 0.001, and 5.2 vs. 9.0 L/min, P-value < 0.0001, 
respectively for pulse wave form analysis.  The corresponding values for 
bioimpedance changes were 5.2 vs. 6.3 L/min, P-value = 0.01 and 4.5 vs. 6.7 
L/min, P-value = 0.0001, respectively. 
 
Figure 5.2. and 5.3. show median HR, CO and MAP, and SVR and SV 
changes respectively, estimated by the LiDCOplus monitor, in the 150 
seconds after vasopressor.  Note that the maximum rate of change in HR was 
early after phenylephrine administration, although the time to peak change 
was longer and similar to that for ephedrine (Table 5.5).  The time to peak 
change in CO was significantly different between groups.  There was a similar 
positive correlation between CO and HR changes in each group (P-value = 
0.87 for the comparison between the regression lines) (Figure 5.4.). 
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Figure 5.5. shows a comparison of time-based changes in CO recorded by the 
LiDCOplus and BioZ monitor, in the 150 seconds after vasopressor.  
Individual responses are shown as thin grey lines, and the ensemble median 
value is depicted as a superimposed thick black line.  Both CO monitors 
showed a significant between-group difference in the percentage CO change, 
and in the same direction, following the first vasopressor administration.  The 
difference between the instruments with respect to the percentage change in 
CO was significantly different between the two vasopressor groups.  Group P 
had larger differences between the instruments than Group E (Figure 5.6.) 
and a weaker correlation between the measurements (r = 0.08, P = 0.7 and 
0.56 respectively, P = 0.015). 
 
 
 
Figure 5.2. Percentage changes from pre-vasopressor values, in cardiac 
output (CO, as measured by LiDCOplus), heart rate (HR) and mean 
arterial pressure (MAP) following the administration of vasopressor 
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Lines represent the median smooth for each parameter 
 
Figure 5.3. Percentage changes from pre-vasopressor values, in stroke 
volume (SV, as measured by LiDCOplus) and systemic vascular 
resistance (SVR) following the administration of vasopressor 
Lines represent the median smooth for each parameter 
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Figure 5.4. Scatter plot showing the correlation between the percentage 
change in peak heart rate with percentage change in peak cardiac output 
from pre-vasopressor value, after vasopressor administration 
For ephedrine r = 0.65; P-value = 0.003 
For phenylephrine r = 0.87, P-value < 0.0001 
P = Phenylephrine 
E = Ephedrine 
CO = cardiac output 
HR = heart rate 
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Figure 5.5. Ensembles of percentage changes from pre-vasopressor 
values in cardiac output as measured with the LiDCOplus and the BioZ 
monitors 
 
Each ensemble shows the percentrage chance for each patient (light gray) 
and the median smooth for the group (black) for the 150 seconds following 
administration of either ephedtrine or phenylephrine. 
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Figure 5.6. Mean percentage changes in cardiac output for the 150 
seconds following first vasopressor administration in each group as 
measured by each device 
 
Figure 5.7. shows a between-group comparison of percentage change from 
pre-vasopressor values of CO and HR in patients receiving vasopressor either 
pre- or post-delivery.  The mean and percentage peak between-group 
differences in CO and HR for the 150 seconds after vasopressor 
administration, were not significantly different pre- and post- delivery (P-value 
= 0.55 and 0.67 for mean, and 0.75 and 0.09 for percentage peak change in 
CO and HR respectively). 
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Figure 5.7. Between-group comparison of patients receiving 
vasopressor pre- or post-delivery - Percentage changes from pre-
vasopressor values, in cardiac output (LiDCOplus) and heart rate 
following the administration of vasopressor 
Lines represent the median smooth for each parameter 
CO = cardiac output 
HR = heart rate 
 
The secondary outcome of the effects of SA on haemodynamics during the 
pre-delivery period, is shown in Figure 5.8.  This is presented as a percentage 
change from baseline at the pre-vasopressor time interval in patients receiving 
vasopressor pre-delivery, or at the pre-uterine incision time interval for those 
patients not receiving vasopressor pre-delivery.  At the pre-vasopressor time 
interval CO had increased significantly from baseline values, due to an 
increase in HR and SV.  In patients not requiring vasopressor before the pre-
uterine incision time interval, CO had also increased significantly, due to an 
increase in SV alone. 
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Figure 5.8. Percentage haemodynamic changes from baseline at the pre-
vasopressor time interval in those patients who received vasopressor 
pre-delivery (n = 20), or at the pre-uterine incision time interval for those 
patients not receiving vasopressor pre-delivery 
95% confidence intervals indicated by the error bars 
HR = heart rate 
MAP = mean arterial pressure 
SV = stroke volume 
SVR = systemic vascular resistance 
CO (LiDCO) and CO (BioZ) = cardiac output derived using the LiDCO and BioZ 
monitors respectively 
# - p < 0.05 for changes from baseline in the subjects receiving vasopressor only 
 - p < 0.05 for changes from baseline for both vasopressor and no vasopressor 
subjects 
 
Bland and Altman comparison of pulse wave form analysis (LiDCOplus) and 
bioimpedance changes (BioZ) was performed at 3 measurement periods 
(baseline, pre-uterine incision, and 40 minutes post induction of SA).  The bias 
at each measurement point was 1.0, 1.0 and 1.6 L/min respectively.  The 
limits of agreement at each measurement point were -1.8 – 3.7, -1.9 – 3.9 and 
-2.0 – 5.2 L/min respectively. 
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5.4. Discussion 
This prospective randomized comparison of the effects of phenylephrine and 
ephedrine on maternal haemodynamics during SA for CS, showed that a 
bolus of 80µg phenylephrine caused a significantly lower maternal CO when 
compared to a bolus dose of 10mg ephedrine, during the 150 seconds after 
vasopressor administration.  However, the mean post-phenylephrine CO 
values remained above baseline (Tables 5.3. and 5.4.), since CO values 
immediately prior to vasopressor administration were higher than baseline.  
The two CO monitors used, based upon pulse wave form analysis and 
transthoracic bioimpedance changes, recorded similar trends in changes in 
CO after vasopressor administration.  The maximum change in HR was also 
significantly different between groups.  There was a strong correlation 
between HR and CO in both groups, following vasopressor administration.  
The peak changes in CO and MAP following phenylephrine occurred 
significantly earlier than those following ephedrine.  SVR changes after the 
vasopressors suggested a marked rise in afterload after phenylephrine.  After 
ephedrine administration, there was a sequence of a transient increase in 
afterload, followed by a transient decrease (possibly 2 mediated) and then a 
sustained increase in SVR (probably mediated by noradrenaline release) 
(Figures 5.2. and 5.3.). 
 
Haemodynamic changes associated with SA for CS are of particular 
importance to anaesthesiologists, both in terms of patient safety and comfort.  
Precipitous decreases in maternal CO, particularly when associated with 
bradycardia, may be life-threatening and place the fetus at risk of hypoxia and 
a poor neurological outcome.  Maternal hypotension is known to be 
associated with nausea and vomiting, which makes the experience of the 
delivery unpleasant for the mother.  Fluid and vasopressor use should thus be 
appropriate for the specific haemodynamic disturbance encountered.   
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Previous studies have employed intermittent measurement of maternal CO, 
using indicator dilution or suprasternal Doppler flow technology (Ueland et al, 
1968; Thomas et al, 1996; Ashpole et al, 2005).  In a randomized comparison 
of the effects of boluses of 5mg ephedrine and 100µg phenylephrine on 
maternal CO and cord gas values, overall CO changes were not different 
between groups.  These investigators used atropine in 11/19 cases of 
phenylephrine-associated bradycardia.  This makes the interpretation of the 
mechanism of CO changes difficult.  The study was primarily powered to 
detect differences in umbilical artery pH, and did not examine CO responses 
to individual boluses of vasopressor as in the current study.  In our trial, 
slowing of the HR following phenylephrine administration was not treated with 
anticholinergics if blood pressure was maintained or elevated following 
vasopressor administration. 
 
There is considerable controversy as to the dose equivalence of 
phenylephrine and ephedrine for vasopressor effect.  A recent investigation 
using continuous infusions found a potency ratio of 83:1 (Saravanan et al, 
2006).  Published studies have employed ratios varying from 20:1 to 250:1.  
Consensus was reached amongst the investigators that in our patient 
population group, a bolus of phenylephrine 80µg was equivalent to ephedrine 
10mg, a ratio of 125:1.  These were regarded as doses that would restore 
MAP to within a range of 20% above or below baseline.  The effectiveness of 
the dose may also be related to the time to peak effect.  In the current study 
phenylephrine had a peak pressor effect at 61.8 seconds, which was later 
than the peak depressant effect on CO (32.2 seconds).  The peak pressor 
effect of ephedrine was at 89.8 seconds while the peak change in CO was 
also earlier (58.8 seconds) than the peak pressor effect.  In the case of 
phenylephrine, this could be due to a gradual improvement in CO that was 
seen following the peak depressant effect (Anrep effect, see below).  In the 
case of ephedrine this could be explained by the early 1 and 2 effects, 
causing an increase in CO, followed by the indirect effect of release of 
norepinephrine from the sympathetic nerve terminals, resulting in the peak 
increase in blood pressure. 
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An early investigation of intermittent CO measurement during SA for CS, 
using indicator dilution, showed that maternal CO was significantly depressed 
in 10/12 patients and greatly improved by a change from the supine to the left 
lateral position (Ueland et al, 1968).  A more recent study employing 
intermittent suprasternal Doppler flow measurements, showed that SA 
employing a median dose of 11mg bupivacaine was associated with a 
decrease in CO of >1litre/minute in 9/16 patients (Robson et al, 1992).  A 
further trial, employing lower doses of local anaesthetic (7 and 10mg 
bupivacaine) in conjunction with subarachnoid sufentanil, demonstrated an 
increase in CO following SA, which was obtunded by the use of an infusion of 
phenylephrine at 0.25 µg/kg/minute (Langesaeter et al, 2008).  In our study, 
employing 10mg spinal bupivacaine, careful left lateral tilt, and 20 mL/kg 
crystalloid coload, there was a significant decrease in SVR, and an increase in 
HR, SV and CO from the baseline value, at the time immediately prior to 
administration of vasopressor during the pre-delivery period, or in SV and CO 
at the time of uterine incision, if no vasopressor was required by this time 
(Figure 5.8.).  In an investigation of sympathovagal balance during SA in the 
non-obstetric population, the maintenance of HR despite sympathetic 
denervation, has been attributed to concomitant diminished parasympathetic 
activity to the heart (Introna et al, 1995).  In our trial, none of the 43 patients 
developed precipitous bradycardia in response to SA, and this event, possibly 
due to reflex activation of the vagus nerve as a result of failure of ventricular 
filling (Kinsella and Tuckey, 2001), appears relatively uncommon.  A recent 
editorial examining the relative contributions of the venous and arterial 
circulation to the hypotensive effects of SA, placed equal emphasis on arterial 
dilatation as on decreased venous return (Sharwood-Smith and Drummond, 
2009).  In keeping with this view, a post hoc between-group comparison in the 
current study of the effects of vasopressor administered before or after 
delivery, suggested that the percentage changes in haemodynamic variables 
following ephedrine and phenylephrine, were independent of the time of 
administration (Figure 5.7.). 
 
From these studies it therefore appears that modest hypotension during SA 
for CS (0 – 20% decrease in baseline blood pressure) is often associated with 
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a decrease in SVR and a partial compensatory increase in CO, mediated by 
an increase in HR and SV.  This may be obtunded by the use of either low 
dose boluses or a low dose infusion of phenylephrine.  Using suprasternal 
Doppler flow measurements during SA for CS, a dose dependent reduction in 
CO has been demonstrated in parturients receiving an infusion of 
phenylephrine at 100µg per minute (Stewart et al, 2008).  Thus, these studies 
and the current investigation suggest that doses of phenylephrine large 
enough to cause marked increases in MAP above baseline, and sinus 
bradycardia, would be associated with depression of CO to below baseline 
values, and should be avoided.  The strong correlation between HR and CO 
changes after both ephedrine and phenylephrine administration, suggests that 
HR, and not MAP, is the most important surrogate marker of CO during SA for 
CS.  After an initial depression of CO by bolus phenylephrine in the present 
study, a gradual recovery of CO was observed during a period of sustained 
increase in MAP and SVR, and decrease in HR (Figure 5.2.).  The associated 
increase in SV (Figure 5.3.) could represent the Anrep effect, which is a 
positive inotropic effect that occurs during an increase in left ventricular 
afterload (von Anrep, 1912). 
 
Current literature supports the fact that the use of ephedrine as a vasopressor 
during elective CS under SA is associated with significantly more neonatal 
acidosis than phenylephrine (Cooper et al, 2002).  In keeping with this 
literature, umbilical arterial pH was lower, and base excess statistically 
significantly lower in patients receiving ephedrine pre-delivery in the current 
study (Table 5.2.).  The clinical significance remains unknown. 
 
Lithium dilution cardiac output (LiDCOTM; LiDCO, Cambridge, United 
Kingdom) is a validated minimally invasive indicator dilution technique for the 
measurement of CO (Kurita et al, 1997).  The LiDCOplus monitor is a beat-to-
beat CO monitor that calculates SV from the arterial pressure waveform using 
an autocorrelation algorithm (Chapter 2).   
 
A recent editorial outlines the rationale for the use of this device in obstetric 
anaesthesia research (Dyer and James, 2008).  In the present study, 
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specifically designed to examine short term haemodynamic changes during 
SA for CS, bioimpedance changes were concurrently measured, in order to 
corroborate the pulse wave form-derived data.  Using the Bland and Altman 
approach, the limits of agreement between absolute values of CO derived 
from LiDCOplus and BioZ were outside the recommended acceptable 30% 
(Critchley and Critchley, 1999) in the present study.  However, the agreement 
between the haemodynamic trends demonstrated by both LiDCOplus and 
BioZ in this study, in response to both vasopressors and oxytocin, provide 
further evidence of the usefulness of the pulse wave form monitor as a 
research tool for the study of acute haemodynamic changes during SA.  The 
larger differences between the instruments in Group P (Figure 5.6.), may 
reflect a tendency of bioimpedance methods to overestimate CO when SVR is 
high (Critchley et al, 2005).  There was a difference between the two monitors 
in the time to peak effect following the administration of vasopressor.  This 
may be due to the fact that the LiDCOplus derives values from the peripheral 
arterial trace, while the BioZ uses centrally measured changes in thoracic 
impedance.  The sampling rate of the two devices was also different, with the 
LiDCOplus sampling every heartbeat, while the BioZ sampled every 10 beats.  
These two effects probably account adequately for the difference in time 
intervals. 
 
In conclusion, this study showed that bolus phenylephrine produced an 
absolute reduction in maternal CO, and decreased CO when compared with 
ephedrine during elective SA for CS.  CO changes correlated strongly with HR 
changes.  HR may therefore be the best surrogate indicator of CO during SA 
for CS.  During SA, haemodynamic changes were characterized by a well-
preserved or increased CO and a marked reduction in SVR.  This suggests 
that low dose phenylephrine, insufficient to cause marked MAP increases 
above baseline associated with sinus bradycardia, may be the most 
appropriate intervention for the initial management of hypotension in most 
cases, in order to restore SVR and CO to baseline levels.  The results also 
suggest that ephedrine is the more appropriate vasopressor when 
hypotension and braycardia occur, since this combination reflects a 
decreased maternal cardiac output.  The agreement between the trends 
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shown by the two CO monitors following both vasopressor and oxytocin 
administration, lends further support to this form of pulse waveform analysis 
as a research tool. 
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5.5. Appendix 
Figure 5.9. Individual recordings of percentage change in cardiac output 
during the 150 seconds after either ephedrine or phenylephrine 
administration 
 
 
 
 
E = Ephedrine 
P = Phenylephrine 
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6. Chapter 6 
6. Haemodynamic changes associated with spinal 
anaesthesia in severe preeclampsia 
 
6.1. Introduction 
Many recent studies suggest that SA for CS is safe in patients with severe 
preeclampsia in the absence of contraindications to regional anaesthesia (Aya 
et al, 2003; Aya et al, 2005; Clark et al, 2005), Chapter 1.  Some studies have 
shown less hypotension and lower vasopressor requirements than during SA 
in healthy parturients.  One investigation found less hypotension during SA in 
severe pre-eclamptics than in preterm women in whom fetal weights were 
similar (Aya et al, 2005).  This eliminated the possibility that the more minor 
degree of hypotension was due to a lesser degree of aortocaval compression 
in preeclamptic patients.  Nevertheless, hypotension and placental 
underperfusion remain a risk (Karinen et al, 1996), and SA may be associated 
with more neonatal acidosis than general anaesthesia (see Chapter 8). 
 
Most studies have employed HR and blood pressure measurements as 
surrogate markers of maternal CO.  Although pulse and blood pressure 
measurements are of value in assessing the safety of an anaesthetic 
technique, the true goal of SA for CS is to maintain maternal CO and 
uteroplacental blood flow.  In healthy patients the maximum change in CO has 
been shown to correlate better with uteroplacental blood flow than upper arm 
blood pressure (Robson et al, 1992).  Furthermore, in severe preeclampsia a 
raised SVR could render blood pressure a poor indicator of CO, but the 
information available on such patients during SA is scanty.  It was therefore 
decided to investigate CO changes during SA for CS in severe preeclampsia.  
Our hypothesis was that SA would result in a clinically insignificant change in 
CO in these patients, other than at the time of oxytocin administration.  Also 
studied were the haemodynamic responses to vasopressors, and to delivery 
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and oxytocin.  In addition, an assessment was made of the haemodynamics of 
recovery from SA. 
 
Ultimately, a better understanding of the peri-operative haemodynamic 
changes could contribute to a reduction in peri-operative pulmonary oedema, 
renal dysfunction, eclampsia and neonatal morbidity. 
 
6.2. Patients and methods 
 
Fifteen patients were recruited to this prospective observational study of the 
haemodynamics of SA for CS in severe preeclampsia.  Preeclampsia was 
regarded as severe if the systolic blood pressure on admission exceeded 
160mmHg and/or the diastolic blood pressure exceeded 110mmHg, obtained 
on at least two separate occasions, or if the patient had symptoms of 
imminent eclampsia (namely severe headache, visual disturbance, epigastric 
pain, hyper-reflexia, dizziness and fainting, or vomiting) and proteinuria on 
urine dipstix was 3+ or worse. Patients with Haemolysis, Elevated Liver 
enzymes and Low Platelets (HELLP) syndrome were eligible for inclusion if 
the platelet count exceeded 75 x109/L. 
 
The study commenced after the approval of the Human Research Ethics 
Committee of the University of Cape Town.  Informed written consent for 
inclusion in the study was taken at the time of decision to proceed to CS.  The 
decision to proceed with operative delivery for either a maternal or a fetal 
indication, was made by the obstetric team independent of the investigators.  
Patients with severe PE, with worsening maternal disease, and requiring 
urgent but not emergency CS, were eligible for recruitment to the study. 
 
Exclusion criteria were: patient refusal, any contra-indication to SA, body 
mass index greater than 35 kg.m-2, chronic hypertension, abruptio placentae, 
placenta praevia, coagulation abnormality, thrombocytopenia (platelet count < 
75 x109/L), local or generalized sepsis, cord prolapse, <28 weeks’ gestation, 
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twin pregnancy, active labour, or a non-reassuring fetal heart trace.  Should 
any spinal anaesthetic take longer than 30 minutes to perform, the patient 
would receive general anaesthesia and be withdrawn from the study. 
  
The antepartum management was according to the established protocol of our 
institution: on admission, all patients with severe preeclampsia have an 
intravenous line placed, and receive seizure prophylaxis consisting of 
magnesium sulphate (MgSO4) as a loading dose of 4g intravenously, followed 
by 1g hourly. Volume expansion using 300 – 500 mL of hydroxyethyl starch 
precedes the use of IV dihydralazine, followed by a balanced crystalloid 
solution administered at <120 mL per hour.  Dihydralazine is administered 
intravenously, either as 2.5 mg boluses or as a continuous infusion.  If there is 
no immediate maternal or fetal indication for delivery, and gestational age is 
less than 34 weeks, the patient is admitted for in-patient expectant 
management, until an indication for delivery arises.  Oral alpha-methyldopa 
and/or nifedipine are used for blood pressure control. However if gestational 
age on admission is more than 34 weeks, delivery is expedited after 
stabilization of the mother.  If CS is anticipated, patients receive 30 mL 
sodium citrate orally in the operating room. 
 
Non-invasive monitoring consisted of electrocardiograph and pulse oximetry.  
CO measurements employed a beat to beat CO monitor that calculates SV 
from the arterial pressure waveform using an autocorrelation algorithm 
(LiDCOplus, LiDCO, London, United Kingdom) (Chapter 2).  A 20G intra-
arterial line was inserted, and calibration of the CO monitor was performed.  
Due to time constraints, one calibration was performed in 5 cases, and two 
separate calibrations, 5 minutes apart, in the remaining 10 patients.  In these 
cases, the average calibration factor was calculated and applied to the data.  
Beat by beat HR, systolic, diastolic and MAP, SV and CO were recorded in an 
Excel Workbook, from the time of calibration until the time of first request for 
analgesia.  Of primary interest in this study was the change in CO in each 
individual patient. In order to evaluate the hypothesis that SA caused no 
clinically significant decrease in CO, a 20% decrease from baseline values 
was used as the clinical criterion. 
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Placement of a central venous line is not required clinically in most patients 
with severe preeclampsia.  Therefore, central venous pressure (CVP) was 
given an arbitrary value of 5mmHg, for the purposes of calculation of SVR.  
Baseline data were obtained post hoc by averaging all haemodynamic 
parameters over the 2 – 6 minutes after calibration, with the patient in the left 
lateral position.  The MAP value for the purposes of calculation of target blood 
pressures for vasopressor administration, was recorded as the mean of three 
consecutive readings not differing from one another by more than 10 percent, 
taken in the 3 minutes prior to sitting up for the induction of anaesthesia. 
 
The management of SA was as follows:  
Intravenous crystalloid coload (modified ringer’s lactate (10 mL/kg)) was 
rapidly administered via a 16G peripheral line, initiated after cerebrospinal 
fluid appeared in the hub of the spinal needle.  Thereafter, no further fluids 
were administered unless excessive haemorrhage occurred.  All patients 
received 2.0mL of hyperbaric 0.5% bupivacaine, plus 10µg of fentanyl, 
administered at the L3/4 interspace. After 20 seconds in the sitting position, 
patients were positioned supine, with 20 degrees of left lateral tilt, to minimize 
aortocaval compression.  Block height was assessed using cold sensitivity to 
ethyl chloride spray.  All mothers received 40% oxygen by face-mask until 
delivery. 
 
Interventions were as follows:  
The first choice vasopressor was phenylephrine, administered by the 
anaesthesiologist in response to HR and blood pressure changes, as is 
normal clinical practice during SA for CS. 
 
If MAP decreased by 20% from baseline, 50µg phenylephrine was 
administered every minute until the blood pressure recovered to within 20% of 
the baseline value. No vasopressor was given if MAP was >110 mmHg.  If 
MAP decreased by 30% from baseline, 100µg phenylephrine was 
administered every minute until the blood pressure recovered to within 20% of 
baseline.  If CO did not increase by 5% above the pre-treatment level when 
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the target MAP had been reached, ephedrine boluses of 5 or 10mg were be 
administered thereafter, according to the same protocol as for phenylephrine, 
should further hypotension occur.  If any patient required more than 50mg 
ephedrine, this was interpreted as tachyphylaxis, and phenylephrine was used 
thereafter.  If HR were to decrease to less than 55 beats per minute in 
association with hypotension (MAP decrease by 30% from baseline), Atropine 
0.5mg and ephedrine 10mg would be administered, and the haemodynamic 
response recorded.  After delivery, phenylephrine (50 – 100µg), or ephedrine 
(5 – 10mg) was administered to maintain MAP within 30% of baseline 
pressure. 
 
Further interventions were as follows: 
Thirty seconds after delivery, oxytocin 2.5IU in 10mL water, was administered 
over a period of 30 seconds.  No vasopressor was administered for up to 3 
minutes after oxytocin, and no further intraoperative oxytocin was 
administered until the end of surgery, unless requested by the obstetrician in 
the case of uterine atony. 
 
Cefazolin 1g was given IV at the end of the surgical procedure.  Intra-
operative maternal blood loss was estimated from suction bottle measurement 
and checking of swabs.  Neonatal Apgar scores, umbilical arterial and 
maternal pH and base deficit, and neonatal weights were recorded. 
 
Statistical Analysis: 
Haemodynamic values were averaged for the following defined time intervals: 
 Baseline measurements 
 Sitting (time from sitting up for SA until induction of SA) 
 Spinal anaesthesia (from induction of SA until the adoption of the supine 
position) 
 Supine (from the return to the supine position until left lateral tilt) 
 Left lateral tilt (from tilt until skin incision) 
 Skin incision (from skin incision until 30 seconds before uterine incision) 
 Uterine incision (30 second time period before uterine incision) 
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 Post-delivery (the 30 second period from delivery until administration of 
oxytocin) 
 Peak oxytocin effect (from administration of oxytocin until peak effect on 
CO) 
 End of surgery (30 second time period prior to skin closure) 
 Recovery from SA (5 minute time period before request for analgesia) 
 
These absolute values were analyzed for differences from baseline using 
ANOVA for repeated measures with the Dunnett correction for multiple 
comparisons. 
 
CO was the main outcome variable considered for testing the hypothesis that 
this haemodynamic variable did not deviate by more than 20% from the 
baseline value in the individual case.  For the testing of this hypothesis, the 
period of oxytocin administration was excluded.  Descriptive statistics of the 
cardiac variables were calculated for the 11 time periods considered.  For CO 
a regression model was used to estimate the mean change from baseline to 
each of the follow-up time intervals.  This model took into account the 
repeated measurements within each patient by allowing a general variance-
covariance structure to be estimated for this purpose.  The 95% confidence 
intervals for the nine differences were adjusted to ensure an overall type I 
error rate of 5%.  This was done using the Dunnett adjustment for multiple 
comparisons of P-values and confidence intervals. 
 
The mean changes from baseline values of the other cardiac variables were 
estimated using the same approach as for CO.  The individual CO time 
profiles were plotted as well as the individual percentage change from 
baseline.  The estimated changes from baseline values at each time interval 
with the adjusted 95% confidence intervals were also plotted.  Fishers exact 
test was used to test for an association between the indicator of a decrease of 
more than 20% in CO at any time point for all patients, and the time indicator 
variable. 
 
Un
ive
sit
y o
f C
ap
e T
ow
n
Chapter 6 
94 
 
The effects of phenylephrine on each haemodynamic parameter were 
measured by averaging the effects before and after each dose in each 
patient, and then averaging between patients.  Pre-values were taken as the 
mean value for the period 30 seconds before phenylephrine administration.  
Post-values were taken as the mean value for the 5 seconds before and after 
the highest value recorded in the 3 minutes after vasopressor administration.  
A similar procedure was followed in order to estimate the haemodynamic 
changes from baseline that had occurred at the time immediately preceding 
the first administration of phenylephrine (i.e. at target MAP).  The post-
phenylephrine values were then compared to the pre-phenylephrine values 
using repeated measures analysis of variance. Data analysis was performed 
using SAS version 9 (SAS Institute Inc., Cary, NC, USA). 
 
6.3. Results 
Fifteen consecutive patients meeting the entry criteria were recruited over a 
period of 14 months.  Two patients refused consent.  Recruitment took place 
from November 2005 to January 2007, at the Maternity Centre of Groote 
Schuur Hospital, Cape Town, South Africa.  Demographic data, relevant 
preoperative drug therapy, and MAP used to calculate the target for 
vasopressor administration, appear in Table 6.1. 
 
Seven patients had had a previous CS, and four had deteriorating renal 
function evidenced by a raised serum creatinine level.  The remainder had 
worsening maternal disease with difficult control of blood pressure. 
 
Median maximum block height was T3 (range T3-T4), and block height at the 
time of request for analgesia was T8 (range T5-T10).  Mean time (SD) for 
completion of fluid infusion was 12.5 (2.6) min.  In no patient was estimated 
blood loss greater than 600mL.  Mean time (SD) from induction of SA until 
request for analgesia, was 114.5 (31.1) min.  There were no block failures.  
Only two patients had symptoms during the surgical procedure; one had 
headache and the other blurred vision and epigastric pain. 
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Table 6.1. Demographic data, relevant preoperative drug therapy, and 
baseline mean arterial pressure 
Case 
No. 
 
G 
 
P 
 
Age 
 
Wt 
 
Ht 
 
GA 
Relevant 
preoperative drugs 
MAP 
1 1 1 26 80 154 33 Mg, nifedipine 139 
2 2 2 27 77 161 36 Mg, nifedipine 147 
3 1 0 28 79 162 32 Mg, nifedipine 138 
4 4 3 40 81 163 31 Mg, nifedipine, dihydralazine, 
-methyldopa 
133 
5 1 0 23 70 160 28 Mg, nifedipine, -methyldopa 142 
6 1 0 24 102 162 33 Mg, nifedipine, dihydralazine, 
-methyldopa 
132 
7 2 1 25 100 174 31 Mg, dihydralazine 130 
8 2 1 30 70 172 37 Nil 135 
9 2 1 28 90 160 34 Nifedipine, -methyldopa 125 
10 3 2 26 69 151 33 Mg, -methyldopa 135 
11 3 1 25 77 155 33 Nifedipine, -methyldopa 138 
12 2 1 24 70 141 32 Mg, nifedipine, -methyldopa 100 
13 1 0 28 60 148 29 Mg, dihydralazine, nifedipine, 
-methyldopa 
110 
14 1 0 28 94 155 34 Nifedipine 128 
15 2 1 24 60 156 34 Mg, dihydralazine 85 
 
G = gravidity 
P = parity 
Wt = weight (kg) 
Ht = height (cm) 
GA = gestational age  
Mg = magnesium sulphate 
MAP = mean arterial pressure (mmHg) used for calculating target pressure for 
vasopressor administration (MAP-20%) 
 
Averaged haemodynamic variables at the defined time intervals are shown in 
Table 6.2.  
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Table 6.2. Haemodynamic variables with duration of time intervals for all 
patients (n = 15) 
 
Mean 
duration (sec) 
HR 
(beats/min) 
MAP  
(mmHg) 
SV   
(mL/beat) 
CO      
(L/min) 
Baseline 
 
120 – 360 
82.5    
(11.8) 
125.8 
(14.9) 
76.2  
(17.8) 
6.2      
(1.4) 
Sitting 
437          
(181) 
91.2  
(14.6)* 
132.5 
(16.1) * 
70.5  
(15.4) 
6.3      
(1.3) 
Spinal 
59              
(16) 
94.1    
(19.2) * 
127.6 
(16.8) 
69.1  
(17.6) * 
6.3      
(1.5) 
Supine 
35              
(11) 
94.5    
(19.8) * 
121.7 
(15.5) * 
77.4  
(19.1) 
7.1      
(1.7) * 
Lateral tilt 
439          
(151) 
83.5    
(15.2) 
114.0 
(17.6) * 
81.0  
(19.9) * 
6.6      
(1.5) 
Skin incision 
233          
(115) 
80.9    
(15.5) 
112.1 
(17.2) * 
81.4  
(16.2) 
6.5      
(1.5) 
Uterine incision 
 
30 
81.6    
(15.5) 
110.8 
(21.3) * 
79.2  
(16.1) 
6.4      
(1.5) 
Post-delivery 
 
30 
84.7    
(12.6) 
114.3 
(15.0) * 
82.9  
(15.9) * 
7.0      
(1.5) * 
Oxytocin Peak 
45              
(14) 
101.5 
(15.9)+ 
80.6 
(15.3)+ 
89.1  
(17.3) 
9.1    
(2.3)+ 
End surgery 
 
30 
79.5    
(11.3) 
102.3 
(13.6)* 
80.1  
(17.9) 
6.3      
(1.3) 
Recovery 
 
300 
71.6    
(11.2) * 
122.1 
(10.1) 
80.7  
(19.3) 
5.7      
(1.2) * 
 
* = Significant difference from baseline values (P-value < 0.05) 
+ = Significant difference from all other time intervals (P-value < 0.01) 
HR = heart rate 
MAP = Mean arterial pressure 
SV = Stroke volume, measured by the LiDCOplus monitor 
CO = Cardiac output 
SVR = Systemic vascular resistance 
 
Data are shown as means (SD).  For baseline values, the range of time is 
shown.  Mean duration refers to the duration of the defined time interval.  
Time intervals defined in the protocol do not have SD indications. 
 
For oxytocin the duration is the mean time from intravenous injection to peak 
effect on CO.  All other haemodynamic indices are calculated at this time 
point. 
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CO remained stable throughout CS and until the time of request for analgesia 
in each patient, except for the period following oxytocin administration (Figure 
6.1.). 
 
Figure 6.1. Cardiac output measurements for each patient at each time 
interval 
 
 Baseline: Baseline measurements averaged following calibration of cardiac 
output monitor 
 Sitting: Time from sitting up for SA until induction of SA 
 Spinal: Time from induction of SA until patient supine 
 Supine: Time from adoption of supine position until left lateral tilt 
 L tilt: Left lateral tilt (from tilt until skin incision) 
 Skin: Time from skin incision until 30 seconds before uterine incision 
 Uterine: 30 second time period before uterine incision 
 Post-delivery: 30 second period from delivery to administration of oxytocin 
 Oxytocin Peak: Time from administration of oxytocin until peak effect on 
cardiac output 
 End surg.: 30 second time period prior to skin closure (end of surgery) 
 Recovery: 5 minute time period before request for analgesia 
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Figure 6.2. Illustrates CO percentage changes in individual cases, excluding 
the peak oxytocin effect.  There were a total of 135 time epochs after the 
baseline period, of which 2 showed a greater than 20% decrease in CO.  The 
two observed decreases were transient and the patients were asymptomatic.  
CO increased to more than 20% above baseline values in several cases at 
various time intervals.  Assuming that the 135 time periods at which CO was 
measured were independent measurements, and considering the test for the 
association between the indicator for a CO decrease of more than 20% from 
baseline, and the time indicator, a Fisher’s exact test indicated no significant 
association (P-value = 1.000). 
 
 
Figure 6.2. Percentage cardiac output change from baseline for 
individual patients, at defined time intervals, as for Figure 6.1. 
Reference lines have been drawn at + and – 20% 
CO = cardiac output 
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Mean changes from baseline values in HR, MAP, SV, CO and SVR, together 
with 95% confidence intervals at all time intervals, for the cohort of 15 
patients, are shown in Figures 6.3.A-E. 
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E 
 
Figure 6.3A-E. Mean absolute changes from baseline values for all 
haemodynamic variables at defined time intervals, as in Figure 6.1. 
A: Heart rate (HR) 
B: Mean arterial pressure (MAP) 
C: Stroke volume (SV) 
D: Cardiac output (CO) 
E: Systemic vascular resistance (SVR) 
Error bars indicate 95% confidence intervals 
P-value < 0.05.  
 
A total of ten patients received phenylephrine, 8 before and 6 after delivery.  
The median (range) doses before and after delivery, were 50µg (0 – 150µg), 
and 0µg (0 – 150µg) respectively.  Seven patients required ephedrine, and 
one developed tachyphylaxis, necessitating a change to phenylephrine, as 
dictated by the protocol.  The median (range) dose of ephedrine was 0 (0 - 45) 
mg.  Vasopressor use is summarized in Table 6.3.  
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Table 6.3. Vasopressor administration pre- and post- delivery 
 
Immediately prior to the first administration of phenylephrine, i.e. when MAP 
was 20% below baseline values, SVR was significantly lower than baseline 
measurements.  CO and HR were not different from baseline at this time 
(Table 6.4.).  
 
Patient 
number 
Phenylephrine
pre-delivery 
(µg) 
Phenylephrine
post-delivery 
(µg) 
Ephedrine  
pre-delivery       
(mg) 
Ephedrine 
post-delivery 
(mg) 
1 0 150 0 0 
2 0 0 0 0 
3 0 0 0 0 
4 50 0 10 0 
5 50 50 0 5 
6 50 100 0 15 
7 0 0 0 0 
8 50 0 5 0 
9 0 0 0 0 
10 0 50 0 0 
11 0 0 0 0 
12 50 0 0 0 
13 50 150 5 45 
14 100 50 10 5 
15 50 0 5 0 
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Table 6.4. Haemodynamic data at baseline and prior to first 
administration of phenylephrine in those patients who received the 
vasopressor (n=10) 
 Baseline 
mean (SD) 
Pre P1   
mean (SD) 
Difference 
between 
means 
99%     CI 
CO          
(L/min) 
6.1 (1.7) 6.3 (1.5) 0.2 -1.0  to  1.4 
SVR 
(dyne.sec.cm-5) 
1616 (362) 1198 (330) -418 -628  to  -208 
MAP     
(mmHg) 
122 (17) 95 (13) -27 -34  to  -21 
SV      
(mL/beat) 
76.9 (19.5) 76.0 (19.7) -0.9 -7.8  to  6.0 
HR   
(beats/min) 
80.4 (11.6) 84.0 (16.1) 4.4 -7.2  to  16.0 
 
Pre P1  = values prior to the first dose of phenylephrine 
CO = cardiac output 
HR = heart rate 
MAP = mean arterial pressure 
SV = stroke volume, derived from the LiDCOplus monitor 
SVR = systemic vascular resistance 
 
99% confidence intervals (99% CI) were used to adjust for multiplicity.  There 
were significant decreases in SVR and MAP. 
 
The administration of phenylephrine was associated with a significant 
increase in MAP and SVR, and a significant decrease in HR, but SV and CO 
were not significantly changed from values immediately prior to phenylephrine 
use (Table 6.5.).  There was a trend towards a decrease in CO.  The mean 
(SD) times to peak effect of the first, second and third doses, were 28.3 (4.2), 
39.6 (30.0) and 24.6 (3.2) seconds respectively.  The infrequent use of 
ephedrine precluded a detailed analysis of the use of this vasopressor. 
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Table 6.5. Effects of phenylephrine on haemodynamic parameters using 
data from all doses of phenylephrine (n = 20) 
 Pre mean 
(SD) 
Post      
mean (SD) 
Difference 
between 
means 
99%              
CI 
CO          
(L/min) 
6.3 (1.5) 5.8 (1.6) - 0.5 -1.1 to 0.2 
SVR 
(dyne.sec.cm-5) 
1155 (297) 1507 (469) 352 59 to 645 
MAP     
(mmHg) 
91 (13) 108 (15) 17 8 to 24 
SV      
(mL/beat) 
75.9 (18.7) 78.7 (20.5) 2.8 -2.4 to 8.1 
HR   
(beats/min) 
84.2 (15.1) 74.9 (10.8) - 9.3 -17.2 to -1.4 
 
Pre = averaged values prior to phenylephrine 
Post = averaged values following phenylephrine 
CO = cardiac output 
HR = heart rate 
MAP = mean arterial pressure 
SV = stroke volume, derived from the LiDCOplus monitor 
SVR = systemic vascular resistance 
HR decreased significantly 
MAP and SVR increased significantly following phenylephrine administration 
 
Data relevant to the neonate include the following: 
The uterine incision to delivery time [mean (SD)] was 54.4 (29.2) sec.  The 
[mean (SD)] neonatal weight was 1697 (520) gm.  The [median (range)] Apgar 
score at 1 minute was 9 (7 – 9) and at 5 minutes was 9 (9 – 10).  The median 
(range) umbilical arterial pH and mean (SD) base deficit were 7.28 (7.19 – 
7.31) and -3.1 (1.9) mmol/L respectively. 
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6.4. Discussion 
 
This observational study describes the maternal haemodynamic response to 
SA for CS in 15 patients with severe preeclampsia, using phenylephrine as 
the first choice vasopressor, as is the current practice in healthy patients 
during SA for CS (Ngan Kee et al, 2005; Ngan Kee and Khaw, 2006).  SA was 
associated with haemodynamic stability in the 15 patients studied (Figure 
5.1.A.); this study therefore confirms the hypothesis that CO decreases were 
clinically insignificant during the procedure.  During only two time intervals out 
of a total of 135 comparisons with baseline values, in two different patients, 
did CO decrease by more than the clinically relevant value of 20% of baseline 
measurements (Figure 6.2. and 6.3D.).The mean baseline SVR was above 
normal despite antihypertensive therapy, and mean baseline CO is in the 
normal range (Table 6.2.), in keeping with previous literature relating to the 
haemodynamics of treated patients with severe preeclampsia (Young and 
Johanson, 2001).  Induction of SA was followed by significant decreases in 
MAP and SVR, which persisted until the end of surgery.  In many patients, CO 
increased to more than 20% above baseline values at several time intervals 
other than at the time of peak oxytocin effect (Figure 6.2.).  Thus the main 
haemodynamic effect of SA was modest afterload reduction.  The use of 
phenylephrine was associated with a trend toward a decrease in CO.  
Although CVP was not measured, the magnitude of the arterial pressure 
changes suggest that an increase in afterload contributed to the mechanism 
(Table 6.5.). 
 
The requirement for vasopressors was low, in keeping with the existing 
literature, which suggests a lower requirement than in normal parturients (Aya 
et al, 2003; Aya et al, 2005; Clark et al, 2005).  Some recent publications have 
recommended that phenylephrine be infused in normal parturients during SA 
for CS at a rate which maintains baseline MAP (Ngan Kee et al, 2004a; Ngan 
Kee et al, 2005).  This technique was however associated with a significant 
incidence of maternal hypertension.  In the present study, when target values 
of MAP for vasopressor administration (a 20% decrease in blood pressure) 
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were reached, CO had not decreased significantly, and in many cases had 
increased (Table 6.4.).  This suggests that maintaining blood pressure at the 
baseline level in this patient population during SA may not be optimal practice, 
especially considering the risk of worsening hypertension in patients with 
severe preeclampsia.  Furthermore phenylephrine, administered in response 
to a 20% decrease in baseline MAP, did not increase CO.  In several cases, 
CO decreased (Table 6.5).  The mean change in CO was not significant but 
this could reflect problems of statistical power. 
 
In a recent study employing whole body impedance cardiography during SA 
for CS, the authors reported on 10 preeclamptic women, of whom 6 had 
severe disease.  Comparative haemodynamic data from healthy women were 
obtained from historical rather than contemporaneous studies (Tihtonen et al, 
2006). Patients received a preload of 10 mL/kg of 6% hydroxyethyl starch, 
and 10 mL/kg/hour thereafter.  Fluid preloading increased CO in the 
preeclamptic group, but not in healthy patients.  The use of ephedrine 
increased both MAP and SVR.  At delivery, increases in the CO of 
preeclamptic patients were due only to increases in HR; SV did not increase, 
in contrast with the healthy patients.  The effects of oxytocin were not 
described.  Of particular clinical relevance was the finding that in the healthy 
patients, haemodynamic values returned to baseline levels after recovery from 
SA, whereas the stroke index and cardiac index in the preeclamptic group 
were significantly lower than pre-surgery levels.  The authors speculate that 
the inability to increase SV at delivery in the preeclamptic group could be due 
either to the existence of a lower preload after delivery than in healthy 
patients, or to diastolic dysfunction resulting in an inadequate adaptation to 
volume load at delivery.  Such changes could predispose these patients to 
life-threatening pulmonary oedema in the early puerperium.  In the present 
study, delivery and oxytocin administration were associated with CO changes 
that were predominantly HR mediated (Chapter 7).  At the time of recovery 
from SA, CO was significantly lower than baseline values.  However the 
magnitude of the effect was only 0.49L, which is well below criteria for a 
clinically relevant decrease, namely 20% of baseline values, or 1.23L.  This 
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decrease in CO is most likely attributable to the significant decrease in HR at 
this time (Figure 6.3A.). 
 
Since CVP was not measured in this study, a default CVP of 5mmHg was 
chosen, for the purposes of calculation of SVR.  Since right atrial pressure is 
very much lower than systemic pressure, this does not impact significantly on 
the calculation of SVR.  Furthermore, in a previous study employing CVP 
measurements before and during SA for CS in preeclampsia, a preload of 1 
litre of crystalloid induced a transient mean increase of less than 5mmHg, and 
CVP values returned towards baseline after induction of SA.  Modest 
crystalloid cohydration was employed in the present study, since there may be 
advantages in administering fluids immediately after induction of SA, thus 
limiting acute CVP increases and the effects of rapid redistribution of 
crystalloid fluid (Ngan Kee et al, 2005). 
 
More than 800 patients with severe preeclampsia were admitted during the 
time period of recruitment to the study (14 months).  The slow recruitment was 
due to two factors.  Firstly, obstetricians in our institution favour induction of 
labour at 34 weeks’ gestation, in the absence of a prior maternal or fetal 
indication for CS.  Thus a relatively small percentage of patients undergo CS 
for a maternal indication.  Secondly, in the great majority of patients with 
severe preeclampsia requiring CS in our institution, the indication is a non-
reassuring fetal heart trace.  The delays in establishing and calibrating non-
invasive CO monitoring would not be ethically justifiable in these patients.  In 
view of the fact that only approximately 50% of patients require a vasopressor 
before delivery, a large cohort of patients and a prolonged time period of 
investigation would be required for adequate power in a randomized trial on 
the effects of phenylephrine and ephedrine on maternal and fetal outcome. 
   
In conclusion, this observational study in 15 patients with severe 
preeclampsia, showed that SA was associated with modest afterload 
reduction and minimal CO changes.  Phenylephrine did not improve CO, and 
further work is required to establish whether a mixed , -agonist is the 
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preferred vasopressor, both from the maternal and fetal point of view, since no 
observations were made in the present study concerning uteroplacental 
perfusion. SV was well preserved at the time of recovery from SA, and there 
was a clinically insignificant decrease in CO at this time.  Combined spinal-
epidural anaesthesia has been successfully used for CS in patients with 
severe preeclampsia (Ramanathan et al, 2001; Teoh and Sia, 2006) and may 
confer benefits in terms of postoperative analgesia, but our data suggest that 
adequate haemodynamic stability, as assessed by CO changes, is provided 
by single shot SA. 
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7. Chapter 7 
7. Haemodynamic effects of oxytocin during 
spinal anaesthesia for caesarean section 
 
7.1. Introduction 
Oxytocin is recognised as an essential drug for administration at delivery, and 
is the first line agent in establishing adequate uterine contraction and in so 
doing, preventing postpartum haemorrhage.  However, as described in 
Chapter 1, oxytocin may cause unpleasant maternal side effects, which spoil 
the experience of the delivery in the awake patient.  Furthermore, this agent 
causes significant haemodynamic instability.  In circumstances of limited 
cardiac reserve, for example impaired ventricular function or significant 
valvular stenosis, precipitous decrease in systemic vascular resistance and 
the accompanying hypotension may be associated with an inadequate 
response in CO to restore normotension, and place the mother at risk.  
Quantification of these effects is thus important, in order to determine the 
optimal dose and method of administration, so that side effects can be 
minimised. 
 
As a secondary outcome in two studies described in this thesis (Chapters 5 
and 6), the haemodynamic effects of oxytocin were described in healthy 
patients and in patients with severe preeclampsia. 
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7.2. Haemodynamic effects of oxytocin in healthy parturients 
7.2.1. Patients and methods 
As part of a randomised study comparing the haemodynamic effects of 
ephedrine and phenylephrine during SA for CS (See Chapter 5 for detailed 
methodology), the haemodynamic effects of a bolus of 2.5IU oxytocin were 
described.  The co-administration of phenylephrine was also studied in 20 
patients.  The aim was to obtund the haemodynamic responses to oxytocin.  
Since the data from one patient was lost, 32 patients received oxytocin alone.  
CO changes were assessed by both pulse wave form analysis (LiDCOplus) 
and transthoracic bioimpedance changes (BioZ) in each patient. 
 
A total of 43 patients were recruited.  Thirty seconds after delivery, 2.5IU of 
oxytocin in 10mL water, was administered IV over a period of 30 seconds, to 
all patients receiving ephedrine prior to delivery, and to all other patients 
except for a subgroup of 20 consecutive patients not having received 
ephedrine prior to delivery.  These 20 patients were randomized to receive IV 
either 2.5IU of oxytocin, or 2.5IU of oxytocin, mixed with 80µg phenylephrine 
in 10mL water, over a period of 30 seconds, starting 30 seconds after 
delivery.  For this purpose, a sealed envelope pre-prepared by the statistician 
was opened immediately prior to delivery.  The anaesthesiologist 
administering oxytocin was blinded as to the treatment group.  No further 
vasopressor was administered for up to 3 minutes after oxytocin 
administration.  The obstetrician was asked to grade uterine contraction as 
good, adequate, or inadequate and requiring further oxytocin, and this was 
recorded. 
 
The response to oxytocin was analyzed as follows: hemodynamic data were 
averaged for 30 seconds prior to the administration of oxytocin.  The data for 
the 150 seconds following oxytocin administration were plotted against time to 
ascertain the time to maximum effect of oxytocin (taken as the highest value 
of CO), and the maximum response to oxytocin was estimated by averaging 
the data for 5 seconds before and after this point.  In the 20 patients 
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randomized to receive either oxytocin or the oxytocin-phenylephrine mixture, 
the change in hemodynamic variables was compared.  A sample size of 5 
patients in each group would have 90% power to detect a difference in mean 
CO of 25% assuming that the common standard deviation is 10%, using a two 
group t-test with a 0.05 two-sided significance level.  Therefore 10 patients 
were included in each group.  The 2-sample t-test was used for comparison of 
all the hemodynamic parameters.  The estimated mean difference and the 
95% confidence intervals were reported.  To account for the multiple testing 
performed in the study, the false discovery rate was controlled by applying the 
method of Benjamini and Hochberg (Benjamini and Hochberg, 1995).  The 
required P-value limit was calculated for the main and the sub-study and 
these bounds are indicated in the legend of the Table 7.1, which reports the 
inference results.  To depict the summary profile of the response to oxytocin 
administration in the two groups, a median smooth was used.  This approach 
gave an estimate that was robust to extreme values and sensitive to acute 
changes in hemodynamic variables.  These were presented as graphic 
ensembles. 
 
7.2.2. Results 
 
Figure 7.1 shows ensembles of responses to oxytocin (percentage change in 
CO and SVR from the pre-oxytocin values) in the 32 patients receiving 
oxytocin alone, derived from the LiDCOplus monitor, and comparative CO 
data from the BioZ monitor. 
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Figure 7.1. Ensembles of changes in cardiac output as shown with each 
monitor in all patients receiving oxytocin alone (n = 32) 
 
Each ensemble shows the percentage change for each patient (light gray) 
and the median smooth for the group (black) for the 150 seconds following 
administration of oxytocin.  The percentage change in CO at peak effect was 
32.7 (32.8) vs. 27.8 (18.9) % in the LiDCOplus and BioZ machines 
respectively. 
 
Figure 7.2. shows ensembles of the CO changes in patients randomised to 
oxytocin or a mixture of oxytocin and phenylephrine. 
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Figure 7.2. Ensembles of cardiac output changes from pre-oxytocin 
values as measured with the LiDCOplus and the BioZ monitors 
 
Figure 7.3 shows ensembles of the responses (percentage change in HR, 
MAP, SV and SVR from pre-oxytocin values) of the 20 patients randomized to 
receive either oxytocin alone, or a mixture of oxytocin and phenylephrine. 
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C 
 
D 
 
Figure 7.3A-D. Ensembles of percentage changes from pre-oxytocin 
values in heart rate (HR – 7A), mean arterial pressure (MAP – 7B), stroke 
volume (SV – 7C), systemic vascular resistance (SVR – 7D) 
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Table 7.1. Haemodynamic data pre- and post oxytocin or mixture of 
oxytocin and phenylephrine 
 
Oxytocin 
(n = 10) 
Oxytocin plus 
phenylephrine  
(n = 10) 
 
 95% Confidence Interval 
Mean SD Mean SD Diff 
Lower 
Limit 
Upper 
Limit P-value* 
Pre-oxytocin 
MAP 90.5 14.7 92.4 15.0 -1.9 -15.9 12.0 0.8 
SV 75.2 13.9 83.0 13.8 -7.8 -20.8 5.2 0.2 
SVR 1107 273 967 213 140 -90.4 370.4 0.2 
HR 86.0 15.4 90.5 13.5 -4.5 -18.1 9.1 0.5 
CO(LiDCO) 6.4 1.28 7.52 1.87 -1.13 -2.63 0.38 0.1 
CO(BioZ) 5.2 1.11 5.76 1.29 -0.56 -1.69 0.57 0.3 
Post-oxytocin 
SV         
peak 93.3 14.6 82.7 12.0 10.6 -2.0 23.1 0.1 
percent-peak 26.1 21.0 0.8 14.5 25.3 8.4 42.3 0.006 
time to peak 53.3 33.59 67.52 39.54 -14.21 -48.68 20.26 0.4 
SVR 
peak 556 201 1329 354 -773 1043 502 <0.0001 
percent-peak -45.8 38.3 41.2 34.9 -87.0 -119.8 -54.2 <0.0001 
time to peak 60.6 33.9 106.6 24.1 -46.0 -73.6 -18.4 0.003 
HR         
peak 98.2 19.7 74.3 12.9 23.8 8.2 39.5 0.005 
percent-peak 15.9 22.8 -16.4 19.4 32.3 12.4 52.2 0.003 
time to peak 71.2 35.8 115.5 26.7 -44.3 -74.0 -14.7 0.006 
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MAP 
peak 63.9 10.90 93.11 16.10 -29.23 -42.15 -16.31 0.0002 
percent-peak -28.9 9.92 2.99 22.11 -31.87 -47.97 -15.77 0.0002 
time to peak 43.4 7.45 86.89 27.32 -43.47 -62.28 -24.65 0.0006 
CO(LiDCO) 
peak 9.1 3.00 6.66 2.20 2.48 0.00 4.95 0.05 
percent-peak 45.3 41.57 -9.33 28.88 54.64 21.01 88.27 0.003 
time to peak 62.9 36.31 84.83 40.03 -21.97 -57.88 13.94 0.22 
CO(BioZ) 
peak 6.4 1.64 6.16 1.91 0.26 -1.42 1.93 0.75 
percent-peak 23.7 18.39 7.01 24.95 16.72 -3.87 37.32 0.11 
time to peak 64.9 29.32 88.20 39.04 -23.30 -55.74 9.14 0.15 
 
* = false discovery rate bound is 0.0057 
HR = heart rate 
MAP = mean arterial pressure 
SV = stroke volume 
SVR = systemic vascular resistance 
CO = cardiac output 
CO (LiDCO) and CO (BioZ) = cardiac output derived using the LiDCO and BioZ 
monitors respectively 
Peak = maximum absolute response to oxytocin or oxytocin plus phenylephrine 
Percent-peak = percentage change in variable from pre-oxytocin value at peak value 
 
 
Table 7.1. shows a detailed between-group comparison of hemodynamic 
parameters pre- and post- administration of oxytocin or the 
oxytocin/phenylephrine mixture.  Absolute peak HR was lower, and SVR and 
MAP significantly higher in the group receiving the mixture.  Percentage 
changes in these parameters, as well as CO as measured by the LiDCOplus 
monitor, were also significantly different in the two groups.  Times to peak 
changes were also different, with the exception of SV and CO changes.  The 
BioZ monitor showed a similar trend in CO change, but between-group 
differences were not significant.  In all patients, uterine contraction was 
assessed by the obstetrician as good. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 7 
118 
 
7.2.3. Discussion 
CO was significantly increased following 2.5IU oxytocin in the 32 patients 
receiving oxytocin alone.  The two monitors indicated similar trends, adding to 
existing evidence suggesting that the LiDCOplus device is a useful beat by 
beat trend monitor in the setting of rapid changes in systemic vascular 
resistance in obstetric anaesthesia (Dyer and James, 2008).  These findings 
were consistent with previous papers investigating the haemodynamic effects 
of bolus oxytocin (Pinder et al, 2002; Langesaeter et al, 2006). 
 
In the twenty patients randomized to receive oxytocin or a mixture of oxytocin 
and 80µg phenylephrine, the hemodynamic responses to oxytocin were 
obtunded but not abolished (Table 7.1, Figures 7.2 and 7.3).  The fact that the 
onset of the hemodynamic effects of oxytocin was not prevented, together 
with the transient delayed depression of HR and CO following the 
administration of the mixture, suggest that the timing of the use of 
phenylephrine to obtund the hemodynamic effects of oxytocin, could be 
improved.  SV remained stable when the mixture was used, suggesting the 
Anrep effect, a positive inotropic effect which occurs in the presence of a 
sustained increase in afterload (von Anrep, 1912).  This preliminary data 
suggest that further studies are required to establish the most effective doses 
and timing of combinations of oxytocin and phenylephrine in order to eliminate 
the unwanted cardiovascular effects of oxytocin.  This could include the prior 
administration of phenylephrine. 
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7.3. Haemodynamic effects of oxytocin in preeclamptic patients 
 
7.3.1. Patients and Methods 
One aspect of a study examining the haemodynamic effects of SA in 15 
patients with severe preeclampsia (Chapter 6), was the haemodynamic 
effects of oxytocin.  For this purpose, the LiDCOplus system was used. 
 
Thirty seconds after delivery, oxytocin 2,5 IU in 10mL water, was administered 
over a period of 30 seconds.  No vasopressor was administered for up to 3 
minutes after oxytocin, and no further intraoperative oxytocin was 
administered until the end of surgery, unless requested by the obstetrician in 
the case of uterine atony.  The response to oxytocin was analyzed as follows: 
hemodynamic data were averaged for 30 seconds prior to the administration 
of oxytocin.  The subsequent data were plotted against time to ascertain the 
time to maximum effect of oxytocin (taken as the highest value of CO), and 
the maximum response to oxytocin was estimated by averaging the data for 5 
seconds before and after this point.  This value was then compared to the pre-
oxytocin value using analysis of variance for repeated measures. 
 
7.3.2. Results 
Figure 7.4. shows ensembles of the responses of the 15 patients to oxytocin 
(HR, MAP, SV, CO and SVR).  Individual responses are shown as thin grey 
lines, and the ensemble average is depicted as a superimposed thick black 
line. 
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E 
 
Figure 7.4A-E. Ensemble of haemodynamic changes following the 
administration of oxytocin 
 
A. HR - Heart rate.  At peak effect, HR increased from 84.7 (12.6) to 101.5 (15.9)* 
beats/min 
B. MAP - Mean arterial pressure.  At peak effect, MAP decreased from 114.3 (15.0) 
to 80.6 (15.3)* mmHg 
C. SV - Stroke volume.  At peak effect, SV increased from 82.9 (15.9) to 89.1 (17.3) 
(ns) 
D. CO - Cardiac output.  At peak effect, CO increased from 7.0 (1.5) to 9.1 (2.3)* 
L/min 
E. SVR - Systemic vascular resistance.  At peak effect, SVR decreased from 1295 
(252) to 718 (282)* dyne.sec.cm-5 
 
* = value significantly different from baseline and post-delivery 
P-value < 0.01 
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7.3.3. Discussion 
A small dose of oxytocin administered 30 seconds after delivery, was 
associated with significant hypotension, and increases in HR and CO (Figure 
7.4.).  These transient haemodynamic effects were greater in these patients 
with severe preeclampsia than in those following the sympathectomy 
associated with SA (Chapter 5).  SV did not increase significantly following 
oxytocin.  By contrast, there were significant increases in both HR and SV 
following the administration of oxytocin in healthy patients (Chapter 7.2.2).  
This may reflect diastolic dysfunction in patients with severe preeclampsia, 
and the findings are in agreement with a recent publication examining CO 
changes during caesarean delivery in patients with severe preeclampsia, 
using whole body bioimpedance technology (Tihtonen et al, 2006).  In patients 
not at risk for uterine atony, the ED90 for oxytocin has been found to be 
0.35IU (Carvalho et al, 2004).  A repeat of this study would be useful in high 
risk patients such as those with severe preeclampsia.  In the interim, the data 
suggest that oxytocin is probably best administered by slow infusion in these 
patients during SA. 
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8. Chapter 8 
8. Neonatal acid base balance: the effects of 
spinal anaesthesia for caesarean section in 
preeclampsia 
8.1. Introduction 
Spinal anaesthesia for caesarean section in patients with severe 
preeclampsia is now widely accepted in the absence of contraindications, 
since maternal haemodynamic stability has been satisfactorily demonstrated 
in several studies (Chapters 1 and 6).  The effect of spinal anaesthesia on 
short term neonatal outcome in healthy parturients, is also summarised in 
Chapter 1 of this thesis. 
 
The first prospective randomised comparison of regional and general 
anaesthesia for caesarean section in preeclampsia was performed as recently 
as 1995.  Three groups of patients with severe preeclampsia were 
randomised to receive epidural, combined spinal-epidural or general 
anaesthesia for caesarean section, with similar haemodynamic stability (as 
assessed by heart rate and blood pressure) and fetal outcome in each group 
(Wallace et al, 1995).  However, patients with non-reassuring fetal heart 
traces were excluded from this study.  No studies have prospectively 
addressed the problem as to whether fetal outcome is influenced by the 
method of anaesthesia in preeclamptic patients requiring emergency 
caesarean section for a non-reassuring fetal heart trace.  It was therefore 
decided to test the hypothesis that the mode of anaesthesia influenced 
markers of neonatal hypoxia.  Patients with preeclampsia and a non-
reassuring fetal heart trace were randomised into 2 groups receiving either 
spinal or general anaesthesia for caesarean section.  A study to examine 
neonatal outcome would require a prohibitively large numbers of patients.  
Therefore surrogate markers of neonatal outcome, primarily umbilical arterial 
base deficit, as well as umbilical arterial pH, Apgar scores, requirements for 
resuscitation, and complications were assessed.  As further secondary 
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outcome measures, maternal haemodynamics, namely pulse rate and non-
invasive blood pressure data, were also collected. 
 
8.2. Patients and methods 
 
Preeclampsia was diagnosed if the diastolic blood pressure after 20 weeks’ 
gestational age was greater than or equal to 90 mmHg on two separate 
occasions at least 4 hours apart, and proteinuria was found of greater than or 
equal to 1 gram or 2+ on urine dipstix in two clean midstream samples taken 
at least 4 hours apart, or greater than or equal to 300mg protein per 24 hours.  
Preeclampsia was regarded as severe if the systolic blood pressure exceeded 
160 mmHg and/or the diastolic blood pressure exceeded 110 mmHg, 
obtained on at least two separate occasions, or if the patient had symptoms of 
imminent eclampsia (namely severe headache, visual disturbance, epigastric 
pain, hyper-reflexia, dizziness and fainting, or vomiting) and proteinuria on 
urine dipstix was 3+ or worse. 
 
Patients with preeclampsia and a non-reassuring fetal heart trace were 
randomised by sealed envelopes into 2 groups of 35, for either spinal or 
general anaesthesia for caesarean section.  Informed written consent was 
taken at the time of decision to proceed to caesarean section.  The study 
commenced after the approval of the Ethics Committee of the University of 
Cape Town. 
  
Exclusion criteria were patient refusal, or any other relative contra-indication 
to either general or spinal anaesthesia, in particular oral intake other than 
clear fluids within 4 hours of the intended surgery, body mass index greater 
than 35 kg/m2, Mallampati score greater than 2, clinical signs of 
hypovolaemia, abruptio placentae, placenta praevia, coagulation abnormality, 
thrombocytopaenia (platelet count < 75x109/L), local or generalised sepsis, 
spinal deformity, cord prolapse, < 30 weeks’ gestation, or twin pregnancy. 
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Should any spinal anaesthetic take longer than 15 minutes to perform, the 
patient would receive general anaesthesia, and the data would be recorded 
as a failure of the technique.  The data from these subjects would be 
assessed as a separate sub-group. 
 
The antepartum management was according to the established protocol of 
our institution:  If the patient was in established labour, an intravenous line 
was inserted, and a balanced crystalloid solution administered at 120 mL per 
hour.  Patients not in labour were allowed free oral fluids.  Seizure prophylaxis 
was administered to patients with severe preeclampsia, and consisted of 
magnesium sulphate (MgSO4), administered as a loading dose of 4g 
intravenously, followed by 1g hourly intravenously.  Dihydralazine was 
administered intravenously as a vasodilator, for additional blood pressure 
control against a standardized protocol that was identical in both groups.  
Prior use of other agents (-methyldopa, morphine and dexamethasone) was 
recorded. 
 
In the absence of labour, a baseline fetal heart rate of less than 100 or greater 
than 150 beats per minute, decreased or absent fetal heart rate variability (< 5 
beats per minute) of 60 minutes’ duration, and the presence of repetitive 
decelerations were considered to be indications for delivery by caesarean 
section.  Intrapartum abnormalities of the fetal heart rate that indicated 
caesarean section were, in addition to the above, the presence of late 
decelerations and variable decelerations greater than 60 beats per minute 
(Table 8.1.). 
 
Un
ive
rsi
ty 
of 
Ca
p
 To
wn
Chapter 8 
127 
 
Table 8.1. Fetal heart rate abnormalities indicating caesarean section 
 
Intrapartum FHR 
abnormality 
Antepartum FHR 
abnormality 
Fetal Heart Rate abnormalities GA SP GA SP 
Loss of STV 1 2 2 2 
Loss of STV, and bradycardia 1 1 1 1 
Loss of STV, early decelerations 2 2 N/A N/A 
Late decelerations 4 4 N/A N/A 
Variable decelerations 2 1 N/A N/A 
Recurrent decelerations, not in labour  N/A N/A 20 21 
Loss of STV and decelerations N/A N/A 1 1 
TOTAL (n) 10 10 24 25 
 
FHR = Fetal heart rate 
STV = Short term variability 
N/A = Not applicable, since defined fetal heart rate abnormalities are specific to the 
presence or absence of active labour 
 
The decision to proceed with operative delivery was made by the obstetric 
team independent of the investigators.  After a non-reassuring fetal heart 
trace had been identified, all patients were placed in the lateral position before 
transfer to theatre, and received 40% oxygen by face-mask. 
 
Both groups of patients received 30 mL sodium citrate orally in theatre.  Non-
invasive monitoring consisted of electrocardiograph, blood pressure and pulse 
oximetry in both groups, as well as capnography in the general anaesthesia 
group. 
 
Both groups had crystalloid infusions established prior to transfer to theatre.  
A total further fluid load of modified Ringer’s lactate (<750 mL) was given in 
the peri-induction period.  Induction was not delayed in either group for the 
specific purpose of fluid administration, in keeping with published guidelines 
for normal parturients (Rout et al, 1993b). 
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After adequate pre-oxygenation, induction of general anaesthesia was with 
thiopentone 5 mg/kg, followed by an appropriate dose of intravenous 
magnesium sulphate (MgSO4) for control of the pressor response to tracheal 
intubation.  The dose of MgSO4 was 45 mg/kg if there had been no prior 
administration of MgSO4, and 30 mg/kg if the patient was currently receiving 
the drug.  Muscle relaxation was achieved with suxamethonium 1.5 mg/kg, 
and 1 minute after administration, a rapid sequence intubation was performed.  
Maintenance of anaesthesia was with 50% nitrous oxide in oxygen, and 0.75 - 
1.5% end-tidal isoflurane, and patients were ventilated to a target end-tidal 
carbon dioxide concentration of 30 - 34 mmHg, using a circle system, 
employing fresh gas flows of 5 litres per minute until delivery.  A maternal 
arterial blood gas measurement was taken immediately post-delivery.  
Neuromuscular blockade was maintained using an infusion of suxamethonium 
(200mg / 200mL Plasmalyte B at 4mg per minute), monitored by a peripheral 
nerve stimulator.  Oxytocin 5 IU, and morphine 0.05 mg/kg, were administered 
intravenously at delivery.  Thereafter a continuous infusion of oxytocin was 
administered (20 IU/L, at 60 - 100 mL per hour).  A further 0.05 mg/kg 
morphine was administered intravenously prior to extubation if the 
haemodynamic and respiratory status allowed it.  Patients were extubated 
awake.   
 
Recordings of heart rate, and non-invasive measurements of systolic, diastolic 
and mean blood pressure (Dinamap, Critikon, Florida) were made at the 
following time points: 
Blood pressure was recorded pre-induction (starting systolic, diastolic and 
mean blood pressures were taken as the mean of two consecutive readings 
taken in the 3 minutes prior to induction of anaesthesia), immediately before 
intubation, and at 1 minute intervals after intubation for 10 minutes, and 
thereafter every 5 minutes until arrival in recovery room. 
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The management of patients in the spinal anaesthesia group was as follows:  
All patients received 1.8 mL of hyperbaric 0.5% bupivacaine, with 10µg of 
fentanyl, administered at the L3/4 interspace in the absence of uterine 
contractions.  After 20 seconds in the sitting position, patients were positioned 
supine, with 20 degrees of left lateral tilt, to minimize aortocaval compression.  
Block height was assessed using cold sensitivity to ethyl chloride spray.  All 
mothers received 40% oxygen by face-mask.  Oxytocin therapy after delivery 
was as for the general anaesthesia group.  Heart rate and blood pressure 
were measured pre-induction of spinal anaesthesia in the same manner as in 
the general anaesthesia group, at 1 minute intervals post-induction for the 
next 10 minutes, and thereafter every 5 minutes until arrival in recovery room.  
Hypotension in either group, defined as a decrease in systolic blood pressure 
of more than 25% below the pre-induction value, was treated with ephedrine 
(5 mg boluses), given every minute until the blood pressure recovered to 
within 25% of the starting value.  However, no ephedrine was given to 
patients with a mean arterial pressure greater than 100 mmHg.  The total 
dose of ephedrine was recorded.  A maternal arterial blood gas measurement 
was taken immediately post-delivery. 
 
Further important time intervals were recorded: 
 Time from arrival in theatre until induction of anaesthesia 
 Induction to skin incision time 
 Induction to uterine incision time 
 Uterine incision to delivery time 
 
All maternal medication received in the 24 hours prior to anaesthesia was 
carefully noted.  Severity of disease (as assessed by the degree of 
hypertension and the requirement for vasodilator and/or seizure prophylaxis 
therapy, and degree of proteinuria) and presence or absence of labour was 
also recorded.  In some patients antenatal fetal assessment was performed 
(umbilical artery Doppler and amniotic fluid index) at the discretion of the 
attending obstetrician.  Resistance index was calculated from Doppler 
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measures of umbilical arteries using peak systolic velocity (S) and the end 
diastolic velocity (D) (Resistance index = S-D/S).  Amniotic fluid index is the 
sum total of the deepest vertical pool of amniotic fluid in 4 quadrants (normal 
range 5 - 25 cm).  Where available, these data were recorded.  Intra-operative 
maternal blood loss was estimated from suction bottle measurement and 
weighing of swabs. 
 
Neonatal outcome was assessed by a paediatrician dedicated to the study, 
and blinded to the method of anaesthesia.  Assessment criteria were as 
follows: 
A. At birth: 
Neonatal weight, gender, gestational age (Ballard score), one and five minute 
Apgar score, arterial cord blood gas, and degree of resuscitation (face mask 
ventilation, intubation and ventilation, cardiopulmonary resuscitation) were 
recorded. 
 
B. In the nursery: 
Signs of respiratory distress using clinical and radiological diagnosis, and the 
need for respiratory support in the form of head box oxygen, nasal continuous 
positive airway pressure, intermittent positive-pressure ventilation, high 
frequency oscillatory ventilation or surfactant replacement therapy, was 
recorded. 
  
A hypoxic-ischaemic encephalopathy score (Thompson et al, 1997) was 
performed in all babies with a 5 minute Apgar score of below 6 or with a cord 
pH of less than 7.1 and a base deficit of more than 10 mEq/L, daily for 5 days.  
An ultrasound scan of the head was done on day 5 in all preterm babies with 
a birth weight of below 1500 gram.  Mortality at discharge was recorded.  All 
the neonatal recordings were normal practice in the neonatal nursery and 
intensive care unit, and no additional blood sampling was performed solely for 
 the purpose of the study. 
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Statistical Analysis: 
Sample size was calculated as follows:   
Previous studies have reported a normal value for umbilical arterial base 
deficit following elective caesarean section of the order of 5  3 mEq/L 
(Ratcliffe and Evans, 1993; Krishnan et al, 1995).  It was hypothesized that a 
mean base deficit of 8 mEq/L or more would, therefore, represent a clinically 
relevant level of acidosis.  Assuming a standard deviation of 7.5, the study 
would have a minimum power of 90% to detect this magnitude of difference 
with 66 subjects (33 in each group).  We therefore studied 70 patients.  The 
Null hypothesis was that the method of anaesthesia (spinal or general) would 
make no difference to neonatal umbilical arterial base deficit in patients with 
preeclampsia and a non-reassuring fetal heart trace undergoing caesarean 
section. 
 
Haemodynamic data were analysed within groups by analysis of variance 
(ANOVA) for repeated measures, and between groups by multiple dependent 
(group and time) ANOVA using the 95% confidence interval method for post 
hoc detection of significant differences.  Qualitative data were assessed using 
appropriate non-parametric tests including the Fisher exact test, chi-square 
and the Kruskal-Wallis analysis of variance for multiple comparisons.  
Correlation between the use of ephedrine and neonatal base deficit was 
performed using regression analysis.  Non-normally distributed data were 
compared between groups using the Mann-Whitney U-test.  Regression 
analysis was also performed on maternal and neonatal umbilical arterial base 
deficit.  All statistical analysis was performed using the Statistica Version 6 
statistical package (StatSoft Inc, Tulsa, OK, USA). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
w
Chapter 8 
132 
 
8.3. Results 
 
Table 8.1. shows the similar fetal heart rate abnormalities that indicated 
caesarean section in the two groups.  Demographic data are presented in 
Table 8.2.  The two groups of 35 patients were similar.  There were no 
differences between groups in the use of non-study medications (alpha-
methyldopa, dihydralazine, morphine or dexamethasone).  Similar numbers of 
patients in each group were in active labour, and the severity of preeclampsia 
(as judged by the requirement for magnesium sulphate therapy, diastolic 
blood pressure >110 mmHg, dihydralazine therapy, both in terms of numbers 
receiving the drug and total dose, and proteinuria) was similar in the two 
groups, as were the gestational ages.  In those patients in whom antenatal 
fetal assessment (umbilical artery Doppler and amniotic fluid index) was 
performed, there were no statistically significant between-group differences.  
No patient was excluded because the allowed time for spinal anaesthesia was 
exceeded, and no patients required conversion from spinal to general 
anaesthesia.  The range of block height obtained was between T2 – T6, with 
19 patients having a sensory level of T4.  No patient complained of pain or 
required supplemental analgesia. 
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Table 8.2. Demographic data 
 
Maternal 
General 
n = 35 
Spinal 
n = 35 
Age (years) (mean ± SD) 26 ± 6 25 ± 7 
Weight(kg) (mean ± SD) 74 ± 11 75 ± 13 
Height (cm) (mean ± SD) 157 ± 13 157 ± 12 
Pre-induction systolic blood pressure (mmHg) 159 ± 30 155 ± 30 
Pre-induction diastolic blood pressure (mmHg) 98 ± 20 97 ± 21 
Pre-induction mean blood pressure (mmHg) 120 ± 22 121 ± 24 
Gravidity (median (range)) 1.5 (1-4) 1 (1-6) 
Parity (median (range)) 0.5 (0-3) 0 (0-5) 
Active labour (n) 11 10 
Induced, not in labour (n) 6 11 
Not induced, no labour (n) 18 14 
Diastolic blood pressure>110 mmHg 20 20 
MgSO4 therapy (n) 19 20 
Dihydralazine therapy (n) 9 13 
Proteinuria 1-2+ (n) 13 12 
Proteinuria 3-4+ (n) 22 23 
Gestational age (weeks) 35.1 (3.2) 34.9 (2.6) 
Gestational age < 35 weeks (n) 18 15 
Gestational age < 34 weeks (n) 11 11 
Gestational age 30 weeks (n) 3 1 
 
 
Fetal / neonatal 
General 
n = 35 
Spinal 
n = 35 
Umbilical artery Doppler (Resistance Index): 
Normal (n) 12 10 
Absent end-diastolic flow (n) 2 3 
Amniotic Fluid Index (Normal 5-25 cm) 
9 (1-16)    
n = 22 
6.5 (1-18) 
n = 20 
Neonatal weight (g) 2236 (728) 2138 (614) 
Placental weight (g) 474 (151) 452 (164) 
   
One severe pre-eclamptic in the general anaesthesia group was 
inappropriately recruited to the study, since she had a normal fetal heart trace.  
She was included in the data analysis.  There were no differences in the 
outcome variables when the data analysis was performed with and without 
this patient.  A further patient in the general anaesthesia group had an 
undiagnosed abruptio placentae, which resulted in a stillbirth; maternal data 
for this patient were analysed, but there were no neonatal data.   
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Consequently, 70 mothers were included in the data analysis, but only 69 
neonates.  There was a single case of sudden infant death syndrome in the 
spinal anaesthesia group on day 5 post-delivery. 
 
Anaesthesia parameters and blood gas values are presented in Tables 8.3 
and 8.4.  The spinal anaesthesia group received significantly more fluid before 
induction of anaesthesia.  Induction to skin incision times were longer by a 
mean of 2.1 minutes in the spinal group, and induction to uterine incision 
times were longer by 2.5 minutes.  There was significantly more blood loss in 
the general anaesthesia group (446 vs. 393 mL); however no patient was 
regarded as having more than normal haemorrhage associated with 
caesarean section, and no patient required transfusion. 
 
Maternal PaCO2 values were significantly lower in the spontaneously 
breathing spinal anaesthesia group patients than in the general anaesthesia 
group patients whose PaCO2 was controlled by the anaesthesiologist (28.9 
vs. 32.4 mmHg). 
 
Considering the primary outcome variable, the mean base deficit in the spinal 
anaesthesia group was significantly higher than in the general anaesthesia 
group (7.13 vs. 4.68 mEq/L). 
 
The neonatal pH data were found to be non-normally distributed.  Median 
umbilical arterial pH and mean standard bicarbonate values were significantly 
lower in the spinal anaesthesia group (7.20 vs. 7.23, and 18.4 vs. 20.4 mEq/L 
respectively; Table 8.4). 
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Table 8.3. Anaesthesia data, including maternal and neonatal measures 
Fluid management General Spinal P-value 
Preload (mL) 393  114 454  110 0.025 
Total fluid (mL) 1053  421 1131 357 0.4 
Blood loss (mL) 446  126 394  64 0.036 
Time points General Spinal P-value 
TTIA (min) 9.7  3.9 11.1  5.7 0.24 
TISI (min) 4.2  2.6 6.3  2.6 0.001 
TIUI (min) 7.1  3.3 9.6  2.9 0.002 
TUID (min) 1.1  0.6 1.2  0.8 0.82 
Duration of Surgery (min) 36.5  13.1 37.3  13.4 0.80 
Ephedrine total dose (mg) 2.7 8.9 13.7  17.5 
0.002 
 
Data are presented as mean  SD 
TTIA = Time from arrival in operating theatre until induction of anaesthesia 
TISI = Time from induction to skin incision 
TIUI = Time from induction to uterine incision 
TUID = Time from uterine incision to delivery 
 
Table 8.4. Blood gas data in both mothers and neonates 
Maternal General Spinal P-value 
pH 7.35  0.07 7.37  0.04 0.064 
PCO2 (mmHg) 32.4  5.1 28.9  3.7 0.002 
PO2 (mmHg) 165.7  52.5 172.5  47.2 0.48 
Base deficit (mEq/L)  6.6  2.8  6.5  2.7 0.69 
Standard bicarbonate (mEq/L) 19.5  2.3 20.0  1.9 0.35 
Neonatal umbilical arterial 
General Spinal 
 
P-value 
pH (median and range) 
7.23 (7.05-
7.4) 
7.20 (6.93-
7.34) 0.046 
PCO2 (mmHg) 50.2  10.5 48.7  12.0 0.44 
PO2 (mmHg) 22.5  18.7 21.0  19.5 0.67 
Base deficit (mEq/L) 4.68  3.3 7.13  4.0 0.02 
Standard bicarbonate (mEq/L) 20.4  3.0 18.4  3.3 0.04 
 
Data are presented as mean  SD, unless stated 
 
Median 1 minute Apgar scores were significantly lower in the general 
anaesthesia group (Figure 8.1.). There were no significant differences in the 5 
minute scores (Figure 8.1.), and no correlation between Apgar scores and 
neonatal umbilical arterial base deficit. 
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Figure 8.1. Apgar scores at one and five minutes in the spinal (SP) 
(n=35) and general anaesthesia (GA) (n=34) groups 
* Significant differences between groups 
P-value < 0.05 
 
Considering categorical data (Table 8.5), there were 22 neonates with a cord 
pH < 7.2, of whom 14 were in the spinal anaesthesia group and 8 were in the 
general anaesthesia group.  Of the 5 neonates with a cord pH < 7.1, 4 were in 
the spinal anaesthesia group and 1 in the general anaesthesia group.  Of the 
7 infants with a base deficit of 8 - 10 mEq/L, 3 were in the spinal anaesthesia 
group and 3 were in the general anaesthesia group, while of the 9 with base 
deficits > 10mEq/L, 3 were in the general anaesthesia group and 6 in the 
spinal anaesthesia group. 
 
* 
* 
 Apgar Scores at 1 and 5 Minutes  
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Table 8.5. Markers for fetal hypoxia 
Apgar score General Spinal P-value 
I Minute Apgar <7 (n = 27) 14 13 1 
5 Minute Apgar <7 (n = 1) 1 0 1 
Neonatal acidosis General Spinal P-value 
Umbilical arterial pH n n   
pH < 7.2 (n = 22) 8 14 0.20 
pH < 7.1 (n = 5) 1 4 0.20 
Umbilical arterial base deficit n n   
Base deficit 5 - 7.9 mEq/L (n = 23) 6 17 0.02 
Base deficit 8 - 10 mEq/L (n = 6) 3 3 1 
Base deficit >10 mEq/L (n = 9) 3 6 0.49 
Neonates requiring resuscitation n n   
Face-mask oxygen (n = 30) 18 12 0.20 
Intubation (n = 5) 3 2 1 
CPR + Drugs (n = 2) 1 1 1 
Total requiring resuscitation 22 15 0.07 
Complications General Spinal P-value 
Respiratory Distress  n n   
Total = 8 5 3 0.6 
Requiring IPPV 2 2 1 
Hypoxic Ischaemic Encephalopathy: 0 0   
  
Ultrasound of Head: Normal in 10 neonates where indicated 
CPR = Cardiopulmonary resuscitation  
IPPV = Intermittent positive pressure ventilation 
 
Neonatal blood gases could not be obtained in 2 patients from the general 
anaesthesia group and 1 patient from the spinal anaesthesia group.  There 
were no significant between group differences apart from a higher incidence 
of mild base deficit in the spinal anaesthesia group (5 - 7.9 mEq/L).  The 
requirements for in-theatre or nursery resuscitation were similar. 
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There was a weak correlation (r = 0.36) between maternal base deficit and 
neonatal base deficit (Figure 8.2). 
 
Figure 8.2. Correlation between maternal and neonatal base deficit (BD) 
in the entire study cohort, showing regression line and 95% confidence 
intervals of the mean 
Maternal BD: Neonatal BD: R = 0.36, P-value = 0.003   
Neonatal BD = 2.73 + 0.5 x X 
 
Maternal BD:Neonatal BD: r = 0.36, p = 0.003
Neonatal Base Deficit = 2.73+0.50*X
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This correlation was stronger in the spinal anaesthesia group (r = 0.47; Figure 
8.3.) than in the general anaesthesia group (r = 0.29; Figure 8.4.): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3. Correlation between maternal and neonatal base deficit (BD) 
in the spinal anaesthesia group, showing regression line and 95% 
confidence intervals of the mean 
Maternal BD: Neonatal BD: R = 0.47 
P-value = 0.005 
Neonatal BD = 2.79 + 0.67  X 
 
 
  
 
 
Spinal Anesthesia
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Figure 8.4. Correlation between maternal and neonatal base deficit (BD) 
in the general anaesthesia group, showing regression line and 95% 
confidence intervals of the mean 
Maternal BD: Neonatal BD: R = 0.29 
P-value = 0.09 
Neonatal BD = 2.45 + 0.37  X 
 
Haemodynamic data for the pre-anaesthetic measurement, the subsequent 
10 minutes, and the immediate postoperative measurement are presented in 
Figure 8.5.  At several time points the heart rate, and the systolic, diastolic 
and mean blood pressures were significantly lower in the spinal anaesthesia 
group.  There was no significant correlation between the number of minutes 
spent at more than 25% below the baseline mean arterial blood pressure and 
the neonatal base deficit in either group (r = 0.23 for the general anaesthesia 
group, and -0.14 for the spinal anaesthesia group).  There was also no 
significant correlation between absolute changes in mean arterial pressure 
and neonatal base deficit in either group (r = 0.09 for the general anaesthesia 
group, and -0.09 for the spinal anaesthesia group).  There was no significant 
between-group difference in the duration of time spent at blood pressures 
<25% baseline.  Significantly more ephedrine was required in the spinal 
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anaesthesia group (13.7 vs. 2.7 mg; Table 8.3), but there was no correlation 
between ephedrine utilization and neonatal base deficit in either group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.5. Changes in heart rate and mean arterial pressure in the 
general anaesthesia (GA) and spinal anaesthesia (SP) groups (mean ± 
SD) 
* Significant differences between groups 
P-value < 0.05 
Time points refer to minutes post induction of anaesthesia 
Prean = Pre-anaesthetic measurement 
End = Immediate post surgery measurement 
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8.4. Discussion 
 
There have been no previous published prospective randomised trials 
comparing spinal and general anaesthesia for caesarean section in severe 
preeclampsia, where the indication for operative intervention is a non-
reassuring fetal heart trace.  The present study addressed the issue of 
neonatal outcome while also comparing haemodynamic data in the two 
groups.  The primary outcome measure was mean neonatal umbilical arterial 
base deficit, since variations in maternal ventilation will alter umbilical arterial 
pH, and therefore umbilical arterial base deficit is a more specific index of the 
metabolic component of acid-base balance (Reynolds et al, 2002).  Spinal 
anaesthesia was associated with a significantly greater mean umbilical arterial 
base deficit and a lower median umbilical arterial pH than general 
anaesthesia.  One minute Apgar scores were lower after general anaesthesia.  
Pulse rate and blood pressure measurements were acceptable in these two 
groups presenting for urgent caesarean section. 
 
It is likely that there are many influences on neonatal outcome following 
caesarean section in preeclampsia.  These include severity of the maternal 
and fetal condition, anaesthesia and surgical management.  Fetal 
development is related to gestational age, and to chronic utero-placental 
insufficiency, which results in intrauterine growth restriction.  In addition, any 
acute maternal deterioration may impact unfavourably on fetal outcome.  The 
equivalence between the two study groups in terms of maternal and neonatal 
demographic and clinical data, in particular the severity of maternal disease, 
the presence or absence of active labour, and the gestational age, allowed 
the influence of anaesthesia to be assessed independently. 
 
To identify perinatal morbidity, the positive predictive value of an antepartum 
fetal heart rate non-stress test in high risk pregnancy is approximately 55% 
(Lenstrup and Haase, 1985), while the positive predictive value of late 
decelerations during labour, for fetal acidaemia is 30 – 40% (Spencer, 1993).  
In the present study, the neonates clearly represented a high risk group, since 
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in addition to the abnormal fetal heart trace, a large proportion of the mothers 
had severe preeclampsia, and most had a compensated metabolic acidosis, 
probably indicating poor tissue perfusion; furthermore, a large proportion of 
the neonates were pre-term.  Fetal scalp blood sampling could not be 
performed due to the possibility of an increased risk of vertical transmission of 
the Human Immunodeficiency Virus. 
 
In our study, considering the data pertaining to anaesthesia, the time from 
induction of anaesthesia to skin incision was statistically but probably not 
clinically significantly shorter in the general anaesthesia group.  Thus, 
potentially harmful delays attributable to spinal anaesthesia (Wainwright, 
1996) did not apply in this study.  The significantly lower Apgar scores at one 
minute in the general anaesthesia group is in keeping with previous studies 
(Ratcliffe and Evans, 1993; Roberts et al, 1995; Mueller et al, 1997), and 
probably represents transient sedation of the neonate from the anaesthetic 
agents. 
 
In elective, uncomplicated term pregnancies, one major retrospective study 
indicated a significantly increased degree of neonatal acidosis (umbilical 
arterial pH), in parturients receiving either spinal or epidural anaesthesia when 
compared with general anaesthesia (Roberts et al, 1995).  The acidosis was 
attributed in part to an increased umbilical arterial PaCO2 due to maternal 
hypoventilation during regional anaesthesia.  There was also a higher 
incidence of maternal hypotension in patients having regional anaesthesia in 
this study.  The significantly lower maternal PaCO2 in the spinal anaesthesia 
group in the present study probably reflects a respiratory compensation in a 
patient with a metabolic acidosis.  The resultant mild hypocarbia may have 
adversely influenced uterine perfusion, although a previous study suggests 
that more severe hypocarbia than that seen in the current investigation may 
be required to decrease uterine perfusion significantly (Levinson et al, 1974).  
No study has examined the influence of maternal ventilation on utero-
placental perfusion in patients with preeclampsia.  A recent meta-analysis 
examined the effects of regional versus general anaesthesia for caesarean 
section on fetal acid-base balance, predominantly in healthy parturients.  This 
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paper suggested that mean values for umbilical arterial base deficit are higher 
in patients receiving spinal than epidural or general anaesthesia, and that this 
was independent of the use of ephedrine (Chapter 1) (Reynolds and Seed, 
2005).  In the current prospective, randomised study, the significantly greater 
mean neonatal umbilical arterial base deficit and lower median umbilical 
arterial pH in the spinal anaesthesia group requires explanation.  
Investigations of the use of ephedrine as the vasopressor in spinal 
anaesthesia for caesarean section in healthy parturients have shown that 
ephedrine is associated with more neonatal acidosis than phenylephrine (Lee 
et al, 2002).  An increased umbilical arteriovenous CO2 difference has been 
demonstrated in a comparison between ephedrine and phenylephrine, 
implying an increased fetal metabolic rate secondary to ephedrine-induced -
adrenergic stimulation (Cooper et al, 2002), Chapter1.  In the current study, 
significantly less ephedrine was used in the general anaesthesia group.  
However, the median pre-delivery dose of ephedrine in the spinal anaesthesia 
group was zero.  There was no correlation between ephedrine utilization and 
neonatal base deficit in the spinal anaesthesia group overall, and in particular 
in the case of neonates with severe acidosis (base deficit >10 mEq/L).  Thus 
the significantly higher base deficit in the spinal anaesthesia group did not 
appear to be attributable to a few patients with severe hypotension. 
 
After the difference in base deficit was discovered, post-hoc analysis was 
performed to examine the influence of disease severity (maternal diastolic 
blood pressure > 110 mmHg) (Table 8.6.). 
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Table 8.6. Influence of maternal disease severity on maternal base 
deficit 
Between-group analysis General Spinal P-value 
DBP <110mmHg (n) 15 15  
NN Base deficit  4.4 ± 3.1  5.2 ± 3.1 0.49 
DBP >110mmHg (n) 20 20  
NN Base deficit  5.0 ± 3.4  8.7 ± 4.0 0.007 
Neonatal acidosis General Spinal  
DBP <110mmHg (n) 15 15  
NN Base deficit  4.4 ± 3.1  5.2 ± 3.1  
DBP >110mmHg (n) 20 20  
NN Base deficit  5.0 ± 3.4  8.7 ± 4.0  
P-value 0.6 0.009  
 
DBP = Diastolic Blood Pressure 
NN = Neonatal 
 
This showed that, in the absence of a diastolic blood pressure > 110 mmHg, 
there was no difference in mean neonatal base deficit between groups.  
However, in those mothers with a diastolic blood pressure > 110 mmHg, the 
spinal anaesthesia group had a significantly greater neonatal base deficit than 
the general anaesthesia group (Table 8.6., upper panel).  Furthermore, when 
this criterion was applied within groups, there was no difference in neonatal 
base deficit in the general anaesthesia group, but in the spinal anaesthesia 
group those neonates whose mothers had a diastolic blood pressure > 110 
mmHg had significantly higher base deficit values than neonates whose 
mothers did not show this degree of hypertension (Table 8.6., lower panel).  
This observation should be interpreted with caution, in view of the fact that the 
original hypothesis was not designed to test differences between groups 
based on maternal disease severity. 
 
It should be noted that following uncomplicated vaginal delivery, umbilical 
arterial base deficit is between 4 and 10 mmol/L (Reynolds et al, 2002).  
Therefore, the range of base deficit found in this study is relatively reassuring.  
Although the degree of acidosis was worse in the spinal anaesthesia group, 
the median value for 1 minute Apgar scores was lower in the general 
anaesthesia group.  A published study concluding that Apgar scores are a 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 8 
146 
 
better predictor of neonatal outcome than fetal pH, suggests that the small 
differences in the base deficit are clinically unimportant given the similar five-
minute Apgar scores in this study (Casey et al, 2001). 
 
Considering the categorical neonatal data, statistical significance was only 
achieved when comparing the incidence of base deficit in the range 5 to 7.9 
mEq/L, where the incidence was higher in the spinal anaesthesia group.  The 
level of fetal acidaemia that correlates with an increasing risk of neurological 
deficit has been found to be a pH of less than 7.0 and a base deficit of more 
than 16meq/L (MacLennan, 1999).  The increased numbers in the spinal 
group in the categories of pH <7.20 and base deficit >10 mEq/L suggest that 
in a much larger study powered to detect differences in these distributive data, 
there might have been a low, but significantly increased incidence of clinically 
important acidosis in the spinal group.  There was a trend towards an 
increased requirement for resuscitative measures in the general anaesthesia 
group (Table 8.5.).  Retrospective analysis suggests that the data had 90% 
power to detect differences in this variable. 
 
There were two neonatal deaths in this study.  The one neonatal death in the 
general anaesthesia group was due to undiagnosed abruptio placentae, which 
resulted in a stillbirth, and could not be attributed to the anaesthetic technique.  
The single case of sudden infant death syndrome at 5 days of age in the 
spinal anaesthesia group, was also unlikely to be attributable to the method of 
anaesthesia. 
 
One early study performed in the absence of acute fetal compromise, 
demonstrated that the differences between base deficit values between 
women with preeclampsia and their fetuses was greater than in healthy 
parturients (simultaneous blood micro-samples were taken from the maternal 
ear and uterine cervix and the fetus) (Tervila and Vartiainen, 1975).  In the 
present study, the correlation (r = 0.36) between maternal base deficit and 
neonatal base deficit, which was stronger in the spinal anaesthesia group 
(r = 0.47) than in the general anaesthesia group (r = 0.29), suggests some 
association between preeclampsia and poor placental perfusion, although the 
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relationship is weak.  Measuring the maternal base deficit may therefore help 
identify infants at greatest risk. 
 
One early investigation comparing general and epidural anaesthesia for 
caesarean section in preeclampsia showed considerable haemodynamic 
instability in the general anaesthesia group, including marked systemic and 
pulmonary hypertension on intubation.  However, the sample sizes were small 
(a total of 17 patients were studied), and no pharmacological measures were 
employed to obtund the intubation response (Hodgkinson et al, 1980).  In the 
current study involving urgent caesarean section, a previously validated 
method of controlling intubation response was employed (Ashton et al, 1991) 
and haemodynamic responses were acceptable.  Similar haemodynamic 
responses were achieved in the spinal anaesthesia group, although the blood 
pressures were significantly lower in this group at several time points.  It 
should however be recognized that cardiac output may correlate better than 
upper limb blood pressure with fetal acidosis (Robson et al, 1992).  In a 
previous study involving a group of 12 preeclamptic patients undergoing 
spinal anaesthesia for elective caesarean section, in whom the placental 
uterine artery circulation was studied using a pulsed colour Doppler 
technique, a marked increase in uterine artery pulsatility index as a sign of 
increased vascular resistance was seen in only one patient during a period of 
severe maternal hypotension (Karinen et al, 1996).  In the current study, blood 
pressure changes of the magnitude measured in the spinal anaesthesia group 
might well have had no clinically detrimental effect on the fetus in normal 
parturients.  However, in the setting of emergency caesarean section in 
severe preeclampsia with fetal compromise, and in combination with mild 
hypocarbia induced by maternal hyperventilation, even a modest lowering of 
the blood pressure could have contributed to decreased placental perfusion.  
This could explain the increased umbilical arterial base deficit demonstrated in 
the spinal group. 
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This study shows that spinal anaesthesia for caesarean section in 
preeclamptic patients with a non-reassuring fetal heart trace may be 
associated with a higher mean neonatal umbilical arterial base deficit and a 
lower median umbilical arterial pH than general anaesthesia.  The clinical 
significance remains to be established. 
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9. Chapter 9 
9. Conclusions and recommendations for the 
practice of spinal anaesthesia for caesarean 
section 
 
9.1. Introduction 
The literature pertaining to the haemodynamics of spinal anaesthesia for non-
emergency caesarean section was extensively reviewed (Chapter 1).  A 
validation study was performed employing recently developed minimally 
invasive cardiac output technology based upon pulse wave form analysis.  
Further studies described in this thesis have addressed several unresolved 
important clinical aspects in this field.  These were: the haemodynamic effects 
of spinal anaesthesia per se, and of fluid, vasopressor and oxytocin therapy in 
healthy parturients.  Also studied were the effects of spinal anaesthesia and 
vasopressor therapy in patients with severe preeclampsia, and short term 
neonatal outcome after spinal anaesthesia in preeclamptic patients. 
 
It must be emphasised that the conclusions drawn from this research are 
applicable to the cohort of patients studied, namely women from an urban, low 
resource, and culturally heterogeneous community, who were referred for 
delivery to secondary or tertiary level care maternity centres in the public 
health sector of South Africa. 
 
9.2. Conclusions 
The LiDCOplus monitor, calibrated with lithium dilution, showed acceptable 
agreement with thermodilution in patients with postpartum complications of 
preeclampsia, suggesting that this form of minimally invasive monitoring could 
have valuable applications in the management of critically ill obstetric patients.  
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From the point of view of obstetric anaesthesia research, the results suggest 
adequate accuracy for measurement of absolute values of CO (Chapter 3). 
 
Although existing literature shows that colloids administered as a preload are 
undoubtedly superior to crystalloid in reducing spinal hypotension, rapid 
crystalloid coload was shown to have a benefit in terms of reducing ephedrine 
requirements pre-delivery during SA for CS, when compared with crystalloid 
preload (Chapter 4). 
 
Meticulous positioning of the patient in order to minimise aortocaval 
compression, together with effective fluid management and choice of dose 
local anaesthetic and combination with opiate, as practiced in the studies 
described in this thesis, have reduced, but not eliminated hypotension during 
spinal anaesthesia for caesarean section. 
 
Spinal anaesthesia in healthy parturients, employing careful left lateral tilt and 
crystalloid coload, induced a marked decrease in systemic vascular 
resistance.  There was a partial compensatory increase in maternal cardiac 
output, on the basis of increases in both heart rate and stroke volume in 
cases in whom significant hypotension occurred (Chapter 5).  This finding, in 
keeping with recent literature, suggests that a considerable component of 
spinal hypotension may be attributable to the effects of SA-induced 
sympathectomy on the arterial circulation. In patients with treated severe 
preeclampsia and baseline SVR at the upper limit of normal, spinal 
anaesthesia was associated with a stable cardiac output, and modest 
afterload reduction (Chapter 6).  This suggests that single shot spinal 
anaesthesia is the method of choice for caesarean section in these patients, 
in the absence of contraindications.  The finding that spinal anaesthesia is 
associated with more neonatal acidosis than general anaesthesia (Chapter 8), 
indicates that even minor degrees of hypotension may cause fetal 
compromise in this high risk group, even if CO is well maintained.  This is in 
agreement with the early literature on the healthy obstetric population, which 
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shows that flow in the widely dilated uterine artery is largely pressure 
dependent (Greiss, 1966). 
 
The LiDCOplus monitor was found to be a useful research tool in the setting 
of rapid changes in haemodynamic indices, in particular SVR.  Following the 
administration of vasopressors, trends in CO change observed with the 
bioimpedance monitor were in the same direction as with the pulse wave form 
monitor (Chapters 5 and 7).  In healthy patients, phenylephrine was found to 
increase SVR and reduce CO in absolute terms, and in comparison with 
ephedrine.  Furthermore, the rapid onset of the pressor effect of 
phenylephrine coincided with the effect on CO, while in the case of ephedrine, 
the pressor effect occurred after CO had increased (Chapter 5).  This 
suggests that not only is phenylephrine more effective in small doses in 
restoring baseline SVR and CO, but the rapid pressor effect could also 
contribute to avoidance of nausea and vomiting.  However, the strong 
correlation between heart rate changes and CO, indicates that should 
phenylephrine be used in doses associated with hypertension and 
bradycardia, this would result in significant decreases in maternal CO.  In 
patients with severe preeclampsia, a small bolus dose of phenylephrine 
caused a return of the SVR to baseline values, reduced HR, and tended to 
reduce CO (Chapter 6). 
 
A small bolus of oxytocin caused a marked decrease in SVR, accompanied by 
hypotension, tachycardia and a compensatory increase in CO.  In healthy 
patients this compensation was due to an increase in HR and SV, while in 
preeclamptic patients the compensation was largely heart rate mediated 
(Chapter 7). 
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9.3. Recommendations 
9.3.1 Recommendations for health service delivery 
In making recommendations for the safe practice of spinal anaesthesia, one 
should consider the widely diverse settings in which mothers are delivered.  
Particularly in busy obstetric units, obstetricians often work under 
considerable pressure, and the medical assessment of patients is sometimes 
not ideal.  Some units in South Africa are positioned in remote locations with 
minimal specialist input.  Of special concern are fluid balance and 
undiagnosed co-morbidities such as valvular heart disease and abnormal 
ventricular function, on the basis of either chronic hypertension or 
cardiomyopathy.  It thus behoves the anaesthesia provider, who is often not a 
specialist, to assess the maternal medical condition carefully, and ensure that 
above all, patients do not receive single shot spinal anaesthesia when there 
are contraindications.  When spinal anaesthesia is selected as the method for 
caesarean section, it is important for all practitioners, particularly 
inexperienced non-physician anaesthesia providers, to understand the 
haemodynamic effects of spinal anaesthesia, and to have clear guidelines for 
the safe use of fluids and vasopressors in each clinical setting. 
 
Although colloids have proven benefits over crystalloid preload, crystalloid 
coloading is an alternative in elective cases, provided it is clearly understood 
that the benefit is short-lived in terms of intravascular half-life.  The added 
expense of colloids in high turnover maternity units probably does not justify 
their routine administration.  Thus a rapid crystalloid coload of 20 mL/kg is 
recommended as the initial fluid intervention in healthy patients.  Should 
further fluids be required, either due to underestimation of the fluid deficit, or 
to blood loss, rapid administration of a colloid solution is recommended while 
blood products are awaited. 
 
The research presented in this dissertation relating to haemodynamic 
changes associated with induction of spinal anaesthesia, shows that afterload 
reduction is the most important effect, and that CO is well preserved. 
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Hypotension during spinal anaesthesia for caesarean section can be 
categorised as part of three main clinical scenarios: 
 
1. Hypotension and an increased heart rate: 
This was the typical response in the studies described in this thesis in healthy 
patients, and maternal CO was increased relative to baseline levels, in partial 
compensation for the decreased SVR and hypotension.  Phenylephrine is 
recommended in this situation, to restore SVR and baseline CO.  Prophylactic 
phenylephrine is not recommended, and may cause unnecessary 
hypertension.  A bolus dose of 80g in response to a 20% decrease in MAP 
restored SVR and CO to baseline values (Chapter 5).  This could be followed 
by low dose continuous infusion (25 – 50 g/min) or intermittent boluses as 
necessary, should blood pressure again decrease.  In patients with 
preeclampsia, a 50g bolus of phenylephrine effectively restored SVR, after a 
20% decrease in MAP (Chapter 6).  The close correlation between heart rate 
and CO changes after the administration of either vasopressor, indicates that 
heart rate is the most important surrogate marker for maternal CO in normal 
clinical practice.  In general, doses of phenylephrine which cause bradycardia 
and hypertension, result in clinically significant reduction in maternal CO and 
cannot be recommended.  In addition, in busy maternity units with limited 
resources, in which a small unknown proportion of patients may have 
impaired ventricular function, high doses of phenylephrine are particularly 
undesirable, since a sudden rise in SVR could be poorly tolerated in this 
situation.  
 
2. Hypotension and bradycardia: 
This is an uncommon situation (no cases in the 44 recruitments to the study 
described in Chapter 5), but potentially life-threatening.  It has been attributed 
to the activation of cardiac reflexes in response to sudden decreased venous 
return and left ventricular end-diastolic volume.  One possibility is the Bezold-
Jarisch reflex, in which sudden underfilling of the left ventricle induces 
activation of C-fibres in the left ventricle, with subsequent increased vagal 
output from the medulla, accompanied by decreased noradrenaline release in 
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the sympathetic nerve terminals and increased activity in the sympathetic 
vasodilator fibres in the muscle beds (Kinsella and Tuckey, 2001; Campagna 
and Carter, 2003).  This results in a profound decrease in CO.  An alternative 
aetiology may be rapid firing of venous baroreceptors (Dickinson, 1993).  
Although not formally studied, the final common pathway includes increased 
vagal output, and logical therapy includes increased uterine displacement, 
together with anticholinergics, preferably atropine if bradycardia is severe, 
followed by ephedrine and/or phenylephrine as necessary, and colloid 
therapy. 
 
3. Persistent severe hypotension, any heart rate: 
Although rare, undiagnosed abnormal ventricular function may require urgent 
intervention with ephedrine, followed by adrenaline.  
 
The use of bolus oxytocin was associated with considerable transient 
haemodynamic instability in healthy and preeclamptic patients.  Co-
administration of phenylephrine obtunded these changes, but there was some 
“overshoot” of the effects of phenylephrine, suggesting that the timing and 
dose of phenylephrine could be improved, in circumstances in which a bolus 
of oxytocin is regarded as necessary (Chapter 7).  If not, slow infusion of 
oxytocin 2.5 – 5.0 IU over 5 minutes is adequate in most cases, since the 
ED90 is 0.35 IU in patients not at increased risk of uterine atony (Carvalho et 
al, 2004), and 3.0IU in patients with labour arrest (Balki et al, 2006). 
 
Spinal anaesthesia appears to be associated with more neonatal acidosis 
than general anaesthesia for caesarean section, as summarised in a recent 
meta-analysis (Reynolds and Seed, 2005).  The same applies in 
preeclampsia, as shown in Chapter 8.  However, the resurgence of the use of 
phenylephrine as a vasopressor for spinal hypotension, is likely to reduce this 
difference, and spinal anaesthesia remains the method of choice in the 
absence of contraindications, in view of the risks associated with tracheal 
intubation.  This is of particular importance in preeclampsia, where intubation 
still carries a risk of mortality (CEMACH, 2007), despite established 
pharmacotherapy to obtund the intubation response (Ashton et al, 1991). 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
Chapter 9 
155 
 
Pulse wave form analysis (LiDCOplus) was shown to be a useful research 
tool in obstetric anaesthesia.  In particular, the demonstration of the exact 
short term haemodynamic changes following the administration of the 
vasopressors ephedrine and phenylephrine, will assist anaesthesiologists in 
their choice of vasopressor during SA for CS (Chapter 5). 
 
The effective use of LiDCOplus to measure CO in patients with complications 
of severe preeclampsia, suggests that thermodilution may be supplanted in 
this area by this minimally invasive device.  In healthy non-pregnant 
volunteers there is poor correlation between pulmonary capillary wedge 
pressure and left ventricular filling volume (Kumar et al, 2004).  This, together 
with the poor correlation between central venous pressure and wedge 
pressure in patients with preeclampsia (Young and Johanson, 2001), 
suggests that the measurement of filling pressures may be unnecessary.  
Instead, all clinical indicators of intravascular volume and fluid responsiveness 
should be used, including passive leg raising (Teboul and Monnet, 2008) and 
measures such as systolic pressure variation, pulse pressure variation, and 
stroke volume variation (Monnet and Teboul, 2007; Belloni et al, 2008). 
 
9.3.2. Recommendations for future research 
In the course of performance of the research for this dissertation, several 
important new topics for study became apparent.  These studies could 
contribute to safe practice of spinal anaesthesia and critical care 
management. 
 
 Prevention is better than cure.  Studies are required to predict which 
patients are likely to become hypotensive during SA for CS.  In this 
regard, heart rate variability has shown great promise.  Assessment of 
preoperative sympathovagal balance is of some value (Hanss et al, 
2006), as is the supine stress test (Dahlgren et al, 2007).  In addition, 
there is a need for the development of practical in-theatre predictors for 
hypotension, such as the recently examined “point correlation 
dimension”, a measure of heart rate variability (Chamchad et al, 2004). 
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 Devices such as LiDCOplus may be used to investigate systolic 
pressure variation, pulse pressure variation and stroke volume 
variation.  These measures of fluid responsiveness would be useful to 
study the venous circulation during spinal anaesthesia, and 
complement the work on the arterial circulation published in this thesis.  
Such studies would require the improvement of existing algorithms to 
allow for the measurement of these indices in spontaneously breathing 
patients (Teboul and Monnet, 2008). 
 
 Similar work in patients with severe preeclampsia could contribute to 
fluid management in untreated hypertensive patients, as well as 
patients with complications such as pulmonary oedema. 
 
 In view of the absence of data on uteroplacental perfusion in the 
studies on spinal anaesthesia in preeclampsia, future research remains 
to demonstrate the optimal use of vasopressors in this clinical setting. 
 
 Future studies are required of the optimal method of administration of 
oxytocin during SA for CS.  These should examine not only 
haemodynamic effects, but also the effects on uterine tone of the exact 
method employed.  This is particularly important in view of the potential 
for receptor down-regulation after repeated doses or prolonged infusion 
(Balki et al, 2009). 
 
 The haemodynamic effects of long-acting oxytocin, carbetocin, require 
study. 
 
 Ergometrine remains an important second line agent for the treatment 
of uterine atony during caesarean section.  The haemodynamics of 
ergometrine during spinal anaesthesia requires further study, in view of 
the known vasoconstrictive side effects. 
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The goal of future research will be both to improve maternal comfort and 
overall experience of the delivery, and to impact upon the high maternal and 
neonatal mortality in poorly resourced and under-privileged population groups 
(Dyer et al, 2009). 
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